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Decreased bioavailable estrogen levels are a major cause of bone loss in 
postmenopausal women, but sex hormones are important regulators of bone mass in 
both sexes. Estrogen signaling in bone occurs mainly through estrogen receptors ERα 
and ERβ.  ERα in particular is important in regulating bone mass and bone’s response 
to mechanical loading, but its particular role in each bone cell type and its cross-talk 
with BMP signaling are not well studied.  ` 
Osteoblast-specific ERα knockout (pOC-ERαKO) and littermate control (LC) 
were bred by crossing Osteocalcin-Cre and ERαfl/fl mice. The effects of removing ERα 
in osteoblasts and osteocytes on bone mass, bone strength, and bone’s response to 
mechanical loading were studied in 10-week-old animals.  In general, cancellous and 
cortical bone mass were both reduced in pOC-ERαKO female mice, while bone mass 
was increased in pOC-ERαKO male mice compared to their sex-matched LC, 
measured by microCT in the proximal and midshaft tibia, femur, and L5 vertebra.  
These bone mass changes correlated with decreased vertebral compressive strength in 
female knockout mice and increased femoral bending strength in male knockout mice.  
After two weeks of in vivo tibial compression, female pOC-ERαKO mice showed a 
greater increase in bone mass in the proximal tibia, where baseline bone mass was 
decreased, and at the tibial midshaft, where baseline bone mass was similar to LC.  
Male pOC-ERαKO mice exhibited a normal response to mechanical loading. 
Next, 10-week-old female pOC-ERαKO and LC mice were administered either 
 RAP-661, a BMPR1a inhibitor, or placebo, and all mice were subjected to daily in 
vivo tibial compression for two weeks.  RAP-661 markedly increased bone mass in 
the L5 vertebra and cancellous tibial metaphysis of both genotypes, but not at the 
femoral midshaft, tibial midshaft, or tibial metaphyseal cortex.  In the vertebra, the 
drug-induced increase in bone mass was less in pOC-ERαKO mice than LC.  Animals 
treated with RAP-661 responded less to mechanical loading in the tibial metaphysis 
than placebo animals, but similarly at the tibial midshaft.  This is the first evidence to 
indicate that BMPR1a may mediate bone’s response to mechanical loading and 
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Chapter 1  
INTRODUCTION 
1.1 Osteoporosis 
 Osteoporosis, a condition of low bone mass, increases fracture susceptibility.  
Each year in the United States, 1.5 million Americans suffer from an osteoporotic 
fracture (1).  It is estimated that 1/3 of women and 1/5 of men over the age of 50 will 
experience an osteoporotic fracture at some point in their lives (2).  The healthcare 
burden of these fractures exceeds $1 billion yearly (3).  By the year 2025, over 3 
million fractures are expected and healthcare costs are anticipated to rise to $25 billion 
per year.  After a patient experiences one fracture due to osteoporosis, the likelihood 
of a second fracture is substantially increased, in a pathology known as the “fracture 
cascade” (4). The need for therapies, treatments, and especially prevention for 
osteoporosis is clear in our society.  
Osteoporosis is characterized by low bone mass and affects 44 million 
Americans (2).  Bone is comprised of two major components: a mineral component, 
mostly of calcium phosphate, and an organic component, mainly of collagen type 1.  
Osteoporosis is diagnosed by measuring bone mineral density (BMD) from dual x-ray 
absorptiometry (DEXA) scans.  From DEXA, a T-score or a Z-score is given, which 
compares the skeleton’s BMD to that of the average young adult or the average adult 
matched for age and sex, respectively.  When a patient’s T-score is 2.5 standard 
deviations below that of an average young adult, osteoporosis is the diagnosis.  Figure 
1.1 depicts compromised cancellous architecture in human iliac crest bone affected by 








Due in part to low estrogen levels, postmenopausal women have the highest 
susceptibility to develop osteoporosis in their lifetimes, but men are also at risk as 
well.  In Figure 1.2, changes in bone mass with age are depicted for both sexes (6).  
Throughout a person’s life, bone is constantly being formed and resorbed in a delicate 
balance to either gain bone mass in a process called modeling (during growth) or 
maintain bone mass in a process called remodeling (after peak bone mass is achieved).  
During growth and maturation, bone is modeled into the respective shapes of each 
bone in the skeleton, and bone mass steadily increases.  Two types of bone are 
modeled: cortical (compact) bone, found in the shafts of long bones and in flat bones 
like the skull, and cancellous bone (spongy or trabecular), found in the ends of long 
bones.  Men on average reach a higher peak bone mass, and peak bone mass achieved 
during growth correlates with bone mass later in life (7).  After peak bone mass is 
achieved around age 30, bone remodeling continues, and the skeleton still is being 
formed and resorbed.    Cortical bone, for example, experiences 2-5% turnover per 
year in the elderly (8).  When this balance is disrupted resulting in the rate of 
resorption exceeding the rate of formation, bone mass decreases.  With age, both 
females and males show a gradual loss of bone mass, but women show a sharp 
decrease in bone mass right after menopause.  However, men also experience a steeper 
 
Figure 1.1 Cancellous bone in human iliac crest in normal bone (left) and 
osteoporotic bone (right). (Used with permission) 
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decline as they age. 
 
 
1.2 Estrogen and Bone 
Estrogen is a key regulator of bone mass.  After menopause, the ovaries stop 
producing estrogen, drastically decreasing circulating levels of the hormone and 
contributing to the rapid bone loss often seen in this demographic.  However, estrogen 
is important in bone in both men and women throughout life by regulating both 
formation and resorption.  Estrogen induces osteoblast differentiation and formation 
and prolongs osteoblast lifespan (9-11).  In osteoclasts, estrogen regulates apoptosis 
(12).  In general, men develop higher peak bone mass due to prolonged puberty and 
increased testosterone levels, which increase periosteal expansion (13, 14).  During 
puberty and beyond, estrogen suppresses periosteal expansion and increases endosteal 
resorption, and ultimately it is required for growth plate fusion in humans (15).
 Estrogen signaling is mediated by two separately coded estrogen receptors 
(ERs), ERα and ERβ, found in the cytoplasm of cells and members of the nuclear 
receptor gene superfamily (16).  When estrogen binds to either ERα or ERβ, the 
receptor dimerizes with another ER, and each receptor phosphorylates (Figure 1.3).  
At this point, the ER complex can either directly bind to DNA estrogen response 
 
Figure 1.2 Men, on average, reach a higher bone peak bone mass than women.  
Women begin to rapidly lose bone mass at the onset of menopause.  Men also 
experience a decline in bone mass with age.  (Used with permission) 
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elements found in the control regions of target genes, or it can be involved in other  
intracellular signaling pathways that will ultimately also regulate gene transcription 
(classical signaling) (7, 17).    ERs are present in many cells of the body, including the 
ovaries, uterus, all bone cells, vasculature, lung, etc (18).  In bone cells, ER expression 
is approximately one-tenth the expression found in reproductive organs (10, 19, 20), 
and the major signaling path of estrogen in bone is through ERα.  ERα expression in 
bone is regulated by levels of estrogen, even though signaling can occur in estrogen-
independent mechanisms (non-classical signaling) (21). 
In 1994, clinical data showed unfused growth plates and osteoporosis in a male 
with an inactivating point mutation in the ERα gene, which has focused research in 
understanding and elucidating the mechanisms of ERα signaling (22, 23).  Further 
human clinical data have correlated polymorphisms in ESR1, the gene that encodes 
ERα, with bone mineral density, fracture risk, and bone’s response to exercise (24-30).  
 
Figure 1.3 Classical sex hormone signaling.  
 Testosterone can be converted to estrogen by the enzyme aromatase.  Estrogen 
binds to either ERα or ERβ, and the receptor dimerizes and phosphorylates.  The 
complex can be involved in further intracellular signaling or direct gene 
transcription in the nucleus 
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Because of estrogen’s complex signaling environment, via classical and non-classical 
pathways, ERα is implicated downstream many signaling pathways important to bone, 
including wnt/β-catenin, insulin-like growth factor 1 (IGF-1), and  bone 
morphogenetic protein (BMP) (31-33). 
To model estrogen deficiency that occurs in post-menopausal women, 
ovariectomy (OVX) in rodents are the gold standard.  When the ovaries are removed 
in rats at 5 months of age, 50% of proximal tibial cancellous bone volume is lost by 14 
days post-surgery (34).  Skeletally mature rats are preferred to growing rats because 
the bone loss that occurs more closely resembles the bone loss observed in post-
menopausal women (34).  Although OVX mice are also used, this model is not as 
standardized, and bone loss varies among mouse strains (35).  OVX has limitations.  
First, it is major surgery and introduces extra stress on the animals.  Second, OVX 
animals tend to gain a considerable amount of weight compared to their controls (36). 
OVX removes the majority of circulating estrogen, which means that any 
estrogen signaling through ERα, ERβ, or other possible routes are all eliminated.  To 
better focus on one aspect of estrogen signaling, knockout mice (KO) are a valuable 
tool.  Because the mouse genome is fully sequenced and easily manipulated, a 
technique called cre/lox recombination can generate mice that lack a specific gene or 
part of a gene, usually corresponding to a protein or a section of a protein rendering it 
unusable (Figure 1.4).  In this technique, two types of mice are used: a cre mouse that 
contains cre recombinase inserted into its genome, and a floxed mouse, that has the 
gene of interest flanked on either end by loxP sites.  When the mice are mated, the cre 
recognizes the 35 base pair loxP sequences and removes the gene in between those 
two sites in the pups.  The effect of removing genes on mouse development, 
appearance, behavior, etc., can indicate the role of a specific gene in a particular 
mechanism.  Initially developed ERαKO and ERβKO mice did not completely remove 
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all receptor protein production (37-39).  In 2000 both complete knockouts were 
generated by removing sections of exon 3 of each gene, which encodes the first zinc 
finger of the DNA-binding domain of each receptor (40).   
From bone analyses of these knockout animals, ERα was shown to be more 
important in skeletal development than ERβ.  Female ERβKO mice had either 
increased (41, 42) or no change (43) in long bone lengths.  In addition, bone mineral 
content (BMC) was increased at measurements taken along the whole body, cranium, 
spine, tibia, and vertebra (44).  Cortical thickness at the femoral midshaft (41) and 
cancellous bone volume fraction in the tibia (43) were both increased, but others have 
indicated no change in these parameters, depending on the knockout animal source 
(44).  In contrast, male ERβKO mice presented with few skeletal abnormalities.  
Whole body and site-specific BMC, femoral lengths, and femoral cortical thickness 
were all similar between knockouts and wildtype animals (43, 44). 
Figure 1.4 Cre-lox technology allows a specific gene, floxed by loxP sites, to be 
removed from all cells with active cre recombinase when a Cre mouse and a floxed 
mouse are bred. 
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Global deletion of ERα had profound effects on bone in both male and female 
mice.  In the incomplete ERαKO female mice, long bone lengths were decreased 
while BMC and bone mineral density were both increased (41).  Cancellous and 
cortical bone were differentially affected.  Tibial cancellous bone volume fraction was 
increased, but cortical bone thickness at the tibial midshaft was increased.  However, 
in the complete ERαKO, long bone lengths were unaffected.  Tibial bone volume 
fraction was still increased, but bone mineral density in both tibial cortical and 
cancellous bone were decreased, as was tibial cortical thickness (43).  In male mice, 
the knockout source was of less importance.  Femoral lengths were shown to be both 
decreased (45, 46) and unchanged (43), but cortical and cancellous BMD and cortical 
thickness in the tibia were decreased (43, 45). 
Although ERαKO and ERβKO mice indicate a crucial role of ERs in bone 
phenotype, confounding characteristics of these global knockout animals make it 
impossible to determine if bone effects are due solely to a lack of ER, or if caused by a 
secondary effect of ER’s absence in other tissues.  For example, IGF-1, an important 
regulator of bone length, was decreased in female ERαKO and increased in female 
ERβKO mice (41).  Estrogen, a key regulator of bone mass as described earlier, was 
systemically increased over six-fold in ERαKO female mice (41, 43).  Furthermore, 
ERαKO female mice had increased body weight, increased testosterone levels, and 
decreased osteocalcin levels (41).  Male ERαKO and ERβKO mice also had increased 
testosterone levels (43).  Male and female ERαKO and female ERβKO mice had 
either reduced or no fertility (40).  Furthermore, because ERα is present other tissues, 
including cardiovascular, brain, adipose, liver, and heart, ERαKO mice become 
diabetic and develop vascular disease as they age at much greater rates than wildtype 
mice (46).  All of these systemic factors interfere with any skeletal interpretations 
about ERαKO or ERβKO mice. 
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To combat the confounding effects in global knockout mice, bone-cell-specific 
knockouts using promoter-driven cres have provided additional information regarding 
ERs and bone.  When a cre is activated by only one promoter, and the promoter is 
present in only one cell type, a receptor can be removed from a specific cell and all 
cells following in the lineage.  Bone has a variety of promoter-driven cre mice 
available, which are outlined in Figure 1.5.  In the past seven years, researchers have 
selectively removed ERα from osteoclast progenitors, osteoclasts, osteoblast 
progenitors, osteoblast precursors, committed osteoblasts, mature osteoblasts, and 
osteocytes (47-52), but the story relating ERα in bone cells to cortical and cancellous 
bone in males and females is complex and incomplete. 
When ERα was conditionally removed from a bone cell type rather than the 
entire genome, systemic effects seen in the global knockout mice were eliminated.  In 
general, body weight, serum hormone levels, and long bone lengths were similar 
between tissue-specific ERαKO and littermate controls (47, 50-52).  In osteoclasts, 
ERα protects cancellous bone mass in females but has no effect on male mice (47).  In 
osteoclast-specific ERαKO mice (pCathK-ERαKO), female mice exhibited decreased 
Figure 1.5 Promoter-driven cre mice allow a gene to be removed at a specific point in 
a cell lineage.  For example, in the osteoblast lineage, Prx1-Cre mice can delete a gene 
in osteoblast precursor cells and all cells following in the lineage. 
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BMD and BV/TV of the tibia and femur due to increased osteoclast surface 
normalized to bone surface (Oc.S/BS) and despite increased bone formation rate and 
increased MAR.  Cortical bone was unaffected.  However, when ERα was removed 
earlier in the osteoclast lineage using the Lysozyme M-cre mouse (LysM-Cre), 
cortical and cancellous bone mass were overall unaffected, but the number of 
osteoclasts was increased (48).  Bone mass in male pCathK-ERαKO was similar to 
controls (47). 
 
Table 1.1 Osteoblast-lineage specific cre mice have been used to generate cell-
specific ERαKO mice.  The bone phenotype exhibited by each knockout is displayed 
below.  However, the results are complex regarding bone mass in males and females 
and in cortical and cancellous bone. 
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No effect on cancellous 
bone, decreased 
cancellous bone mass 
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In mice lacking ERα in osteoblast lineage cells, the story is even more complex 
(Table 1.1).  When ERα was removed at the osteoblast progenitor (pPrx1-ERαKO) or 
osteoblast precursor (pOsx1-ERαKO) stage, cortical bone was decreased in both males 
and females but cancellous bone was largely unaffected (53).  Femoral midshaft 
cortical thickness, cancellous BV/TV, and periosteal bone formation rate were all 
decreased in both targeted knockouts, attributed to attenuated osteoblastogenesis 
detected from cell culture assays.  When the same researchers removed ERα from 
committed osteoblasts (pCol1a1-ERαKO) or osteocytes (pDMP1-ERαKO), cortical 
and cancellous bone mass were both unchanged between knockouts and controls in 
both males and females (53).  However, others have found conflicting results.  In 
pOC-ERαKO mice, where ERα is removed from mature osteoblasts, female cortical 
and cancellous bone mass were both reduced in the tibia, due to effects on both 
osteoblast number and osteoclast number to a greater degree (51).   In male pOC-
ERαKO mice, bone phenotype was unaffected except at 6 months, where tibial 
BV/TV was decreased.  Furthermore, in opposition to the previous pDMP1-ERαKO 
mice, others have found that trabecular BV/TV and BFR were decreased while 
N.Oc/BS remained unchanged (52, 54).  Cortical bone in female mice and cortical and 
cancellous bone in male mice were not affected by ERα absence in osteocytes.  
Elucidating the role of ERα in osteoblasts, osteocytes, and osteoclasts is incomplete 
and needs further research to resolve some of these discrepancies. 
 
1.3  Mechanical Loading and Bone 
 Bone responds to its mechanical environment.  In situations of increased 
loading, bone mass increases.  Tennis players show increased cortical thickness in 
their dominant playing arms compared to the contralateral limb (55).  Also, dynamic 
 11 
jumping exercises have been shown to increase BMC at multiple bone sites in children 
over a 7-month program  (56).  At the other end of the spectrum, bone loss can occur 
in situations of bone disuse, such as with astronauts during space flight or during 
immobilization (57, 58). 
Because of their ability to increase bone mass, controlled loading models in 
rodent long bones are a promising measure to overcome bone loss and have been 
widely developed as a means of studying how bone responds to loading.  Across many 
vertebrate animals, bone strains induced by normal physiological activity are similar, 
despite difference in bone size and loads applied during activity (59).  Before 
beginning any loading experiment, measuring bone stiffness at the cortical midshaft 
by applying a range of loads is common practice to determine the appropriate peak 
magnitude of load for a given experimental design. 
Two main categories of loading models exist: bending and compression.  In 
four-point bending models of the rat and mouse tibia, up to 100 cycles of loading for 
5-12 days were administered to engender 850-3500 microstrain (strain*10
-6
, με) at the 
tibial midshaft (60, 61).    These models do induce new bone formation, but much of 
the bone formation is woven bone, which is not as highly organized or as dense as 
lamellar bone and is more a response to injury than to normal physiologic loading (60, 
62). 
Because they are more physiologically relevant and produce lamellar bone, 
axial compression rodent models have replaced the bending controlled loading models 
(62-66).  In rats, loading the ulna at 20N to induce 3500-4500 με at the midshaft 
produced a clear lamellar cortical bone response after 9 days (62).  Frequency 
variation from 10-20Hz and cycle variation from 1200-12,000 cycles per day had no 
effect on the amount of bone formation (62).  Similar ulnar loading was developed in 
mice as well, with smaller loads (3-4.3N) 5 days per week for 2 weeks to result in 
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2000-3000 με at the midshaft (63).  In mice, 2000 με corresponded to lamellar 
formation at the periosteal surface but no formation on the endocortical surface, while 
3000 με induced woven bone at the periosteal surface and lamellar bone on the 
endocortical surface. 
Mouse tibial loading models have emerged as valuable tools for studying bone 
adaption to loading without creating woven bone (64, 65).  Its advantages include the 
possibility of using genetically modified mice (unlike the rat), the ability to study both 
cortical and cancellous bone (unlike the ulna), and the ability to induce lamellar 
instead of woven bone formation in a more physiologically relevant axial loading 
direction.  Two main tibial compression protocols, with some variations, are present in 
the literature.  The first model applies strain-, age-, and sex-dependent peak loads that 
correspond to 1200 με at the midshaft are applied for 1200 cycles each day, at a rate of 
4Hz and a dwell of 100ms between each loading cycles (64) (Figure 1.6).  When 
applied for 2 weeks, this loading protocol increased bone mass similarly in 10-week-
old males and females, with greater increases in the cancellous metaphysis than at the 
tibial midshaft (67, 68).  Older female mice still respond to loading, but a higher load 
level is required, corresponding to 2100 με.  Furthermore, it has been used to rescue 
bone loss in male mice after orchidectomy (69).  The second tibial compression model 
loads for fewer cycles, fewer days per week, with longer rests between each load cycle 
(65).  Although this loading protocol increased bone mass in 8-week-old animals, 
trabecular bone mass was lost with loading in 12-week, 20-week, and 26-week-old 
mice (65, 70).  The first loading protocol is more consistently osteogenic than the 
latter, showing a 65% vs. only 44% increase, respectively, in tibial BV/TV after 6 
weeks of loading (71).  For a more detailed loading and strain gauging protocol, see 
Appendix A.  
In designing and interpreting in vivo loading studies, a variety of factors need 
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consideration.  Ulnar loading measures purely cortical bone response, while tibial 
loading allows analysis of both cortical and cancellous bone, but a range of loading 
protocols with varying waveforms, rests between cycles, and number of cycles per 
day.  Growing mice may response differently than those who have reached skeletal 
maturity, at around 16 weeks of age (72).  Strain of mice also plays a role, as some 
strains are more mechanoresponsive than others (73).  In addition, cortical and 
cancellous bone phenotype varies by mouse strain, which can impact bone response. 
 
1.4  Mechanotransduction: Estrogen and BMPs 
Mechanotransduction is the process by which bone converts mechanical 
stimuli into chemical, cellular, and tissue-level responses.  Controlled mechanical 
loading initially was used to study the tissue-level responses by looking at changes in 
bone mass, architecture, and shape with loading.  The cellular signaling pathways 
involved in generating this anabolic response are of particular interest, and cover a 
wide range of signaling pathways, including wnt/β-catenin, parathyroid hormone 
(PTH), insulin-like growth factor (IGF-1), hormones including estrogen and 
testosterone, and bone morphogenetic proteins (BMPs) (31).  Many of these pathways 
are interconnected either directly or indirectly.  ERα in particular is proposed to be 
Figure 1.6 A) In vivo tibial waveform commonly used to stimulate bone growth in the 
cancellous metaphysis and the cortical midshaft. B) Mouse situated in custom loading 
device prepared for in vivo tibial loading to begin. 
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involved with many of the above networks.  However, much of the signaling research 
on bone mechanotransduction has been through in vitro studies using cultured 
osteoblasts stimulated by fluid shear flow over the cells or bending the apparatus on 
which the cells are seeded.  In vivo studies to determine the role of ERα and its 
interaction with other pathways, such as with BMPs, are needed. 
Estrogen and its receptors influence bone mechanoadaptation.  In humans, 
females responded more to exercise pre-puberty than post-puberty after estrogen 
levels rise (74).  Analogously, low dose estrogen administered during rat unlar loading 
suppressed periosteal bone formation but enhanced endosteal bone growth (75).  
Furthermore, osteoblast-like cells derived from rats and subjected to four-point 
bending proliferate in response to strain, estrogen, and even more when the two are 
combined (76).  ERα over ERβ was shown to be highly important in how bone 
responds to mechanical strain.  Expression of ERα is reduced in osteocytes following 
rat ulnar loading in both sexes, but is increased in osteoblast-like cells after strain in 
osteoblast-like human cells (77, 78).  Osteoblast-like cells from ERαKO mice do not 
proliferate in response to strain as cells from wildtype mice do (79, 80).  Furthermore, 
in human osteoblast-like cells, proliferative response to strain is abrogated when an 
ER modulator is administered to block all ERα signaling (81). 
To further study ERα’s role in bone mechanotransduction, controlled loading 
models have been applied to both global and cell-specific ERαKO mice.  Similar to 
the in vitro cell cultures from ERαKO mice, female ERαKO mice responded less to in 
vivo ulnar loading, showing a 70% less increase in Ct.Ar after 2 weeks (6, 80).  
However, the cancellous bone response to mechanical loading was similar compared 
to controls (82).  In males, global ERα deletion induced a greater response to tibial 
mechanical loading in both cancellous and cortical bone (82).  From sciatic 
neurectomy, a limb disuse animal model, ERαKO male and female mice lost less 
 15 
cancellous bone, but similar cortical bone, compared to controls.  Importantly, these 
global ERαKO models exhibit systemic effects, such as increased body weight, as 
mentioned previously, and so the effects of ERα in each bone cell type cannot be 
determined.  The need for in vivo loading studies in bone cell-specific ERαKO mice is 
clear, but has not been fully explored, especially in cancellous bone (Table 1.2).  
Female mice deficient in ERα at the osteoblast progenitor or precursor stage showed 
decreased osteogenic response to loading in cortical bone, but cancellous bone was not 
studied (83).  In mice with ERα removed at the committed osteoblast or osteocyte 
stage, the cortical response to tibial loading was similar between female knockout and 
controls, in opposition to the global ERαKO models (54).  Again, the response in 
cancellous bone was not studied.  From hindlimb suspension, a limb disuse animal 
model, female pDmp1-ERαKO mice lost more cancellous bone than controls (52).   
 
Table 1.2 The responses to mechanical loading in cancellous and cortical bone have 
not been fully explored in mice with ERα removed at particular points along the 
osteoblast lineage using promoter-drive cres. 















































 BMPs are members of the TGF-β super family of growth factors.  Synthesized 
by skeletal and non-skeletal tissues throughout development, BMPs regulate many cell 
and tissue processes.  BMPs were first identified by their ability to induce ectopic 
bone formation, but over 20 BMPs are currently identified (84, 85).  The BMP cell 
signaling pathway is complex (Figure 1.7).  In canonical signaling, BMPs activate 
type II receptors, which include BMPR1A (Alk-3), AMPR1B (Alk-6), and Act-1a 
(Alk-2).  An activated type II receptor then activates a type I receptor, which 
phosphorylates and induces phosphorylation of Smad1,5,8.  pSmad1,5,8 forms a 
complex with Smad4, and the entire complex can directly regulate gene transcription 
in the nucleus (86).  Because there are 3 kinds of type I receptors and 3 kind of type II 
receptors, many signaling combinations are possible and result in varying gene 
expression or repression.  Useful for studying BMP signaling are BMP antagonists, 
including gremlin, noggin, and follistatin. 
In bone, BMPs 2, 4, and 6 are highly expressed (87).  BMPs can induce 
osteoblast differentiation and regulate osteoblastogenesis and osteoclastogeneis (88, 
89).  BMP2 enhances fracture healing in mice by inducing endochondral ossification 
and enhance chondrogenesis, BMP2 enhances fracture healing in mice (89-91).  
Currently, BMPs are FDA-approved for bone regeneration applications such as after 
fractures and osteotomies.  
BMPs have been implicated in bone’s response to mechanical loading.  In 
vitro, BMPs were upregulated in osteoblasts to fluid shear (32), and when noggin, an 
inhibitor, was given, osteoblasts did not proliferate in response to fluid shear.  In vivo, 
BMPs were upregulated in mice after one day of tibial loading (92, 93).  
Interactions between estrogen and BMP signaling have been shown in vitro in 
both competitive and cooperative mechanisms.  In fact, BMP Smads and ERα may 
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directly interact (94).  After BMP-2 treatment in myoblasts, ER expression was 
increased (95).  BMP-2 also was shown to induce phosphorylation of Smad 1,5,8, 
downstream in BMP signaling, and this activity was enhanced with estrogen 
treatment.  In contrast, Smad4 has been shown to inhibit transcription of genes 
involved in estrogen signaling (96).  Antiestrogens suppressed BMP-4 expression in 
an ERα-dependent manner (97).   
 Attention has focused on BMPR1a, a type II receptor involved in bone BMP 
signaling.  Although the global BMPR1a KO is embryonically lethal, other animal 
models have implicated its importance in bone (98).  Using the Og2-Cre (osteocalcin 
2) mouse, BMPR1a was removed from post-natal osteoblasts (99).  Growing mice 
were smaller than wildtype littermates, but as the mice aged, the knockout mice had 
         d 
Figure 1.7 Canonical BMP signaling involves type I and type II receptors.  When 
BMP binds to a type II receptor, a type I receptor is activated and phosphorylated.  
Then, Smad 1,5,8 is phosphorylated and binds to Smad4. This complex can 
mediate gene transcription in the nucleus. (Used with permission) 
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increased bone mass due to decreased bone resorption rates.  Similarly, BMPR1a was 
deleted from osteoblasts through tamoxifen induction, which allows targeted deletion 
in growing or adult animals for a specified range of time (100).  These mice exhibited 
increased bone mineral density and cancellous bone mass and showed a decrease in 
both bone formation and, to a greater extend, bone resorption.  When BMPR1a was 
deleted in osteoclasts, bone volume and trabecular thickness were both increased, 
which correlated with increased bone formation rate (101). 
 To further study BMPR1a in bone, a soluble BMPR1a was developed that 
binds to BMP2 and BMP4 with high affinity (102).  The drug, RAP-661, prevents 
canonical BMP signaling through BMPR1a.   When administered to wildtype 12-
week-old mice, bone mineral density and cancellous bone volume fraction increased 
in a dose-dependent manner after 2, 4, and 6 weeks.  Femoral bending strength was 
also increased in RAP-661-treated animals, indicating a possible cortical effect as 
well.  Histomorphometry analysis indicated that the drug induces an early increase in 
osteoblast number followed later by a decrease in osteoclast number.  Therefore, 
soluble BMPR1a may impact both bone formation and bone resorption as a means of 
increasing bone mass.  Possible interactions with ERα and mechanical loading have 
yet to be determined. 
 
1.5 Aims 
 Osteoporotic fractures are ultimately the failure of bone to perform its main 
function, bearing loads.  Understanding the cellular and molecular mechanisms that 
bring about changes in bone in response is critical for prevention and treatment of 
osteoporosis.   Estrogen levels are severely reduced in post-menopausal women, but 
the hormone is important in both sexes during bone modeling and remodeling.  ERα in 
particular has been implicated in bone’s response to mechanical loading.  Although 
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many bone cell-specific ERαKO mice exist, ERα’s role in each cell type is 
incompletely understood.  This thesis aims to better understand ERα signaling in 
osteoblasts by generating pOC-ERαKO mice to examine bone phenotype (Aim 1), 
studying their response to skeletal mechanical loading (Aim 2), and determining the 
interactions among ERα, BMP signaling, and mechanical loading (Aim 3). 
 
Aim 1 
Because global ERαKO mice have confounding systemic effects, the direct 
role of ERα in bone is unknown.  Because estrogen regulates osteoblasts and 
osteoclasts, we hypothesized that without ERα in osteoblasts, bone mass would be 
decreased.   We bred female mice with osteoblast-specific ERα deletion (pOC-
ERαKO) by crossing OC-Cre and ERαfl/fl mice and examined both growing (12 weeks 
old) and skeletally mature animals (18 weeks old).  By measuring body mass, ovary 
and uterine mass, crown/rump length, and serum levels of estrogen, testosterone, IGF-
1, and OC, we ascertained that systemic effects were eliminated in this bone cell-
specific ERαKO model.  To characterize the effect of genotype on bone mass and 
architecture in both cortical and cancellous bone, microCT was performed at multiple 
bone sites: the cortico-cancellous proximal tibia, cortical tibial midshaft, cortico-
cancellous L5 vertebra, and the cortico-cancellous distal femur.  In addition, both the 
L5 vertebra and femora were subjected to mechanical testing to failure to determine 
whole bone stiffness and strength.  Changes in osteoblast and osteoclast bone cell 
activity were measured from immunohistochemistry analysis of the cancellous 
proximal tibia.  Bone formation rate and mineralizing surface were determined from 




 Both cortical and cancellous bone mass were reduced in female pOC-ERαKO 
mice (Aim 1), and osteoblast proliferation was reduced in osteoblast-like cells lacking 
ERα (79).  Therefore, we hypothesized that male pOC-ERαKO mice would also show 
reduced bone mass, and that both sexes of pOC-ERαKO mice would respond less to 
mechanical loading.  To this end, we bred male and female pOC-ERαKO mice 
backcrossed to a C57Bl/6 background.  At ten weeks of age, we measured bone 
stiffness at the tibial midshaft from in vivo strain gauging to determine parameters for 
in vivo tibial mechanical loading.  Left tibiae from male and female pOC-ERαKO and 
littermate control (LC) mice were loaded in vivo for two weeks, with the right limb as 
an internal control. As in Aim 1, we tested for systemic effects in these now 
backcrossed animals.  We measured basal bone phenotype resulting from the 
osteoblast-specific ERα deletion through microCT of the cortico-cancellous vertebral 
body and cortical femoral midshaft.  Bone strength and stiffness were assessed from 
femoral and vertebral whole bone mechanical testing.  To analyze the response to 
loading in knockouts vs. LC, microCT was performed at the tibial cortical midshaft 
and cortico-cancellous tibial metaphysis.  Furthermore, osteoblast and osteoclast bone 
cell activity were measured from immunohistochemistry, and again bone formation 
rate and mineralizing surface were assessed at both the tibial midshaft and metaphysis. 
 
Aim 3 
 Elucidating the signaling mechanisms of estrogen and ERα is complex.  ERα 
has been shown to interact with BMP signaling.  By inhibiting BMP signaling using 
RAP-661, a soluble receptor that binds to and prevents signaling through the BMPR1a 
receptor, bone mass in female mice is increased in a dose- and time-dependent 
manner.  We hypothesized that RAP-661 would rescue bone loss in female pOC-
ERαKO mice, and that bone mass could be further increased through mechanical 
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loading.  Also, we hypothesized that in LC animals, both mechanical loading and drug 
administration would cooperatively increase bone mass.  We bred female pOC-
ERαKO and LC mice and subjected all animals to 2 weeks of in vivo left tibial 
mechanical loading.  Half of the mice from each genotype were given an IP injection 
of RAP-661, while the other half were administered a placebo.  After euthanasia, basal 
bone phenotype in drug-treated and placebo-treated mice of both genotypes was 
assessed from microCT analysis of the L5 vertebra and femoral midshaft.  Bone 
strength and stiffness were determined from whole bone mechanical tests.  To 
determine the combinations of interactions of ERα, RAP-661, and mechanical loading, 
cancellous and cortical bone mass and architecture were assessed from microCT of the 
tibial midshaft and metaphysis.  Osteoblasts and osteoclast activity were also 
measured in the cancellous proximal tibia from IHC. 
 
1.6  My contributions 
Aim 1 was published in The Journal of Bone and Mineral Research: 
Melville KM, Kelly NH, Khan SA, Schimenti JC, Ross FP, Main RP, van der 
Meulen MCH.  Osteoblast-specific Estrogen Receptor Alpha Knockout Mice 
Have Compromised Bone Mass and Strength.  JBMR 2014. 29(2):370-9.   
 
Previously, I presented part of this Aim at the American Society for Bone and Mineral 
Research Meeting 2012 as a podium presentation: 
Melville KM, Bruhn TM, Khan SA, Schimenti JC, Ross FP, Main RP, van der 
Meulen MCH.  Osteoblast-specific Estrogen Receptor Alpha Knockout Mice 
have Compromised Bone Mass and Architecture.  American Society for Bone 
and Mineral Research Annual Meeting 2012.  Minneapolis, MN.   
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The authors’ roles for this Aim were: Study design: MCHM, KMM, RPM, FPR, 
NHK, JSC, SAK. Study conduct: KMM, NHK. Data collection: KMM, NHK. Data 
analysis: KMM. Data interpretation: KMM, MCHM, FPR. Drafting manuscript: 
KMM. Revising manuscript content: KMM, MCHM, FPR, NHK, RPM. Approving 
final version of manuscript: all authors. KMM takes responsibility for the integrity of 
the data analysis. 
 
Aim 2 is under review for submission to The Journal of Bone and Mineral Research: 
Melville KM, Kelly NH, Surita G, Buchalter DB, Schimenti JC, Main RP, 
Ross FP, van der Meulen MCH.  Estrogen receptor alpha in osteoblast lineage 
cells regulates bone mass differentially in both sexes and attenuates bone’s 
response to mechanical loading in female mice. JBMR. Under Review.   
 
Previously, I presented part of this Aim at the Proceedings of the 60th Annual Meeting 
of the Orthopaedic Research Society as a podium presentation: 
Melville, KM, Kelly NH, Surita G, Schimenti JC, Ross FP, Main RP, van der 
Meulen MCH.  ERα in osteoblasts is required for cancellous bone mass but 
attenuates bone’s anabolic response to mechanical loading.  Proceedings of the 
60th annual meeting of the Orthopaedic Research Society.  New Orleans, LA.   
 
The authors’ roles for this Aim were: Study design: KMM, FPR, MCHM. Study 
conduct: KMM, NHK, DBB. Data collection: KMM, NHK, GS, DBB. Data analysis: 
KMM. Data interpretation: KMM, MCHM, FPR. Drafting manuscript: KMM. 
Revising manuscript content: KMM, MCHM, FPR, RPM. Approving final version of 




Aim 3 is in preparation for submission to The Journal of Bone and Mineral Research: 
Melville KM, Kelly NH, Schimenti JC, Ross FP, Pearsall S, van der Meulen 
MCH. Inhibiting BMP 2/4 signaling increases cancellous bone mass and 
reduces bone’s response to mechanical loading in female mice.   
 
The authors’ roles for this Aim were: Study design: KMM, FPR, SP, MCHM.  Study 
conduct: KMM, NHK.  Data collection: KMM, NHK.  Data anlysis: KMM.  Data 
interpretation: KMM, FPR, MCHM.  Drafting manuscript: KMM.  Revising 
manuscript content: KMM, MCHM, FPR.  Approving final version of manuscript: all 
authors.  KMM takes responsibility for the integrity of the data analysis. 
 
Appendix A is in press: 
Melville KM, Robling AG, van der Meulen MCH (2014) Axial tibial loading 
of bone.  AJ van Wijnen, JJ Westendorf, eds. Osteoporosis and Osteoarthritis, 
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Chapter 2  
FEMALE MICE LACKING ESTROGEN RECEPTOR-ALPHA IN 




2.1  Introduction 
Osteoporosis, characterized by low bone mass, greatly increases skeletal 
fracture risk.  Each year in the United States, osteoporotic fractures affect 1.5 million 
individuals and cost $17 billion in treatment (1).  Due to the increasingly aged 
population, by 2025 treatment costs are predicted to rise to $25 billion (2).  To reduce 
this economic burden and the cost of patient suffering, clinical strategies to maintain 
and even increase bone mass are essential and require understanding the complexity of 
cell signaling in bone. 
Bone mass is regulated by a number of factors, including the sex hormones 
estrogen and testosterone, circulating parathyroid hormone (PTH) and insulin-like 
growth factor (IGF-1), and biophysical stimuli including the mechanical environment. 
By suppressing bone resorption and remodeling, estrogen regulates bone mass in both 
men and women during pubertal growth and throughout adulthood (3-5).  At the onset 
of menopause, women experience a sharp decline in circulating estrogen that is 
accompanied by decreased bone mineral density, which can lead to osteoporosis and 
increased fracture risk (6, 7).  Primarily due to this rapid hormonal decline, the 
majority of osteoporosis-related fractures occur in women (8).  However, reduced 
bone mass and unfused growth plates were found in a male with an inactivating point 
mutation in the estrogen receptor alpha (ERα) gene, indicating that estrogen plays a 
role in bone mass in both sexes (9).  Other research has also highlighted the 
                                                 
1
 Reprinted with permission: Melville KM, Kelly NH, Khan SA, Schimenti JC, Ross FP, Main RP, van 
der Meulen MCH.  Osteoblast-specific Estrogen Receptor Alpha Knockout Mice Have Compromised 
Bone Mass and Strength.  JBMR 2014. 29(2):370-9. 
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importance of estrogen in the male skeleton and the pathogenesis of osteoporosis (10).  
While estrogen acts through two estrogen receptors (ER), ERα and ERβ, coded 
by separate genes, the steroid impacts bone mainly via ERα, which is present in 
chondrocytes, osteoblasts, osteocytes, and osteoclasts (3). Studies of global ERα 
knockout (ERαKO) mice show that ERα has a profound effect on bone tissue in 
growing and adult animals (11-13).  Focusing on females, ERαKO mice had shorter 
bones compared to littermate controls during growth and maturation, in addition to 
increased cancellous and cortical bone mineral density in the tibia (14-17).  
Importantly, estrogen acts through ERα and/or ERβ in many organ systems, not 
limited to bone, resulting in confounding systemic effects in female global ERαKO 
mice, including increased body and uterine masses (15, 17).  Also, serum levels of 
estrogen and testosterone were both increased (12, 17, 18), while that of serum IGF-1 
was decreased (17).  Because estrogen and IGF-1 are major independent regulators of 
bone mass, the role of ERα in bone is difficult to isolate and interpret in mice lacking 
the gene globally.  Given these facts, a logical approach is to delete the gene in 
individual bone cell types with the goal of gaining a better understanding of the cell-
specific effects of estrogen signaling, knowledge that will contribute to prevention of 
fractures and new treatments for osteoporosis. 
Recent generation of bone-specific ERαKO mice revealed that expression of 
the receptor in chondrocytes, osteoblast progenitors, osteoblasts, osteocytes, or 
osteoclasts is important for maintaining bone mass during both growth and aging. 
However, the relationships between ERα and cancellous and cortical bone in females 
and males are complex and conflicting (19-23).  Osteoclast-specific female ERαKO 
mice exhibited osteoporosis with cancellous architecture similar to that seen in post-
menopausal women, due to reduced apoptosis of osteoclasts and subsequent high bone 
turnover rates, but cortical bone was unaffected (22, 23).  When ERα was deleted from 
 33 
 
osteoblast progenitors, cortical but not cancellous bone mass was reduced in males and 
females (19).  In osteocyte-specific ERαKO mice, cortical bone was unaffected in both 
sexes, while cancellous bone was reduced in males but not females (21).  Use of OC-
Cre mice to delete ERα in osteoblasts reduced cancellous and cortical bone mass in 
females only, but no changes in bone mass in either sex were found when the gene 
was deleted in osteoblasts using col1a1-Cre mice (19, 20).  To study the skeletal 
structural compromise that occurs with osteoporosis, bone strength, which is 
dependent upon bone mass, bone architecture, and material properties, must be 
considered (24).  Importantly, the effect of ERα deletion in osteoblasts on whole bone 
strength at cortical and cancellous sites has not been studied in these models. 
Therefore, the aim of this work was to determine the role of ERα in osteoblasts 
and osteocytes on cortical and cancellous bone mass and strength.  To this end, we 
bred female osteoblast-specific ERαKO mice using the osteocalcin-Cre mouse.  
Having eliminated the possible role of systemic effects, we focused on relating bone 
mechanics to skeletal phenotype using micro-computed tomography, histology, 
dynamic histomorphometry, and whole bone mechanical testing in growing and 
skeletally mature mice. 
 
2.2  Methods 
2.2.1 Generation of osteoblast-specific ERαKO mice (pOC-ERαKO) 
pOC-ERαKO mice were generated by breeding mice with exon 3 of the DNA-
binding domain of the ERα gene (Esr1) flanked by loxP sequences, ERαfl/fl (13), to 
mice containing a transgene encoding Cre recombinase driven by the human 
osteocalcin promoter, OC-Cre,  provided by Dr. Thomas Clemens (The Johns Hopkins 
University, Baltimore, MD) (25, 26).  The resulting compound heterozygous mice, 
OC-Cre;ERαfl/+, were bred back to ERαfl/fl mice to produce female osteoblast-specific 
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ERα knockout mice, OC-Cre;ERαfl/fl (pOC-ERαKO), and littermate controls, ERαfl/+ 
(LC).  The OC-Cre mice were inbred to the C57BL/6 strain, while ERαfl/fl mice were 
on a mixed C57Bl/6 and 129Sv background. Mice were housed 3-5 per cage with 
12:12 light:dark hour cycles with ad libitum access to food and water.  All animal 
procedures were approved by Cornell University’s Institutional Animal Care and Use 
Committee. 
Mouse genotyping was conducted by lysed tail PCR using the primers: 5’-
CAAATAGCCCTGGCAGAT-3’ (forward) and 5’-TGATACAAGGGACATCTTCC 
-3’ (reverse) to detect the Cre transgene, while the floxed ERα gene was detected 
using the primers: 5’-TGGGTTGCCCGATAACAATAAC-3’ (forward) and 5’-
AAGAGATGTAGGGCGGGAAAAG-3’ (reverse).   
 Femoral shaft DNA was purified for PCR to detect the floxed ERα gene using 
the primers above.  Briefly, femurs were dissected, the bone marrow was flushed, and 
bone ends were cut off to isolate the diaphysis.  DNA purification was performed 
following the manufacturer’s instructions (QIAamp DNA mini kit, Qiagen). 
 
2.2.2 Mass and Serum Hormone Measurements 
 Female LC and pOC-ERαKO mice were aged to 12 (LC n=16, pOC-ERαKO 
n=17) and 18 weeks of age (LC n=10, pOC-ERαKO n=10).  Body mass was recorded 
at 4, 8, 12, and 18 weeks of age. Ovarian and uterine mass were measured at 12 and 18 
weeks of age.  Blood was collected through cardiac puncture at euthanasia, kept on ice 
for 4 hours, and then stored at 4°C overnight.  Blood was centrifuged at 2,000g for 20 
min to obtain serum, which was stored at -20°C.  Serum was assayed using kits for 
estrogen (E2, CalBiotech EW180S-100, Spring Valley, CA), testosterone (T, 
CalBiotech TE187S-100, Spring Valley, CA, 12wk mice only), osteocalcin (OC, 
ALPCO 31-50-1300, Salem, NH), IGF-1 (ALPCO 22-IGF-R21, Salem, NH), and 
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TRACP5b (IDS SB-TR103, Scottsdale, AZ).  T, OC, and IGF-1 assays were 
performed by the MECORE Laboratory (St. Joseph Hospital, Bangor, ME). 
2.2.3 Microcomputed Tomography 
 Right tibiae were harvested and fixed in 4% paraformaldehyde for 24hr at 4°C 
and then transferred to 70% ethanol.  Right femora and L5 vertebrae were harvested, 
wrapped in PBS-soaked gauze, and stored at -20°C.  Bones were scanned using 
microcomputed tomography (microCT) at room temperature with an isotropic voxel 
resolution of 15μm (μCT35, Scanco Medical AG, Switzerland; 55kVp, 145μA, 600ms 
integration time).  In each tibia, two volumes of interest (VOIs) were analyzed: a 
cancellous region manually contoured in the proximal tibia excluding the cortical shell 
beginning ~0.5mm distal to the growth plate and extending 10% of total bone length, 
and a cortical region centered at the midshaft and extending 2.5% of total bone length.  
In the distal femur, cortical bone was manually separated from cancellous bone 
beginning ~0.5mm proximal to the distal growth plate and extending 2mm proximally.  
In each vertebra, cortical bone was manually separated from cancellous bone 
extending the entire height of the vertebra.  Measurable outcomes for cancellous 
regions included bone volume fraction (BV/TV), trabecular thickness (Tb.Th), 
trabecular separation (Tb.Sp), and cancellous tissue mineral density (cn.TMD).  
Measurable outcomes for the cortical regions included cortical area (Ct.Ar), marrow 
area (Ma.Ar, tibia only), total area (T.Ar, tibia only), maximum and minimum 
moments of inertia (IMAX, IMIN), cortical thickness (Ct.Th), and cortical tissue mineral 
density (ct.TMD).  Mineralized tissue was separated from non-mineralized tissue 
using age- and bone-specific thresholds.   
 
2.2.4 Dynamic Histomorphometry 
 Ten and 3 days before euthanasia, mice were administered calcein through 
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intraperitoneal injection (30mg/kg).  Left tibiae were dissected at euthanasia and fixed 
in 70% ethanol.  Bones were embedded in acrylosin and sectioned with a D profile 
tungsten-carbide blade to 5μm thickness using a rotary microtome (Leica RM2265, 
Germany) by the Bone Histology/Histomorphometry Laboratory (Yale University 
Department of Orthopaedics and Rehabilitation, New Haven, CT).  Two slides per 
mouse and 4-5 mice per genotype were analyzed to measure single and double 
fluorescent labels on cancellous bone in longitudinal sections of the proximal tibia and 
on cortical bone in transverse sections of the tibial midshaft (OsteomeasureXP 
v3.2.1.7, Osteometrics, Decatur, GA).  Outcome measures were mineralizing surface 
(MS), mineral apposition rate (MAR), and bone formation rate (BFR).  
 
2.2.5 Histology 
 After microCT scanning, right tibiae from both 12- and 18-week-old animals 
were decalcified for 2 weeks in 10% EDTA, embedded in paraffin, and sectioned 
longitudinally in the sagittal plane at 6μm thickness using a rotary microtome (Leica 
RM2255, Germany).   
To measure growth plate thickness, five evenly spaced lines were averaged for 
2 slides per mouse, 6 mice per genotype on sections stained with Safranin O/Fast 
Green/Alcian Blue (OsteomeasureXP v3.2.1.7, Osteometrics, Decatur, GA).   
To quantify osteoclast number, sections of the proximal tibiae were stained for 
tartrate-resistant acid phosphatase (TRAP).  Sections were deparaffinized and 
rehydrated, and then placed in TRAP buffer for 10 min (3.28g Na-acetate, 46.01g Na-
tartrate in 1L distilled water; Sigma-Aldrich).  Sections were then incubated at 37°C in 
TRAP staining solution for 100min (40mg Napthol AS-MIX, 4mL N-N-
dimethylformamide, 240mg Fast Red Violett LB Salt, 2mL Triton X-100; Sigma-
Aldrich, in 200mL TRAP buffer).  After counterstaining with hematoxylin, sections 
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were dehydrated and cover slipped.  Beginning distal to the primary spongiosa, the 
number of positively-stained osteoclasts in the cancellous tissue normalized to bone 
surface was counted for 2 slides per mouse, 6 mice per genotype.   
For pro-collagen I and ERα immunostaining, longitudinal sections of the 
proximal tibiae were deparaffinized and rehydrated.  Antigen retrieval was achieved 
using 0.1M hot citrate buffer (20min pro-collagen I, 10min ERα).  Endogenous 
peroxidase blocking was performed with 2% hydrogen peroxide (5 min), 2.5% 
periodic acid (5 min) and 0.02% sodium borohydride (5 min).  Protein blocking was 
done using serum-free protein block for 20min for pro-collagen I (Dako) and using 
goat normal serum for 4hr for ERα (Vectastain ABC kit).  Sections were incubated in 
either anti-pro-collagen I primary antibody (undiluted, SP1.D8, Developmental 
Studies Hybridoma Bank, Iowa City, IOWA) or anti-ERα primary antibody (1:100, 
abcam 75635, Cambridge, MA) overnight.  Secondary antibody was delivered for 1hr 
(anti-mouse IgG for pro-collagen I and anti-rabbit IgG for ERα, Vectastain ABC kits), 
and staining was visualized using diaminobenzidine.  Sections were dehydrated and 
cover slipped.  For osteoblast activity, the number of positively-stained osteoblasts for 
pro-collagen I was counted and normalized to bone surface for 2 slides per mouse, 6 
mice per genotype in the cancellous tissue beginning distal to the primary spongiosa.   
 
2.2.6 Mechanical Testing 
 Prior to testing all bones were thawed to room temperature and kept moist in 
PBS.  Femur length, and vertebral height, length, and width were measured using 
calipers.  Right femora were loaded to failure in three-point bending in the anterior-
posterior direction with a span length of 6 mm at a rate of 0.1 mm/s (858 Mini Bionix, 
MTS, Eden Prairie, MN).  L5 vertebrae were loaded in compression at a rate of 0.05 
mm/s to failure.  For femora, bending strength and stiffness were calculated from load 
 38 
 
and displacement data.   For vertebrae, compressive strength and stiffness were 
calculated (27).   
2.2.7 Statistics  
 Differences between pOC-ERαKO and LC mice for mass, serum (except for 
TRAP5b), and histomorphometry were determined using Student’s t-tests in each age 
group.  For microCT, mechanical testing, TRAP5b serum levels, and histology (pro-
collagen I, TRAP, growth plate thickness), a 2-factor ANOVA (age, genotype) with 
interaction was used with Tukey’s HSD post-hoc (JMP Pro 10).  Significance was set 
at p<0.05.   
 
2.3 Results 
2.3.1 Generation and characterization of pOC-ERαKO mice 
To study the effects of ERα absence in osteoblasts on bone strength, we 
crossed mice expressing the floxed ERα gene with animals transgenic for Cre driven 
by the human osteocalcin promoter.  Mice were viable and born at the expected 
Mendelian ratio.  The absence of ERα in osteoblasts in pOC-ERαKO mice was 
confirmed by PCR of genomic DNA of femoral shafts and ERα IHC in the proximal 
tibia (Figure B.1).   
As others have reported, we found Cre expression in hypertrophic 
chondroctyes in addition to osteoblasts and osteocytes when OC-Cre mice were 
crossed with ROSA26-Cre reporter mice and longitudinal tibial sections were stained 
with X-Gal to detect β-galactosidase activity (data not shown) (28).  However, we 
found no subsequent growth plate effects in the pOC-ERαKO mice.   Specifically, the 
growth plates in the pOC-ERαKO mice had normal cell alignment and organization, 
and did not differ in thickness compared to LC mice at 12 or 18 weeks of age (Figure 
2.1, Table 2.1).  In addition, femoral and tibial lengths were not different between 
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pOC-ERαKO and LC mice in either  age group, indicating normal endochondral 






Figure 2.1 Representative IHC, histology, and dynamic histomorphometry images for 
sagittal sections of the proximal tibiae of pOC-ERαKO and LC female mice.  (A) 
Tibial growth plate thickness did not differ between pOC-ERαKO and LC based upon 
measures from growth plates stained with Safranin-O.  (B) In the cancellous bone of 
the proximal tibia, fewer osteoblasts per bone surface were positive for pro-collagen I 
activity (red arrow) in pOC-ERαKO compared to LC.  (C) Osteoclast number 
normalized to bone surface was similar between pOC-ERαKO and LC mice at both 
age groups as indicated by TRAP staining in cancellous bone in the proximal tibia. 
(D) Reduced cancellous bone volume fraction is apparent in undecalcified sections of 
the proximal tibiae in pOC-ERαKO mice compared to LC.  Dynamic 
histomorphometry measurements from double calcein labeling were not significantly 
different between genotypes.  Scale bar = 20μm for A, B; 80μm for C, D.  A, B, C, are 
at 12wk and D is at 18wk.  
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LC pOC-ERαKO LC pOC-ERαKO 
GP.Th (mm) 0.117 ± 0.0051 0.114  ± 0.0038 0.106 ± 0.014 0.109 ± 0.024 
N.Ob/BS (mm
-1
) 3.44 ± 1.8 2.00 ± 0.88
a  2.07 ± 0.98 1.36 ± 1.1a 
N.Ocl/BS (mm
-1
) 3.44 ± 0.21 3.47 ± 0.60 2.06 ± 0.65
b 1.43 ± 0.46b 
Data are represented as mean ± SD.  GP.Th, growth plate thickness; N.Ob, number 
of positively stained osteoblasts for pro-collagen I; BS, bone surface; N.Ocl, number 
of positively stained osteoclasts for TRAP.   
apOC-ERαKO different from LC, b18wk different from 12wk, p < 0.05 by 2-factor 
ANOVA with interaction. 
 In contrast to the global ERαKO mice, systemic effects were not present in our 
osteoblast-specific ERαKO mice.  No differences in body, ovarian, or uterine mass 
were measured between female pOC-ERαKO and LC mice (Table B.1).  Altered 
serum levels of E2, T, IGF-1, and OC found in the global ERαKO mouse that may 
have produced secondary skeletal effects were eliminated in this tissue-specific 
knockout model; these parameters were all similar between pOC-ERαKO female mice 
and LC (Figure 2.2).    
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2.3.2 Bone mass and architecture 
 Previously, bone mass was altered in both global and bone-specific ERαKO 
mice.  In our osteoblast-specific ERαKO mouse, cancellous bone mass was severely 
reduced at the three sites examined compared to LC mice at 12 weeks of age (Figure 
2.3, Table 2.2).  Bone volume fraction (BV/TV) was significantly reduced in the 
proximal tibia (-35%), L5 vertebral body (-35%), and distal femur (-30%).  The same 
decrease in all measured parameters continued in 18-week-old animals.  Mean BV/TV 
 
Figure 2.2 Unlike global ERαKO mice, serum levels of estrogen (A), testosterone (B), 
IGF-1 (C), and osteocalcin (D) were unaltered in female pOC-ERαKO mice compared 
to controls at both 12 and 18 weeks of age (n=6-10 per genotype per age).  Data are 
represented as mean ± SD. 
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remained significantly less in the proximal tibia (-7%), vertebra (-44%), and distal 





Figure 2.3 Lack of ERα in osteoblasts significantly reduced cancellous and cortical 
bone mass in pOC-ERαKO female mice.  Sagittal sections through the proximal 
tibiae, L5 vertebrae, and distal femora are shown from representative microCT scans 
of 12-week-old female pOC-ERαKO and LC mice.  Bone volume fraction was 
reduced 35% in the proximal tibia, 35% in the L5 vertebra, and 30% in the distal 
femur.  Cortical area was reduced 4% in the L5 vertebra and 13% in the distal femur.  




Table 2.2 Cancellous parameters measured by microCT for the proximal tibia, L5 




Changes in cancellous trabecular architecture correlated with decreased bone 
mass (Table 2.2).  Reduced BV/TV in pOC-ERαKO mice was due primarily to 
increased trabecular separation (Tb.Sp), which was markedly increased in all three 
cancellous sites at both ages. The proximal tibia had the greatest increase in Tb.Sp, 
which was increased 45% at 12wk and 60% at 18wk in pOC-ERαKO mice.  In the 
distal femur, Tb.Sp was increased in pOC-ERαKO mice compared to LC in both 12- 
and 18-week-old animals (+40% and +76%, respectively), and in the vertebra (+14% 
and +25% for 12wk and 18wk, respectively).  Regardless of bone site or genotype, 
Tb.Sp increased with age in all animals.  Trabecular thickness (Tb.Th) was decreased 
in pOC-ERαKO mice compared to LC in both age groups only in the vertebra (-14% 
and -21% at 12 and 18wk, respectively), contributing to the overall reduced vertebral 
BV/TV.  Tb.Th, like Tb.Sp, increased significantly with age in the tibiae and vertebra, 
but not in the femur. 
Cancellous tissue mineral density (cn.TMD) was not affected by osteoblast-
specific deletion of ERα (Table 2.2).  However, cn.TMD decreased significantly with 
age at the proximal tibia (-3% LC, -5% pOC-ERαKO) but increased with age in the 
distal femur (+4% LC, +2% pOC-ERαKO). 
The cancellous changes in the corticocancellous distal femur and vertebra of 
pOC-ERα mice were accompanied by analogous but smaller cortical changes (Table 
2.3).  Cortical area (Ct.Ar) was reduced in the distal femur and L5 vertebra cortexes in 
pOC-ERαKO mice compared to LC at 12wk (-13% and -4%, respectively) and 18wk 
(-14% and -11%, respectively).  This decrease in bone mass corresponded with lower 
overall cortical thickness (Ct.Th) at both sites at 12wk (-8% for femur, -10% for 
vertebra) and 18wk (-14% for both bones).  In the distal femur only, maximum and 
minimum moments of inertia (IMAX,  IMIN) were reduced at 12wk in pOC-ERαKO mice 
(-16% and -17%, respectively) and at 18wk (-11% and -12%, respectively).  In both 
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genotypes, femoral Ct.Ar was greater in 18wk than 12wk mice (+11% for LC, +10% 
for pOC-ERαKO) as were IMAX and IMIN (+16% for both in LC, +23% for both in 
pOC-ERαKO).  Tissue mineral density in the cortical shell (ct.TMD) was reduced in 
pOC-ERαKO mice compared to LC at both ages in the distal femur (-2% at 12wk, -
3% at 18wk), but not in the L5 vertebra.  However, ct.TMD increased with age in the 
L5 vertebra, by 2% in LC and 3% in pOC-ERαKO mice.  In the corticocancellous 
regions of the distal femur and L5 vertebra, decreased bone mass in pOC-ERαKO 
mice was present in both the cortical shell and the cancellous region.  
Cortical bone mass was also reduced compared to LC in the tibial diaphysis, 
but less so than in the cancellous envelope of the metaphysis (Figure 2.4).  At the 
tibial midshaft, Ct.Ar was decreased in both 12- and 18-week-old female pOC-
ERαKO mice compared to LC (-8% and -7%, respectively) (Table 2.3).  At both ages, 
this decrease in bone mass was due to decreased Ct.Th (-7% at both ages) and lower 
ct.TMD (-2% at 12wk, -1% at 18wk).  In older animas, Ct.Th and ct.TMD were 
significantly greater than younger animals for both genotypes.  IMAX at the tibial  
 
Figure 2.4 Deletion of ERα from osteoblasts reduced cortical bone mass.  
Transverse sections at the tibial midshaft from microCT scans of 12-week-
old female pOC-ERαKO (top) and LC mice (bottom) are shown.  Cortical 
area was 8% less in 12-week-old pOC-ERαKO mice compared to LC.  Scale 
bar = 0.25mm. 
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 Table 2.3 Cortical parameters measured by microCT for the tibial 
midshaft, L5 vertebra, and distal femur of 12- and 18-week-old female 
pOC-ERαKO and LC mice 
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midshaft was not affected by osteoblast-specific ERα deletion, but the minimum 
moment of inertia IMIN was significantly reduced in pOC-ERαKO mice at both ages (-
19% at 12wk and -14% at 18wk).  Marrow area in the tibial midshaft was also 
unchanged by ERα deletion in osteoblasts; thus, the smaller cortex reflected a lack of 
periosteal expansion along the minimum axis. 
 
2.3.3 Bone cell activity 
Decreased BV/TV in the cancellous tissue of the proximal tibiae of pOC-
ERαKO mice reflected changes in osteoblast activity (Figure 2.1).  When normalized 
to bone surface, the number of pro-collagen I-positive osteoblasts was decreased in 
pOC-ERαKO females compared to LC at 12wk (-42%) and 18wk (-34%) (Table 2.1).  
Systemically, serum TRACP5b levels were reduced in pOC-ERαKO mice at both 
12wk (-29%) and 18wk (-37%), reflecting the decreased cancellous bone mass 
(Figure 2.5).  However, local osteoclast number indicated by TRAP staining was not 
different between genotypes at either age when normalized to bone surface in the 
proximal tibia (Figure 2.1, Table 2.1).   
Decreased bone mass was evident in undecalcified longitudinal sections of the 
proximal tibia of pOC-ERαKO animals (Figure 2.1), but dynamic histomorphometric 
measurements were not statistically different between genotypes for either cancellous 
bone in the proximal tibia or at endosteal or periosteal surfaces at the tibial midshaft. 
  
2.3.4 Whole bone strength 
The decreases in cortical and cancellous bone mass and compromised 
architecture resulting from deletion of ERα in osteoblasts corresponded to 
compromised whole bone strength.  In both age groups, vertebral and femoral strength 




mechanical testing to failure (Figure 2.6).  Femoral bending strength was reduced 
11% at 12wk and 10% at 18wks, while vertebral strength was reduced 25% at both 
ages in pOC-ERαKO mice.  Bone strength increased significantly with age (+27% 
femur, +17% vertebra for pOC-ERαKO; +26% femur, +18% vertebra for LC).  
Interestingly, vertebral compressive strength correlated linearly with BV/TV for LC 
but not pOC-ERαKO mice through regression analysis (Figure B.3).  BV/TV 
accounted for 43% of the variation in vertebral compressive strength for LC mice 
(p=0.0006) but BV/TV had no predictive value for vertebral strength in pOC-ERαKO 
mice.   Although femoral bending stiffness was decreased in pOC-ERαKO mice 
compared to LC at both 12wk (-13%) and 18wk (-15%), vertebral compressive 
stiffness was not significantly different between genotypes.  Femoral and vertebral 
stiffness also increased significantly with age (+40% femur, +43% vertebra for pOC-
ERαKO; +42% femur, +34% vertebra for LC).    
 
Figure 2.5 pOC-ERαKO mice had significantly lower TRACP5b levels at both 12 
and 18 weeks of age, indicating reduced osteoclast number resulting from lower 
bone mass.  Data are represented as mean ± SD.   
a
pOC-ERαKO different from 
LC, 
b





 We successfully deleted ERα from osteoblasts and osteocytes in female mice 
by mating ERαfl/fl and OC-Cre mice without producing systemic hormone effects.  
Serum E2, T, IGF-1, and OC were unchanged in pOC-ERαKO mice, as were ovarian 
and uterine masses, confirming the lack of systemic effects that may independently 
alter bone phenotype.  During growth, the pOC-ERαKO and LC mice did not differ in 
 
Figure 2.6 Whole bone strength and stiffness were compromised in pOC-ERαKO 
female mice.  (A) In three-point bending to failure, pOC-ERαKO female mice had 
decreased femoral bending strength at both 12 weeks (-11%) and 18 weeks (-10%) 
of age.  (B) L5 vertebrae of pOC-ERαKO female mice were 25% weaker at both 12 
and 18 weeks of age in compression testing to failure.  (C) Femur bending stiffness 
was reduced 13% and 15% in 12- and 18-week-old pOC-ERαKO mice, respectively, 
compared to LC.   (D) Vertebral compressive stiffness was not different between 
genotypes.  n=10-17 per genotype and age.  Data are represented as mean ± SD.  
a
pOC-ERαKO different from LC, b18wk different from 12wk, p<0.05 by 2-factor 
ANOVA with interaction. 
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body mass, and long bone lengths were similar between genotypes at both 12 and 18 
weeks of age.  In contrast, the pOC-ERαKO mice had decreased cancellous and 
cortical bone mass compared to littermate controls, which negatively impacted whole 
bone strength and stiffness, indicating that ERα in osteoblasts is a critical component 
of successful accrual of bone mass and strength in female mice. 
The role of ERα in bone was studied initially using global ERαKO mice, 
which have a drastically different skeletal phenotype opposite that seen in our pOC-
ERαKO and other osteoblast-specific ERαKO mouse models (11-13).  While our 
pOC-ERαKO female mice had decreased cancellous and cortical bone mass, the 
global ERαKO female mice had increased bone mass and bone mineral density (16, 
17).  However, systemic effects indicate that other tissues were affected by global ERα 
deletion. Female mice had increased serum estrogen levels leading to increased uterine 
mass and decreased serum IGF-1 levels resulting in shorter bones (12, 15, 17, 18).  
Because estrogen and IGF-1 have major indirect actions on bone (29, 30), the skeletal 
phenotype seen in the global ERαKO mice is influenced by these secondary effects 
and those arising from the direct role of ERα in bone.  These conflicting results led 
researchers to create conditional knockouts, such as our pOC-ERαKO mouse. 
Estrogen acts in bone-residing cells primarily through ERα to alter gene 
transcription, but also exhibits non-genomic effects (31, 32) and so is likely to have 
distinct effects on different lineages as they mature and differentiate, as has been 
shown though osteoblast lineage deletions of RANKL (28).  Recently, two other 
conditional ERαKO mouse models focusing on osteoblasts were generated, with 
results that are similar to ours or in significant conflict with ours.  Määttä et al. also 
used the OC-Cre promoter transgenic mouse to create animals with an osteoblast-
specific deletion of ERα (ERαΔOB/ΔOB) (20).  Bone phenotype was analyzed in both 
males and females at 3.5, 6, and 12 months of age.  As in our 12- and 18-week-old 
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pOC-ERαKO mice, BV/TV in the proximal tibia and cortical bone volume at the tibial 
diaphysis were reduced in female ERαΔOB/ΔOB mice at 3.5 months.  However, this 
phenotype disappeared with age.  At 6 months, bone mass was still decreased in the 
proximal tibia, but Tb.Sp was no longer different between genotypes, while by 12 
months of age, no tibial cancellous phenotype difference was seen by microCT 
analysis in the tibiae.  We cannot confirm their results for older mice, as our study 
only included growing (12 wk) and skeletally mature (18 wk) animals.   
In contrast to the work of Määttä et al. and our study, Almeida et al. found no 
cortical or cancellous bone phenotype in a female osteoblast-specific ERαKO mouse 
(ERαf/f;Col1a1-Cre), using the Col1a1-Cre promoter, which is expressed in mature 
osteoblasts and osteocytes (19).  Femoral cancellous bone mass and cortical thickness 
were unaltered in 12- and 26-week-old female mice, and spine and femoral BMD were 
unchanged in female mice from 4 to 12 weeks of age.  However, when the same 
authors deleted ERα in osteoblast progenitor cells using either Osx-Cre or Prx-Cre 
mice, BMD of the femur and cortical thickness in the femur mid-diaphysis were 
decreased in female mice, but cancellous bone mass remained unchanged at the 
proximal femur.  These findings indicate that ERα is not required in either osteoblasts 
or their progenitors for cancellous bone mass accrual in females; in contrast, cortical 
bone was affected by absence of ERα in osteoblast progenitors but not mature 
osteoblasts.  Much of the discrepancy in the results found in ERαf/f;Col1a1-Cre model 
vs. the ERαΔOB/ΔOB models and our pOC-ERαKO models can be attributed to the use of 
different Cre models and timing of their cellular effects.  The OC-Cre targets 
osteoblasts during the mineralization phase, while the Col1a1-Cre targets osteoblasts 
earlier, during the matrix maturation phase (33).  Interestingly, when ERα was ablated 
only in mature osteocytes using the 10kb DMP1-Cre mouse, cancellous and cortical 
bone were both unaffected in female mice, suggesting that ERα may play a stronger 
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role in osteoblasts than in osteocytes when combined with our study’s results (21).   
The OC-Cre mouse is an established model used to ablate genes in mature 
osteoblasts and osteocytes (26).  Crossing these mice with ROSA26-Cre reporter mice 
has shown that Cre expression is limited to osteoblasts and osteocytes, but expression 
in hypertrophic chondrocytes has been reported (28, 34).  Because hypertrophic 
chondroctyes differentiate into osteoblasts during endochondral ossification, the 
possible effects of ERα in growth plate cartilage cannot be ignored in examining the 
bone phenotypes of pOC-ERαKO mice.  In a cartilage-specific ERαKO female mouse, 
the skeleton developed normally during growth, but continued to grow beyond 4 
months of age, resulting in increased femur length compared to controls (35).  Femoral 
growth plate height, however, was not different between cartilage-specific ERαKO 
mice and controls, which is consistent with our results, in which tibial growth plate 
height and long bone lengths were similar between pOC-ERαKO and LC.  In contrast, 
female ERαΔOB/ΔOB at 3.5 months of age had increased tibial growth plate height 
compared to controls but no difference in bone length (20).  While we cannot explain 
the growth plate discrepancy between similarly generated mice, we can infer that the 
skeletal phenotype seen in pOC-ERαKO is indeed bone-mediated as opposed to an 
effect on cartilage because bone lengths and growth plate structure were unaffected. 
Although mouse models cannot directly translate to human clinical data, ERα 
clearly plays an important role in both the mouse and human skeletons. In human 
clinical data, a mutation in the ERα gene increased bone mineral density and resulted 
in osteopenic bone (9).  Polymorphisms in ERα are correlated with bone mass in 
humans (36).  Our data show that when ERα is deleted from osteoblasts, bone mass 
and strength are compromised at cortical and corticocancellous sites in female mice, 
pointing to a crucial role of ERα in these cells.  The receptor has been proposed to be 
involved in a number of bone signaling networks, including those activated estrogen, 
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IGF-1, wnt/β-catenin, and BMP-2 (37-39).  The majority of these studies examined 
the interaction between estrogen signaling and other signaling pathways using 
osteoblast cultures in vitro.  Availability of osteoblast-specific ERαKO mice will 
facilitate future studies on osteoblastic ERα signaling in vivo.  As we increase our 
understanding of estrogen signaling in bone, we may have the opportunity to develop 
new drugs for preventing and treating osteoporosis, especially in post-menopausal 
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Chapter 3  
ESTROGEN RECEPTOR ALPHA IN OSTEOBLAST LINEAGE CELLS 
REGULATES BONE MASS DIFFERENTIALLY IN BOTH SEXES AND 
ATTENUATES BONE’S RESPONSE TO MECHANICAL LOADING IN 
FEMALE MICE 
3.1 Introduction 
Sex hormones are important regulators of bone mass in males and females.  
During puberty, estrogens inhibit, while androgens stimulate, periosteal bone 
formation in humans, contributing to generally higher bone mass in males (1).  The 
decline in estrogen associated with menopause is a primary contributor to post-
menopausal osteoporosis in females (2-4).  In men sex hormone levels also decline 
with age and correlate with gradual bone loss (5-7).  Point mutation in estrogen 
receptor alpha (ERα), the primary receptor effector of estrogen in bone, caused 
unfused growth plates and osteoporosis in a single reported human case (8).  Since 
then, the role of ERα in skeletal health in both males and females has been a focus (9-
11). 
To better understand the role of estrogen in bone cells, global ERα knockout 
(ERαKO) and cell-specific ERαKO mice that remove ERα at specific points in the 
osteoblast-osteocyte lineage were developed.  However, outcomes are conflicting 
concerning the cortical and cancellous bone status in males and females.  Global 
deletion of ERα increased cancellous and cortical tibial bone mineral density in 
females, but decreased cortical and cancellous bone mass in males (12-16).  However, 
systemic effects that include altered hormone levels and body weight differences 
confound bone results in global knockouts (14, 16).  When ERα was removed from 
osteoblast progenitors or precursors, using Prx1- or Osx-Cre mice, respectively, 
cortical bone mass decreased in females and young males, while cancellous bone was 
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unaffected (17).  ERα deletion in mature osteoblasts (OC-Cre) decreased cortical and 
cancellous bone mass (18, 19), but bone mass was unchanged with deletion in 
committed osteoblasts in females (Col1a1-Cre) (17).  Bone mass in young and 
growing male mice was unaffected by ERα deficiency in osteoblasts in both targeted 
knockouts.  Finally, when ERα was removed from osteocytes (Dmp-1-Cre), female 
and male mice exhibited no change in or decreased bone mass, respectively (20, 21).   
 Bone is mechanosensitive. Bone mass can increase in response to dynamic 
loading, but decreases with disuse in adult animals (22, 23).  In vivo rodent loading 
models are established methods for studying the response of cancellous and cortical 
bone to controlled, dynamic bone loading (24-26).  Although ERα has been implicated 
in bone mechanotransduction (27, 28), the response to mechanical loading has not 
been well-studied in bone cell-specific ERαKO mice.  ERα in females has no effect on 
bone’s anabolic response to mechanical loading when removed at the osteocyte stage 
of the lineage (20).  In male mice, the response to mechanical loading has not been 
reported in any bone cell-specific ERαKO mouse.   
No study to date has investigated cancellous and cortical bone adaptation to 
mechanical loading in male and female mice generated using the OC-Cre to remove 
ERα at the stage of mature osteoblasts (pOC- ERαKO). To generate these animals and 
littermate controls we crossbred OC-Cre and ERα floxed mice.  At 10 weeks of age, 
we subjected the left tibiae to two weeks of in vivo mechanical loading, with the right 
limb as an internal control, and analyzed bone mass and architecture through 
microCT, dynamic histomorphometry, and immuno-histochemistry (IHC).  In 
addition, we examined bone mass, morphology, and strength of L5 vertebrae and 
femoral midshafts in LC and targeted animals.  We hypothesized that ERα deficiency 
in mature osteoblasts and osteocytes would decrease bone mass in both female and 




3.2  Methods 
3.2.1 Generation of osteoblast-specific ERαKO mice 
 pOC-ERαKO and littermate control (LC) mice were generated by breeding 
mice containing a transgene encoding Cre recombinase driven by the human 
osteocalcin promoter (OC-Cre, provided by Dr. Thomas Clemens, The Johns Hopkins 
University, Baltimore, MD) (29, 30) with mice in which exon 3 of the DNA-binding 
domain of the ERα gene (Esr1) was flanked by loxP sequences (ERαfl/fl, provided by 
Dr. Kahn, University of Cincinnati, Cincinnati, OH) (31).  Mice were inbred to be 
>99% pure C57Bl/6 by speed congenics (DartMouse Speed Congenic Core Facility, 
Geisel School of Medicine at Dartmouth, Hanover, NH) and genotyped as described 
(19).  Mice were housed 3-5 per cage with ad libitum access to food and water.  All 
animal procedures were approved by Cornell University’s IACUC. 
 
3.2.2 In vivo tibial mechanical loading 
 At ten weeks of age, single element strain gauges (EA-06-015LA-120, 
Micromeasurements) were surgically attached to the tibial midshafts of female and 
male LC and pOC-ERαKO mice (n=5-6 per genotype).  A series of cyclic compressive 
loads (-2 to -12N) were applied to the left and right tibiae in our custom tibial loading 
device, and bone stiffness was calculated from the load and strain data as previously 
described (32).  Bone stiffness was used to calculate the peak load required to induce 
1200 microstrain (με) at the tibial midshaft during compressive tibial loading.  Bone 
stiffness was similar among pOC-ERαKO and LC male and female mice (0.00671 ± 
0.0010 N/µε LC female, 0.00763 ± 0.00068 N/µε pOC-ERαKO female, 0.00760 ± 
0.00029 N/µε LC male, 0.00767 ± 0.00016 N/µε pOC-ERαKO male). A peak load of -
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9.0N was applied to all animals in the subsequent loading experiment. 
 The left tibiae of male and female LC and pOC-ERαKO mice (n=12-14 per 
group) were loaded in compression in vivo for 2 weeks (32).  In brief, a cyclic 
compressive load was applied at a rate of 4Hz for 1200 cycles per day, 5 days per 
week, in a triangular waveform with a peak load of -9.0N, dwell of 100ms between 
successive load cycles, and dwell load of -0.5N.     
 
3.2.3 Mass and serum marker measurements 
 Three days after the last day of mechanical loading, mice were euthanized via 
isoflurane overdose and cardiac puncture.  Blood was stored overnight at 4°C and 
centrifuged at 2,000rpm for 20min to separate serum.  Serum was assayed (n=8-10 per 
group) for estrogen (E2, females only, CalBiotech EW180S-100, Spring Valley, CA), 
insulin-like growth factor 1 (IGF-1, ALPCO 22-IGF-R21, Salem, NH), osteocalcin 
(OC, ALPCO 31-50-1300), tartrate-resistant acid phosphatase 5b (TRAP5b, IDS SB-
TR103, Scottsdale, AZ), and pro-collagen I N-terminal peptide (PINP, MyBioSource 
703389).  Body mass and female uterine and ovarian masses were recorded at 
euthanasia. 
 
3.2.4 Microcomputed tomography 
 At euthanasia, left and right tibiae were stored overnight in 4% 
paraformaldehyde or 70% ethanol and then scanned in 70% ethanol at 15µm voxel 
resolution (μCT35, Scanco Medical AG, Switzerland; 55kVp, 145μA, 600ms 
integration time).  Mineralized tissue was separated from non-mineralized tissue using 
gender- and bone-specific thresholds.   For each tibia, the metaphyseal cancellous core 
and cortex were analyzed separately, and the cortical midshaft analyzed as previously 
described (19). 
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 Right femora and L5 vertebrae were wrapped in PBS-soaked gauze and stored 
at -20°C prior to microCT scanning at 15um resolution.  The cancellous core and 
cortical shell of the vertebrae were analyzed as previously described (19). For the 
femur, a cortical volume of interest extending 0.5 mm, centered at the midshaft, was 
analyzed. 
 Cancellous bone outcome measures were bone volume fraction (BV/TV), 
trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and cancellous tissue 
mineral density (cn.TMD).  Cortical bone outcome measures were cortical area 
(Ct.Ar), marrow area (Ma.Ar, tibial and femoral midshaft only), maximum and 
minimum moments of inertia (IMAX, IMIN), cortical thickness (Ct.Th), and cortical 
tissue mineral density (ct.TMD).   
 
3.2.5 Dynamic histomorphometry 
 Ten and three days before euthanasia, mice (n=6-7 per group) received 
injections of calcein (30mg/kg IP).  After microCT scanning, tibiae were embedded in 
acrylosin and sectioned by the Bone Histology/Histomorphometry Laboratory (Yale 
University Department of Orthopaedics and Rehabilitation, New Haven, CT).  Both 
transverse sections of the tibial midshaft and longitudinal sections of the tibial 
metaphysis were analyzed to measure single and double fluorescent labels on bone 
surfaces (2 slides per animal, OsteomeasureXP v3.2.1.7, Osteometrics, Decatur, GA).  
Measurable outcomes were mineralizing surface (MS), mineral apposition rate 
(MAR), bone formation rate (BFR), and woven bone area (Wo.Ar). 
 
3.2.6 Histology 
 Left and right tibiae not used for dynamic histomorphometry were decalcified 
in 10% EDTA for two weeks, processed, and embedded in paraffin (n=6-7 per group).  
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Tibiae were sectioned longitudinally at 6µm using a rotary microtome (Leica 
RM2255, Germany).  Sections were stained for TRAP and pro-collagen I as 
previously described (19). The number of positively-stained osteoclasts (TRAP) or 
osteoblasts (pro-collagen I) in the cancellous metaphysis was quantified and 
normalized to bone surface (2 slides/animal, OsteomeasureXP v3.2.1.7).  Growth plate 
thickness was quantified from sections stained with Safranin O/Fast Green/Alcian 
Blue by averaging five evenly spaced lines (2 slides per mouse, n=6 mice/group, 
OsteomeasureXP v3.2.1.7).   
 
3.2.7 Mechanical testing 
 Prior to mechanical testing, femora and L5 vertebrae were thawed to room 
temperature and kept moist with PBS.  Femora were testing in three-point bending to 
failure, and vertebrae were tested in compression to failure in the cranial-caudal 
direction as previously described (858 Mini Bionix, MTS, Eden Prairie, MN) (19).  
Whole bone strength and stiffness were determined from the load-displacement data 
for bending and compression. 
  
3.2.8 Statistics 
For serum, bone lengths, in vivo bone stiffness, vertebral and femoral 
microCT, and mechanical testing data, a one-way ANOVA was used for each sex.  In 
comparing the loaded and control tibiae for tibial microCT, dynamic 
histomorphometry, histology, and IHC data, a repeated measures ANOVA with 
interaction was used for each sex with a Tukey HSD post-hoc test.  The between-
subject factor was genotype, and the within-subject factor was loaded (left) vs. control 
(right).  Significance was set at p<0.05. 
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3.3  Results 
3.3.1 Generation and characterization of pOC-ERαKO mice 
 To determine the role of ERα in osteoblasts in bone growth and in their 
response to mechanical loading, we generated male and female pOC-ERαKO and LC 
by mating OC-Cre and ERαfl/fl mice. Because the global ERαKO mouse possessed 
systemic effects that confound the role of ERα in bone alone (13, 14, 16, 33), we 
measured body weight, crown/rump length, ovarian and uterine weight (females only), 
tibia and femur length, and serum levels of E2 and IGF-1 (Figure C.1, Table C.1).  
All outcome measures were similar between pOC-ERαKO and LC within each sex, 
except for femoral length, which was greater in pOC-ERαKO males vs. LC.  
 
3.3.2 Female pOC-ERαKO mice exhibit decreased bone mass 
 To assess changes in bone structure and geometry, microCT analysis was 
performed on the L5 vertebrae, femoral midshafts, and proximal and mid-diaphyseal 
control tibiae (Table 3.1, Table 3.2).  Cancellous BV/TV was lower in pOC-ERαKO 
female mice by 16% in the vertebral body and by 25% in the tibial metaphysis, due to 
lower Tb.Th in the vertebra (-6.2%), and due to increased Tb.Sp in the tibia (+28%) 
(Figure 3.1, Table 3.2).  Analogously, cortical bone at these two cortico-cancellous 
sites was also affected, but to a lesser extent than the cancellous tissues.  In the 
vertebral shell, both Ct.Ar (-11%) and Ct.Th (-11%) were lower in the knockouts 
compared to LC.  From compression testing, the lower bone mass found in both 
cortical and cancellous regions of the pOC-ERαKO vertebra correlated with lower 
compressive strength (-18%), but compressive stiffness was unchanged. The tibial 




Figure 3.1 Vertebral cancellous and cortical bone morphology and strength were 
differentially affected by ERα deletion in osteoblasts in 12-week-old pOC-ERαKO 
females and males compared to LC.  (A) Vertebral body BV/TV was decreased due to 
(D) decreased Tb.Th in female knockouts compared to LC.  (A) In male pOC-ERαKO 
mice, BV/TV in the vertebral shell was similar between genotypes.  (E) The vertebral 
shell had thinner cortices in female pOC-ERaKO mice compared to LC, resulting in 
(B) decreased Ct.Ar.  Vertebral shell Ct.Ar and Ct.Th in pOC-ERaKO male mice 
were not different from LC.  The cortical and cancellous morphology changes seen in 
female and male pOC-ERαKO mice contributed to (C) a decrease in compressive 
strength in vertebral compression tests in females, but no change in compressive 
strength in male knockouts or (F) in compressive stiffness in either sex. 
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Table 3.1 Cancellous and cortical bone in general were differentially affected by ERα 
deletion in 10-week-old pOC-ERαKO females and males measured by microCT in the 
vertebral body, vertebral shell, and femoral midshaft. 
 Female Male 
  LC pOC-ERαKO LC pOC-ERαKO 
BV/TV 0.189 ± 0.029 0.160 ± 0.015* 0.243 ± 0.042 0.288 ± 0.042 
Tb.Th 
(μm) 
48.3 ± 2.7 45.3 ± 0.85* 50.2 ± 5.1 53.9 ± 5.0 
Tb.Sp 
(μm) 
225 ± 21 277 ± 16 175 ± 13 158 ± 10* 
cn.TMD 
(mg HA/cc) 
632 ± 10 639 ± 7.6 646 ± 22 653 ± 17 
Ct.Ar 
(mm2) 
0.329 ± 0.0084 0.292 ± 0.017* 0.321 ± 0.043 0.329 ± 0.029 
Ct.Th 
(μm) 
65.5 ± 3.0 58.0 ± 2.0* 62.1 ± 4.9 63.6 ± 4.0 
IMAX 
(mm4) 
0.142 ± 0.0088 0.139 ± 0.014 0.136 ± 0.019 0.141 ± 0.020 
IMIN 
(mm4) 
0.0297 ± 0.0026 0.0284 ± 0.0025 0.0333 ± 0.0073 0.0338 ± 0.0044 
ct.TMD 
(mg HA/cc) 
791 ± 7.5 787 ± 8.1 795 ± 6.3 798 ± 9.0 
Ct.Ar 
(mm2) 
0.726 ± 0.027 0.675 ± 0.021* 0.934 ± 0.088 1.06 ± 0.097* 
Ma.Ar 
(mm2) 
0.890 ± 0.046 0.908 ± 0.053 1.17 ± 0.096 1.24 ± 0.13 
Ct.Th 
(mm) 
0.180 ± 0.0040 0.167 ± 0.0095* 0.193 ± 0.0077 0.202 ± 0.011 
IMAX 
(mm4) 
0.195 ± 0.020 0.175 ± 0.015* 0.351 ± 0.063 0.430 ± 0.072* 
IMIN 
(mm4) 
0.107 ± 0.0077 0.103 ± 0.0072 0.167 ± 0.029 0.206 ± 0.039* 
ct.TMD 
(mg HA/cc) 
945 ± 8.9 933 ± 9.1* 925 ± 8.2 930 ± 6.8 
Data are mean ± SD.  BV/TV, bone volume fraction; Tb.Th, trabecular thickness; Tb.Sp, trabecular 
separation; cn.TMD, cancellous tissue mineral density; Ct.Ar, cortical area; Ma.Ar, marrow area; Ct.Th, 
cortical thickness; IMAX and IMIN, maximum and minimum moments of inertia; ct.TMD, cortical tissue mineral 
density*pOC-ERαKO different from LC, p<0.05 by one-factor ANOVA for each sex. 
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Table 3.2 Female10-week-old pOC-ERαKO mice responded more to 2 weeks of 
tibial compression than LC while male pOC-ERαKO mice responded similarly to 
LC, measured by microCT in the proximal tibia and tibial midshaft. 
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 At the tibial midshaft, the non-loaded right limbs in pOC-ERαKO female mice 
showed no difference from LC mice in Ct.Ar, Ct.Th, IMAX, IMIN, or other parameters 
(Table 3.2).  At the femoral midshaft, however, Ct.Ar (-7.0%) and Ct.Th (-7.3%) were 
lower, as were IMAX and ct.TMD (-10% and –1.3%, respectively) (Figure 3.2, Table 
3.1).  These changes in bone geometry and architecture at the femoral midshaft did not 
correspond with changes in either maximum moment or bending stiffness in 3-point 
bending tests in targeted mice compared to LC.  
 Female pOC-ERαKO mice had similar PINP and OC but decreased TRAP5b 
serum levels compared to LC, probably reflecting the overall lower bone mass and 
therefore overall lower bone turnover in the knockouts. 
 
3.3.3 Male pOC-ERαKO mice exhibit increased bone mass 
 The bone phenotype seen in male pOC-ERαKO mice compared to their 
littermate controls was opposite that seen in females (Table 3.1, Table 3.2).  In the 
vertebral body, Tb.Sp was lower in knockouts (-9.9%) while Tb.Th remained 
unchanged, but these changes did not result in an overall alteration in BV/TV (Figure 
3.1).  In the right tibial metaphysis, cancellous BV/TV was greater by 34%, due 
largely to increased Tb.Th (+14%) (Table 3.2).  In the cortical shell of the tibial 
metaphysis, pOC-ERαKO mice had larger IMAX (+15%) compared to LC, but 
unchanged Ct.Ar, IMIN, Ct.Th, and ct.TMD.  The cortical shell of the vertebrae was 
unaffected by ERα deletion in osteoblasts and osteocytes. Compressive strength and 
stiffness were not different in pOC-ERαKO males compared to LC, reflecting the 
cortical bone mass and geometry at that site.  
At two purely cortical regions, the right femoral and tibial midshafts, cortical 
bone mass was significantly greater in male pOC-ERαKO mice.  In the femur, Ct.Ar 
(+14%), IMAX (+23%), and IMIN (+23%) were larger, which were reflected in greater 
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maximum bending moment (+15%) but no change in whole bone stiffness from 
bending tests (Figure 3.2).  Similarly, at the right tibial midshaft, male pOC-ERαKO 
mice had larger Ct.Ar (+6.9%), IMAX (+16%), and IMIN (+10%). 
 Serum levels of PINP and TRAP5b in males were similar between genotypes. 
Serum osteocalcin levels were decreased in knockouts, despite the higher bone mass 
found in male pOC-ERαKO mice. 
 
 
Figure 3.2 Femoral midshaft bone morphology and strength were differentially 
affected in 12-week-old pOC-ERαKO females and males compared to LC.  Female 
pOC-ERαKO mice had (A) decreased Ct. Th, (D) decreased Ct.Ar , and (B) 
decreased IMAX compared to LC.  (C,F) Maximum moment and bending stiffness 
were not different between genotypes in females from 3-point bending mechanical 
tests.  Male pOC-ERαKO mice exhibited an opposite bone phenotype compared to 
LC than that found in females.  (D) Ct.Ar , (B) IMAX, and (E) IMIN were all increased 
in male pOC-ERαKO mice, which resulted in (C) increased maximum moment in 3-
point bending tests. Ct.Ar, cortical area; Ct.Th, cortical thickness; IMAX and IMIN, 
maximum and minimum moments of inertia.  Data are mean ± SD, n=8-12 per group. 
*pOC-ERαKO different from LC, p<0.05 by one-way ANOVA for each sex. 
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3.3.4 ERα in osteoblasts suppresses the anabolic response to mechanical loading in 
female mice 
 At the tibial metaphysis, cancellous bone responded robustly to mechanical 
loading in both LC and gene-deleted females (Figure 3.3).  BV/TV, Tb.Th, and 
cn.TMD were increased after two weeks of loading (Table 3.2).  Likewise, cancellous 
MS, MAR, and BFR were increased in loaded vs control limbs (Table 3.3).  
Osteoblast activity from pro-collagen I IHC normalized to bone surface was increased 
in loaded vs. control tibiae (Figure 3.5), as expected with increased bone mass (Table 
3.3).  Both BV/TV and Tb.Th increased significantly more in response to mechanical 
loading in mice lacking ERα in mature osteoblasts than in LC.  BV/TV increased 97% 
in pOC-ERαKO and 43% in LC, due to increased Tb.Th (+60%, +39%, respectively).   
Although BV/TV was lower in knockout mice in the control limbs compared to LC, 
Tb.Th was not different between control right tibiae.   Osteoclast number measured by 
TRAP histology normalized to bone surface was not affected by loading or by 
genotype; however systemic levels of TRAP5b were lower in female pOC-ERαKO 
mice compared to LC (Figure 3.5), most likely due to overall lower bone mass found 
in these animals.  Serum levels of PINP were similar between genotypes (Figure C.1).  
Tibial growth plate thickness increased with loading, and was increased in control 
limbs of knockouts (Table 3.3).  
 Similar to the cancellous region of the tibial metaphysis, Ct.Ar, Ct.Th, IMAX, 
IMIN, and ct.TMD in the cortical shell of the tibial metaphysis increased in response to 
mechanical loading.  Both IMIN and Ct.Th were decreased in the control tibiae of pOC- 
ERαKO female mice compared to LC, yet these two parameters responded more to 
mechanical loading in pOC-ERαKO mice.  IMIN increased 64% in pOC-ERαKO but 
only 44% in LC.  Ct.Th increased 37% in knockouts but 27% in LC.  Ct.Ar responded 





Figure 3.3 Tibial metaphyseal bone mass was in general reduced in pOC-ERαKO 
female mice but increased in pOC-ERαKO male mice, and pOC-ERαKO female mice 
responded more to 2 weeks of tibial compression.   Representative transverse 3D 
microCT reconstructions (0.51mm thick) of the tibial metaphysis in (A) female and 
(D) male 12-week-old LC (top) and pOC-ERaKO mice (bottom) after 2 weeks of left 
tibial loading.  (B) Cancellous bone in female pOC-ERaKO mice had 25% lower 
BV/TV in the unloaded right tibia compared to LC.  After two weeks of tibial 
loading, BV/TV increased more (+97%) in pOC-ERaKO mice than in LC mice 
(+43%). (E) Male pOC-ERaKO had increased BV/TV in the tibial metaphysis 
compared to LC, but 2 weeks of loading did not alter BV/TV in left vs. right limbs for 
either genotype.  (C,F) Cortical shell bone area increased similarly between 
genotypes within each sex after loading, and Ct.Ar was unaffected by ERα deletion in 
both sexes.  
BV/TV, bone volume fraction; Ct.Ar, cortical area.  Data are mean ± SD, n=12-14 
per group. 
†
Loaded tibia different from Control, p<0.05 by repeated measures 
ANOVA with interaction for each sex.  Bars not sharing same letter are significantly 
different from one another from Tukey HSD post-hoc only when interaction term 




Figure 3.4 Tibial midshaft cortical bone mass was similar between pOC-ERαKO and 
LC mice, but knockouts responded more to 2 weeks of tibial compression; male pOC-
ERαKO had increased cortical bone mass but responded similarly to loading as LC 
mice.  Representative transverse 3D microCT reconstructions (45um thick) of the 
tibial midshaft in (A) female and (D) male 12-week-old LC (top) and pOC-ERaKO 
mice (bottom) after 2 weeks of left tibial loading.  (B,C) Although Ct.Ar was not 
different between LC and pOC-ERaKO female mice in the right, control limb, after 2 
weeks of tibial loading, Ct.Ar increased more in pOC-ERaKO mice (+41%) vs. LC 
(+28%), as did IMAX. (E,F) Male pOC-ERaKO mice had increased Ct.Ar and IMAX at 
the tibial midshaft in the right unloaded limbs, and both genotypes showed a similar 
increase in Ct.Ar and IMAX after 2 weeks of mechanical loading. 
Ct.Ar, cortical area; IMAX, maximum moment of inertia.  Data are mean ± SD, n=12-
14 per group. *pOC-ERαKO different from LC, †Loaded tibia different from Control, 
p<0.05 by repeated measures ANOVA with interaction for each sex.  Bars not sharing 
same letter are significantly different from one another from Tukey HSD post-hoc 
only when interaction term (load*genotype) was significant. Scale bar = 0.5mm. 
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At the tibial midshaft, female pOC-ERαKO mice responded more to mechanical 
loading than LC despite having similar bone architecture in contralateral limbs 
(Figure 3.4).  Ct.Ar increased more in pOC-ERαKO mice (+41%) than in LC (+28%), 
as did IMAX (+76% in pOC-ERαKO and +53% in LC) (Table 3.2).  Ct.Th, IMIN, and 
ct.TMD increased similarly between genotypes with two weeks of tibial loading.  New 
bone formed on both the periosteal and endosteal surfaces of the tibial midshaft, as 
indicated by increased MS, MAR, and BFR at the periosteum and increased MAR and 
BFR at the endosteum (Table 3.3).  As such, Ma.Ar decreased with loading (-4.9% 
pOC-ERαKO, -6.5% LC).  Of note, woven bone formation was present at the tibial 
midshaft of both genotypes of female mice in response to loading, but not in the 
metaphysis. 
 
Figure 3.5 Representative IHC and histology images for sagittal sections of the 
proximal tibiae of LC (top) and pOC-ERαKO (bottom) female mice in loaded and 
control limbs.  (A) N.Oc/BS was unchaged between genotypes and was not altered 
with 2 weeks of tibial mechanical loading in either pOC-ERαKO or LC mice. (B)  
N.Ob/BS increased with 2 weeks of in vivo tibial loading similarly in both genotypes. 
N.Ob/BS, number of osteoblasts staining positively for pro-collagen I normalized to 
bone surface; N.Oc/BS, number of osteoclasts staining positively for TRAP normalized 
to bone surface. Scale bar = 80μm for A, 20μm for B 
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3.3.5 The response to mechanical loading is unchanged in male pOC-ERαKO mice  
 After 2 weeks of tibial loading in male mice, cancellous trabeculae thickened 
(+16% pOC-ERαKO, +28% LC) and cn.TMD increasd (+2.6% pOC-ERαKO, +4.0% 
LC) in the loaded limb compared to the contralateral limb in both genotypes in the 
tibial metaphysis (Table 3.2).  Overall BV/TV did not change with loading as in 
previous similar experiments with male C57Bl/6 mice (26, 34) (Figure 3.3).  
Although overall bone mass was unchanged with loading, osteoblast activity and 
osteoclast number normalized to bone surface were both increased in loaded vs. 
contralateral tibial metaphyses, as was tibial growth plate thickness (Table 3.3, Figure 
3.6).  Cancellous MS increased 12% in pOC-ERαKO and 16% in LC with loading, but 
MAR and BFR were unchanged (Table 3.3).   
 
 
Figure 3.6 Representative IHC and histology images for sagittal sections of the 
proximal tibiae of LC (top) and pOC-ERαKO (bottom) male mice in loaded and 
control limbs. (A,B) Osteoclast number and osteoblast activity normalized to bone 
surface both increased after 2 weeks of in vivo tibial mechanical loading in male 
pOC-ERαKO and LC mice. N.Ob/BS, number of osteoblasts positively stained for 
pro-collagen I normalized to bone surface; N.Oc/BS, number of osteoclasts 
positively stained for TRAP normalized to bone surface. Scale bar = 80μm for A, 
20μm for B. 
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In the cortical shell of the metaphysis, Ct.Ar, IMAX, and IMIN increased in 
response to 2 weeks of mechanical loading.  Despite pOC-ERαKO mice having higher 
bone mass in the cancellous metaphysis and increased IMAX in the cortical shell 
metaphysis, LC and pOC-ERαKO showed similar responses to in vivo tibial loading. 
At the cortical tibial midshaft, Ct.Ar increased 1.4% in pOC-ERαKO with 
loading and 2.8% in LC (Figure 3.4).  Most new bone formation reflected periosteal 
expansion, as shown through increased Per.MS and Per.MAR, but no change in 
Ma.Ar. However, endosteal MS increased with loading in both genotypes, while IMAX 
and IMIN also were higher. Cortical geometry in pOC-ERαKO male mice responded 
similarly to mechanical loading as LC mice. 
 
3.4 Discussion 
We generated 10-week-old female and male mice lacking ERα in mature 
osteoblasts and osteocytes by breeding ERαfl/fl and OC-Cre mice.  Serum 
measurements, bone length, and growth plate analyses revealed that systemic effects 
were not present in females and limited in males, who showed decreased serum 
osteocalcin levels and increased femur length. When ERα was removed in mature 
osteoblasts, cancellous and cortical bone mass were lower at most sites in females; in 
contrast, pOC-ERαKO male mice in general showed increased cancellous and cortical 
bone mass. When mice were subjected to two weeks of in vivo mechanical tibial 
loading, female pOC-ERαKO mice formed more bone in response to loading than LC.  
In contrast, genotype did not affect the skeletal response to mechanical loading in 
males. 
ERα in osteoblasts clearly has a role in bone mass accrual and its response to 
mechanical loading, depending upon the stage of deletion.  Our previous work and that 
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of Määttä et al., found similar reduced bone mass in female mice when ERα was 
deleted in mature osteoblasts using the OC-Cre-driven promoter (18, 19).  Määttä et 
al. did not find genotype differences in males, except at 6 months of age, at which 
time tibial BV/TV and Tb.N were lower in knockouts.  Of note, our current study 
examined 10-week-old mice, whereas the Määttä study analyzed older mice at 3.5, 6, 
and 12 months of age.  In addition, genetic background can profoundly affect bone 
structure and mass (35, 36).  Our mice were backcrossed fully to a C57Bl/6 
background, whereas the background of Määttä, et al. was not reported. 
ERα mediates mechanosensitivity in bone. In osteoblast cultures, cells lacking 
ERα responded less to mechanical strain (37).  Similarly, the response to mechanical 
loading was decreased in global ERαKO female mice compared to controls, but has 
not been widely studied yet in bone cell-specific ERαKO mice of either sex (12).  In 
the present study, when ERα is deleted in mature osteoblasts and osteocytes using the 
OC-Cre promoter, female pOC-ERαKO mice showed an increased anabolic response 
to tibial loading compared to controls, whereas male knockouts responded similarly to 
LC.  In contrast, lack of ERα osteoctyes did not alter cortical bone’s anabolic response 
to mechanical loading in female mice, pointing to a critical role of ERα in osteoblasts 
in the female skeletal response to increased mechanical loading (20).  However, 
Kondoh et al. performed hindlimb unloading in Dmp1-ERαKO female mice and 
showed an accelerated loss of bone mass compared to littermate controls (21).  
Coupled with our data, ERα in osteoblasts but not osteocytes regulates the magnitude 
of bone’s response to loading, but ERα in osteocytes regulates bone mass during 
disuse.    Whether mechanical stimuli are increased or decreased, the absence of ERα 
in mature osteoblasts or osteoctyes enhances sensitivity to the loading environment in 
ER-deficient bone (38). 
During puberty, sex steroids promote bone growth and are major contributors 
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to sexual skeletal dimorphism in humans (1).   Later in puberty, estrogen suppresses 
periosteal apposition and leads to growth plate fusion in both sexes (38, 39).  Adult 
males have greater bone mass due to a prolonged puberty and high testosterone levels 
that increase periosteal apposition (40).  In pOC-ERαKO male mice, because the 
growth-suppressive effects of estrogen do not act on mature osteoblasts or osteocytes 
via ERα, the stimulating effects of testosterone on bone growth may be enhanced and 
might help to explain the higher bone mass phenotype found in these animals.  
Females lacking an estrogenic response via ERα in mature osteoblasts may accrue 
bone mass during growth more slowly resulting in the decreased bone mass found in 
female pOC-ERαKO mice. 
The formation of woven bone in response to mechanical loading at both the 
periosteal and endosteal surfaces of the tibial midshaft in female pOC-ERαKO and LC 
mice is a limitation of this study, as we aimed to analyze lamellar bone formation from 
skeletal loading.  A peak load of -9.0N was required to produce 1200με at the 
midshaft cortex, and similar load levels have been used previously for mouse tibial 
loading (32, 41).  Following mechanical loading, the amount and variety of 
differentially expressed genes depends on whether lamellar or woven bone is being 
generated (42).  The possible effects of woven vs. lamellar bone on data interpretation 
from the current study cannot be discounted.  However, female pOC-ERαKO also 
responded more to mechanical loading in the proximal tibiae, where woven bone was 
not present, indicating that ERα does regulate the skeletal response to mechanical 
loading during accrual of lamellar bone.  Bone mass in the proximal tibiae of pOC-
ERαKO female mice was lower than that of LC mice.  Because load levels were 
normalized for a target strain level at the cortical midshaft, a site at which bone mass 
and stiffness were similar between genotypes, we cannot distinguish whether the 
increased response to mechanical load in the cancellous tissues of the female pOC-
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ERαKO was caused purely by genotypic effects or a combination of genotype and 
different strains in the cancellous tissues of the knockouts relative to the LC. 
Use of a cre-recombinase driven by the OC promoter (pOC) has been widely 
used in the literature (30).  Although the OC-Cre mouse has been a tool to knockout 
specific receptors and proteins in mature osteoblasts and subsequent osteocytes, cre 
expression has been detected in the growth plate (43).  Previously in our mixed 
background strain of female pOC-ERαKO mice, we found no differences in growth 
plate thickness or in tibial or femoral lengths compared to LC (19).  However, in the 
current animals, on a pure C57Bl/6 background, female pOC-ERαKO mice had 
thicker tibial growth plates but no differences in tibial or femoral bone length.  In 
contrast, growth plate thickness was not different in pOC-ERαKO males, yet femoral 
length was increased and tibial length was unaffected.  Määttä et al. found increased 
tibial lengths in male pOC-ERαKO mice at 3 months of age (18).  These results are 
difficult to interpret, as mouse growth plates never fuse and cannot be directly 
correlated to the actions of human growth plates. OC-Cre expression in the growth 
plate may affect growth plate thickness and bone length.  However, overall body mass 
and crown/rump length were not altered in pOC-ERαKO mice of either sex. 
Because declining sex hormones contribute greatly to osteoporosis in the 
elderly, especially post-menopausal women who have severely decreased estrogen 
levels, recent research has focused on understanding the role of estrogen signaling via 
its receptors in bone (9, 44).  Here ERα in mature osteoblasts and osteocytes 
differentially regulated bone mass in males and females.  Removing ERα increased the 
skeletal response to mechanical loading at cortical and cancellous sites in females, but 
did not affect skeletal adaption to physical stimuli in male mice.  Further research 
should emphasize elucidating the cellular mechanisms and signaling pathways 
involved in estrogen signaling in bone, which may provide valuable insight into the 
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Chapter 4  
INHIBITING BMP2/4 SIGNALING INCREASES CANCELLOUS BONE 
MASS IN FEMALE OSTEOBLAST-SPECIFIC ERα KNOCKOUT MICE AND 
REDUCES BONE’S RESPONSE TO MECHANICAL LOADING 
 
4.1 Introduction 
 Estrogen helps regulate bone mass throughout life in both sexes (1, 2).  Late in 
puberty in females, estrogen levels rise to suppress periosteal apposition and enhance 
endosteal resorption, contributing to the skeletal sexual dimorphism that results in 
lower peak bone mass in women on average (3).  Postmenopausal women, due in part 
to low estrogen bioavailability, are especially susceptible to osteoporosis and 
subsequent fracture (4).  Classical estrogen signaling in bone is mediated mainly 
through estrogen receptors ERα and ERβ, which can be involved in further 
intracellular signaling or can bind to estrogen response elements to directly facilitate 
gene transcription in the nucleus (5).  Because of osteopenia found in a male patient 
with an inactivating mutation of ERα (6) and reports correlating ERα polymorphisms 
with bone mineral density and osteoporosis (7, 8), the role of ERα signaling in bone is 
of particular interest.  Multiple pathways have been proposed to interact with ERα in 
bone, including IGF-1, BMP, and wnt/β-catenin (9-11).   
 Knockout mouse models are valuable tools for elucidating the role of ERα in 
bone, but basal bone phenotype results vary among mouse models.  In global ERαKO 
female mouse models, both increased and decreased cortical and cancellous bone mass 
were reported (12-14).   When ERα was deleted at the osteoblast progenitor or 
precursor stage, cortical bone mass was decreased but cancellous bone mass was 
unchanged (15).  Previously, we and others bred mice lacking ERα in mature 
osteoblasts and osteoctyes (pOC-ERαKO) (16, 17).  In general, female pOC-ERαKO 
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mice had decreased bone mass compared to littermate controls (LC), while male 
knockouts had increased bone mass compared to LC.  In osteocyte-specific ERαKO 
female mice, cancellous bone mass was shown to be decreased or maintained, but 
cortical bone mass was unaffected (18, 19).  Furthermore, the response to in vivo 
mechanical loading was enhanced in female pOC-ERαKO mice in both cortical and 
cancellous bone (Melville In Review), while the response to loading in osteocyte-
specific ERαKO female mice was similar to controls (19).  These loading results are in 
conflict with those from global ERαKO mice, which showed a decreased response to 
mechanical loading (14, 20), and with exercise studies in postmenopausal women, 
whose bones were not as mechanoresponsive as estrogen-replete women (21).  The 
effects of removing ERα from the entire body vs. one cell type elicit varying results, 
supporting the complexity of ERα signaling.  
 Bone morphogenetic proteins (BMPs) were first discovered as initiators of 
ectopic bone formation and are members of the TGF-β super family of growth factors.  
When activated by a BMP, a type II receptor phosphorylates a type I receptor, 
resulting in Smad 1,5,8 phosphorylation (22).  Phosphorylated Smad 1,5,8 
(pSmad1/5/8) binds with Smad 4 and this complex mediates gene transcription 
directly.   Secreted by virtually all cells of the body, BMPs are critically involved in 
cellular development and growth.  In bone, BMPs can enhance fracture healing and 
aid in osteoblastogenesis and osteoclastogensis (23, 24).  Furthermore, mechanical 
stimulation both in vitro and in vivo differentially regulated the expression of BMPs 
and their receptors (25, 26).     
 BMPR1a, a type I receptor in BMP signaling, is especially important in bone.  
When BMPR1a was removed from osteoblasts and osteoclasts in cell-specific KO 
mice, bone mass was increased through both decreased bone formation and bone 
resorption, suggesting that signaling through this receptor promotes bone formation 
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(27, 28).  RAP-661, a decoy receptor for BMPR1a, binds with high affinity to BMP-2 
and BMP-4, both highly expressed in the skeleton.  When administered for 1-6 weeks, 
RAP-661 increased bone mineral density and bone mass in wildtype mice in a dose- 
and time-dependent manner (29).   Although BMP signaling has been shown to 
interact with ERα in bone, much of the evidence is in vitro (30-32).  The interactions 
among ERα, BMP signaling, and mechanical loading are not well researched in vivo. 
 We hypothesized that blocking BMP2/4 signaling through BMPR1a would 
increase bone mass in pOC-ERαKO and LC females to a similar extent, and that bone 
mass would increase in response to mechanical loading less in animals in which 
BMP2/4 signaling is blocked.  We bred female pOC-ERαKO and LC mice.  At 10 
weeks of age, all animals underwent 2 weeks of daily in vivo tibial mechanical 
loading.  Half of the animals from each genotype were injected twice weekly with 
RAP-661, while the remaining half received an IgG placebo control.  Changes in bone 
mass and architecture from drug administration were determined through micro-
computed tomography (microCT) of the L5 vertebra and femur.  Also, whole bone 
strength and stiffness were measured through whole bone mechanical tests.  To 
determine the interactions among osteoblastic ERα, BMPR1a, and mechanical 
loading, microCT of the cortico-cancellous tibial proximal metaphysis and the cortical 
tibial midshaft were analyzed.  Osteoblast and osteoclast activity were measured at the 
proximal tibia from immunohistochemistry.   
 
4.2 Methods 
4.2.1 Generation of osteoblast-specific ERαKO mice 
 pOC-ERαKO and littermate control (LC) mice were generated by breeding 
mice containing a transgene encoding Cre recombinase driven by the human 
osteocalcin promoter (OC-Cre, provided by Dr. Thomas Clemens, The Johns Hopkins 
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University, Baltimore, MD) (33, 34) with mice in which exon 3 of the DNA-binding 
domain of the ERα gene (Esr1) is flanked by loxP sequences (ERαfl/fl, provided by Dr. 
Kahn, University of Cincinnati, Cincinnati, OH) (35).  All mice were inbred to the 
C57Bl/6 strain and genotyped as described (17).  Mice were housed 3-5 per cage with 
ad libitum access to food and water.  All animal procedures were approved by Cornell 
University’s Institutional Animal Care and Use Committee.  
 
4.2.2 In vivo tibial mechanical loading 
 The left tibiae of female LC and pOC-ERαKO mice (n=20 per group) were 
loaded in compression in vivo 5 days per week for 2 weeks as described previously 
(36).  In brief, a cyclic compressive load was applied at a rate of 4Hz for 1200 cycles 
per day, 5 days per week, in a triangular waveform with a peak load of -7.0N.  A dwell 
of 100ms at -0.5N was inserted between each load, and the dwell-to-peak time was 
75ms.   A peak load of -9.0N corresponded to 1200ue at the tibial midshaft from strain 
gauging but induced woven bone at the tibial midshaft (Chapter 3).  Therefore, the 
current experimental mice were loaded at -7.0N.  Twice weekly, mice received 
injections of either RAP-661, a receptor decoy for Type 1 BMP Receptors, (IP, 5 
mg/kg, n=10 per group) or a placebo (IgG, IP, 5 mg/kg, n=10 per group) (ref Pearsall).  
Body mass was recorded daily to monitor well-being.  Crown/rump lengths were 
measured at euthanasia. 
 
4.2.3 Microcomputed tomography 
 After euthanasia by CO2 inhalation, left and right tibiae were fixed in 4% 
paraformaldehyde for 24 hours, and then scanned in 70% ethanol at 15um voxel 
resolution (μCT35, Scanco Medical AG, Switzerland; 55kVp, 145μA, 600ms 
integration time).  For each tibia, the cancellous core and cortical shell of the 
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metaphysis scans were separated and analyzed separately, and the cortical midshaft 
was also analyzed as previously described (17). 
 Right femora and L5 vertebrae were wrapped in PBS-soaked gauze and stored 
at -20°C prior to microCT scanning at 15um resolution.  To analyze the scans, the 
cancellous core and cortical shell of the vertebrae and the cortical femoral midshaft 
were analyzed as previously described (Melville under review). 
 Cancellous bone outcome measures were bone volume fraction (BV/TV), 
trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and cancellous tissue 
mineral density (cn.TMD).  Cortical bone outcome measures were cortical area 
(Ct.Ar), marrow area (Ma.Ar, tibial and femoral midshaft only), total area (T.Ar, tibial 
and femoral midshaft only), maximum and minimum moments of inertia (IMAX, IMIN), 
cortical thickness (Ct.Th), and cortical tissue mineral density (ct.TMD).  Mineralized 
tissue was separated from non-mineralized tissue with bone site-specific thresholds.    
 
4.2.4 Histology 
 After microCT scanning, left and right tibiae were decalcified in 10% EDTA 
for two weeks, processed, and embedded in paraffin (n=7 per group).  Tibiae were 
sectioned longitudinally at 6µm using a rotary microtome (Leica RM2255, Germany).  
Sections were stained for TRAP and pro-collagen I as previously described (17). The 
number of positively-stained osteoclasts (TRAP) or osteoblasts (pro-collagen I) in the 
cancellous metaphysis was quantified and normalized to bone surface (2 slides/animal, 
OsteomeasureXP v3.2.1.7).  Growth plate thickness was quantified from sections 
stained with Safranin O/Fast Green/Alcian Blue by averaging five evenly spaced lines 
(2 slides per mouse, n=7 mice/group, OsteomeasureXP v3.2.1.7).   
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4.2.5 Mechanical testing 
 Prior to mechanical testing, femora and L5 vertebrae were thawed to room 
temperature and kept moist with PBS.  Femora were tested in three-point bending to 
failure, and vertebrae were tested in compression to failure in the cranial-caudal 
direction as previously described (858 Mini Bionix, MTS, Eden Prairie, MN) (17).  
Whole bone strength and stiffness were determined from the load-displacement data 
for bending and compression. 
  
4.2.6 Statistics 
For bone lengths, vertebral and femoral microCT, and mechanical testing data, 
a two-factor (drug, genotype) ANOVA with interaction was used with a Tukey HSD 
post-hoc test.  For tibial microCT, histology, and IHC data, a repeated measures two-
factor ANOVA with interaction was used with a Tukey HSD post-hoc test.  The 
between-subject factors were drug and genotype, and the within-subject factor was 
loaded/left vs. control/right.  Significance was set at p<0.05. 
 
4.3 Results 
4.3.1 Blocking BMP2/4 signaling increased bone mass and strength in vertebra but 
not femur 
 At 10 weeks of age, we administered either RAP-661 drug or IgG control 
placebo (5mg/kg, IP) twice weekly to female pOC-ERαKO and LC mice.  After 2 
weeks of treatment, the L5 vertebra and femoral midshaft were evaluated by microCT 
(Table 4.1, Figure 4.1).  In the cancellous vertebral core, RAP-661 increased BV/TV 
(+47% LC, +54% pOC-ERαKO) through both trabecular thickening (+26% LC, +27% 
pOC-ERαKO) and decreased trabecular separation (-11% LC, -8.9% pOC-ERαKO). 
Cn.TMD was also significantly increased (+7.1% LC, +7.7% pOC-ERαKO).  
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Analogous to cancellous changes, in the cortical shell of the vertebra RAP-661 
increased all measured parameters: Ct.Ar (+11% LC, +22% pOC-ERαKO), Ct.Th 
(+20%, LC only), IMAX (+31%, LC only), IMIN (+9.1% LC, +15% pOC-ERαKO), and 
ct. TMD (+2.9% LC, +1.6% pOC-ERαKO).  Because of the drug’s effects on both 
compartments of the coricocancellous vertebra, vertebral strength was increased 38% 
in LC and 54% in pOC-ERαKO from whole bone compression tests.  The increase in 
vertebral strength was similar between genotypes. 
 In contrast, in the purely cortical region of the femoral midshaft, RAP-661 
treatment did not affect bone mass or strength.  Overall Ct.Ar, IMAX, IMIN, and ct.TMD 
were not altered by blocking BMP2/4 signaling.  Two weeks of drug treatment were 
osteogenic at the endocortical surface, as evident from increased Ct.Th (+8.2%, LC 
only) due to decreased Ma.Ar (-11%, LC only). Femoral strength and stiffness, 
measured from whole bone mechanical testing, were unaltered by RAP-661 treatment 
in both genotypes. 
 
4.3.2 Effects of RAP-661 are partially mediated by ERα in osteoblasts  
 Cell-specific removal of ERα from mature osteoblasts and osteocytes 
decreased cortical and cancellous bone mass in female mice as shown by us and others 
(16, 17).  We endeavored to determine if RAP-661 would increase bone mass in pOC-
ERαKO animals to a similar extent as LC.  In agreement with previous work, placebo-
treated pOC-ERαKO female mice had decreased BV/TV (-13%) from decreased 
Tb.Th (-6.9%) in the cancellous vertebral core, along with decreased Ct.Ar (-8.6%) 
and ct.TMD (-0.61%) in the vertebral cortical shell (Figure 4.1, Table 4.1).  
Similarly, pOC-ERαKO mice had decreased femoral midshaft Ct.Th (-1.2%) and 





Figure 4.1 RAP-661 and ERα deletion in osteoblasts had differential effects in 
vertebra and femur from microCT analysis and whole bone mechanical tests in 10-
week-old pOC-ERaKO and LC female mice.  (A) In the vertebra, cancellous 
BV/TV was reduced in pOC-ERaKO mice, while RAP-661 treatment increased 
BV/TV markedly in both genotypes.  (B) RAP-661 increased Ct.Ar in the cortical 
shell more in LC than pOC-ERaKO mice.  (C) RAP-661 treatment increased 
vertebral whole bone strength in both genotypes to a similar extent.  In the femur, 
RAP-661 had no effect on (D) Ct.Ar, (E) IMAX, or (F) maximum moment from 
whole bone tests.  pOC-ERaKO mice were similar to LC mice in all three 
parameters in the femur. 
  
BV/TV, bone volume fraction; Ct.Ar, cortical area; Comp. Strength, compressive 
strength; IMAX, maximum moment of inertia; Max, maximum 
#
pOC-ERαKO different from control in corresponding drug-treatment group,  
†
drug-treated different from control in corresponding genotype;  
groups not sharing the same letter above bars are significantly different from one 




Table 4.1 Cancellous and cortical parameters measured by microCT for the L5 
vertebra and right femoral midshaft in 10-week-old pOC-ERαKO and LC mice 
injected with either placebo or RAP-661 
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Even though RAP-661 increased bone mass and strength in the vertebra, the 
effects were somewhat genotype-dependent in the cortical shell.  Vertebral Ct.Ar and 
Ct.Th both increased after 2 weeks of drug treatment, but the effects were greater in 
LC than in pOC-ERαKO mice.  Vertebral IMAX was only enhanced by RAP-661 in LC 
mice.  The cancellous core of the vertebra was affected similarly by RAP-661 in both 
genotypes.  At the femoral midshaft, genotype and drug had little effect on bone mass 
and architecture.   Drug treatment increased Ct.Th and decreased Ma.Ar in LC mice 
only, suggesting only an endosteal effect.  Although blocking BMP2/4 signaling 
increased bone mass, when ERα was absent in osteoblasts and osteocytes, some of the 
osteogenic effects of RAP-661 were attenuated. 
 
4.3.3 RAP-661 increases bone mass in the cancellous tibial metaphysis but not the 
cortical tibial metaphysis or cortical midshaft 
 The bone-building effects of RAP-661 treatment were bone-specific, as 
evidenced by the increased bone mass in the vertebra but not femur in 10-week-old 
LC and pOC-ERαKO mice after 2 weeks of treatment.   However, the bone effects 
varied by site even within a single bone from microCT analysis.  Comparing the right 
control tibiae, RAP-661 increased cancellous metaphyseal BV/TV (+60% LC, +68% 
pOC-ERαKO) due to increased Tb.Th (+19% LC, +18% pOC-ERαKO) (Figure 4.2, 
Figure 4.3, Table 4.2).  Cancellous TMD was also increased after 2 weeks of drug 
treatment, but only in LC animals (+4.3%).  The increase in cancellous bone mass 
appeared to be largely due to decreased osteoclast number rather than increased 
osteoblast number from TRAP histology and pro-collagen I IHC (Table 4.3, Figure 
4.4).  N.Oc/BS was decreased in control tibiae after 2 weeks of treatment, while RAP-
661 did not alter N.Ob/BS.  In contrast, in the cortical shell of the tibial metaphysis 





Figure 4.2 Cancellous BV/TV and Ct.Ar were increased with RAP-661 treatment over 
placebo in both genotypes.  Representative images are reconstructed from tibial 
metaphyseal microCT scans of RAP-661- and placebo-treated 10-week-old pOC-ERaKO 
and LC female mice after 2 weeks of daily left tibial loading.  Mechanical loading 
increased Ct.Ar more in placebo animals than drug-treated animals for both genotypes, 
but BV/TV was only increased with loading in pOC-ERαKO placebo animals. Scale bar 









Figure 4.3 RAP-661 drug treatment increased (A) BV/TV in both limbs and 
(B) Tb.Th in control limbs for 10-week-old female pOC-ERaKO and LC mice 
from microCT analysis at the tibial metaphysis.  Two weeks of daily tibial 
compression increased (C) BV/TV in placebo-treated pOC-ERaKO mice and 
(D) Tb.Th in placebo-treated animals of both genotypes.  Loading increased 
Tb.Th more in pOC-ERaKO than LC mice.   
 
Data are mean ± SD for BV/TV, bone volume fraction (A) and Tb.Th, 
trabecular thickness (B), as well as respective (Loaded-Control) paired 
differences (C,D).  
*loaded greater than control in corresponding genotype and drug-treatment 
group, 
#
pOC-ERαKO different from LC in corresponding limb and drug-
treatment group, 
†
drug-treated different from placebo in corresponding 
genotype and limb; groups not sharing the same letter above bars are 




Figure 4.4 RAP-661 treatment decreased osteoclast number but did not affect 
osteoblast number. Numbers of both cell types were altered with 2 weeks of in vivo 
tibial loading.  (A, C) N.Ob/BS of the cancellous metaphysis was increased with in 
vivo loading in 10-week-old pOC-ERaKO and LC mice in placebo groups but not in 
RAP-661 drug-treated groups, measured from pro-collagen I immunohistochemistry.  
(B,D) N.Oc/BS was decreased in placebo- and RAP-661-treated groups after in vivo 
loading of both genotypes from TRAP histology.  Drug treatment also decreased 
N.Oc/BS in both pOC-ERaKO and LC.   
 
Data are mean ± SD for N.Ob/BS, number of osteoblasts normalized to bone surface; 
and N.Oc/BS, number of osteoclasts normalized to bone surface; as well as 
respective (Loaded-Control) paired differences (C,D).   
*loaded different from control in corresponding genotype and drug-treatment group,  
†
drug-treated different from placebo in corresponding genotype and limb. 
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not affected when BMP2/4 signaling was blocked.  
 
4.3.4 RAP-661-treated animals respond less to daily in vivo tibial compression than 
placebo controls 
Because BMPs were upregulated after in vivo and in vitro bone loading, we 
wanted to see if blocking BMP2/4 signaling would have an effect on how bone 
responded to in vivo tibial loading with and without ERα signaling in osteoblasts.  We 
subjected pOC-ERαKO and LC female mice to two weeks of daily left tibial 
compression, while treating animals twice weekly with either RAP-661 or placebo.  
As has been shown previously, 2 weeks of loading increased cancellous and cortical 
bone mass in the tibial metaphysis and tibial midshaft in placebo-treated animals.  
However, RAP-661-treated animals responded differently than their placebo controls, 
and the loading-drug interactions varied by bone site. 
 In the cancellous compartment of the tibial metaphysis, 2 weeks of loading 
increased BV/TV, Tb.Th, and cn.TMD in placebo animals compared to the right 
control limbs (Table 4.2, Figure 4.2, Figure 4.3).  However, placebo animals 
responded more to loading than RAP-661-treated animals.  Tb.Th increased 18% in 
LC and 29% in pOC-ERαKO placebo animals, but only 3.4% in LC and 9.0% in pOC-
Table 4.2 Histology and immunohistochemistry data for the proximal tibia after 2 
weeks of left tibial daily loading in 10-wk female pOC-ERαKO and LC mice 
injected with either placebo or RAP-661 
 96 
ERαKO drug-treated animals.  Similarly, cn.TMD increased 2.9% in LC and 4.1% in 
pOC-ERαKO placebo animals, but only 1.2% in LC and 2.1% in pOC-ERαKO drug-
treated animals.  Overall BV/TV did not change with loading in drug-treated-animals, 
and increased 21% in the pOC-ERαKO placebo animals but not in the LC placebo 
animals.  While N.Oc/BS decreased with loading in both treatment groups, N.Ob/BS 
increased only in placebo animals, suggesting that the drug treatment affected bone 
formation with loading but not bone resorption with loading (Figure 4.4). 
 Analogous to the cancellous compartment, the cortical shell of the tibial 
metaphysis responded to loading more in placebo animals than RAP-661-treated 
animals.   After 2 weeks of loading, Ct.Ar, Ct.Th, IMAX, and IMIN all increased in 
loaded limbs compared to control limbs in placebo animals in both LC and pOC-
ERαKO mice (Figure 4.2, Figure 4.5, Table 4.2).  However, tibial loading increased 
Ct.Ar, IMAX, and IMIN more in placebo animals than in drug-treated animals for both 
genotypes, while Ct.Th increased similarly in both treatment groups.  For example, 
Ct.Ar increased 16% in LC 21% in pOC-ERαKO placebo animals with loading, but 
only 11% in LC and 13% in pOC-ERαKO animals.  In contrast, mechanical loading 
increased ct.TMD in drug-treated groups similarly (+1.5% LC, +1.3% pOC-ERαKO) 
but had no effect in placebo animals. 
 Although bone mass was increased at the cortical midshaft with two weeks of 
tibial loading, the loading effects at this site were not drug-dependent (Figure 4.6).  
Ct.Ar, Ct.Th, IMAX, and IMIN all responded similarly to in vivo loading in placebo and 
drug-treated LC and pOC-ERαKO mice.  ct.TMD and Ma.Ar were unaltered with 
loading, regardless of treatment group or genotype.  Interestingly, the loading effects 






































Figure 4.5 (A,B) In the cortical shell of the metaphysis, bone mass increased in 
10-week-old pOC-ERaKO and LC female in response to 2 weeks of daily tibial 
loading from microCT analysis.  (C,D) The load-induced increases in Ct.Ar and 
IMAX were less in RAP-661 drug-treated animals than placebo-treated animals. 
 
Data are mean ± SD. Ct.Ar, cortical area; IMAX, maximum moment of inertia. 
*loaded different from control in corresponding genotype and drug-treatment 
group, #pOC-ERαKO different from LC in corresponding limb and drug-treatment 
group, †RAP661 drug-treated different from placebo in corresponding genotype 
and limb; groups not sharing the same letter above bars are significantly different 
from one another from a Tukey HSD post-hoc where a>b>c 
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Figure 4.6 Daily tibial loading for two weeks increased Ct.Ar and IMAX in RAP-661- 
and placebo-treated 10-week-old pOC-ERaKO and LC female mice similarly.  (A,B) 
Representative transverse images are reconstructed from tibial midshaft microCT 
scans.   
Numbers indicate Ct.Ar relative to value in LC, placebo, control limb (100).   
*loaded different from control in same genotype and treatment group; section thickness 
= 45 um; scale bar = 0.25mm. 
 
RAP-661-treated and placebo-treated 10-week-old pOC-ERaKO and LC female mice 
responded similarly to 2 weeks of daily in vivo tibial loading from microCT analysis at 
the cortical midshaft for both (C,E) Ct.Ar and (D,F) IMAX.  RAP-661 drug treatment 
did not affect either genotype at this location. 
 
Data are mean ± SD.  Ct.Ar, cortical area; IMAX, maximum moment of inertia. 
*loaded different from control in corresponding genotype and drug-treatment group. 
 99 
4.4 Discussion 
This work is the first to examine how blocking BMPR1a signaling and 
removing ERα in osteoblasts affect bone’s response to mechanical loading in vivo.  At 
10 weeks of age, pOC-ERαKO and LC female mice were mechanically loaded in vivo 
for 5 days a week for 2 weeks in the left tibia with the contralateral limbs as control.  
Half of the animals in each genotype were administered RAP-661, a soluble BMPR1a 
receptor that prevents BMP2/4 signaling in bone, twice weekly while the other half 
received an IgG-matched control during the loading experiment.  We found that 
administering RAP-661 increased bone mass in the cancellous tibial metaphysis and 
vertebral cortical shell and cancellous body, but not in the cortical tibial metaphysis, 
tibial midshaft, or femoral midshaft.  In addition, the anabolic response to tibial 
loading was reduced in the cortical and cancellous metaphysis in drug-treated animals, 























Table 4.3 Two weeks of tibial loading increased bone mass at the tibial 
metaphysis and tibial midshaft in 10-week-old pOC-ERαKO and LC 
female mice, as indicated by p-values from a two-factor repeated measures 
ANOVA. RAP-661 drug treatment only affected the cancellous 
metaphysis, resulting in significantly increased bone mass over placebo 
values.  In general, placebo-treated animals in the cancellous metaphysis 
responded more to loading than RAP-661-treated animals.  At the tibial 
midshaft, drug and genotype had no effect. 
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Previously, RAP-661 increased bone mass in the tibial metaphysis in growing 
C57Bl/6 mice in a time- and dose-dependent manner (29).  In the present study, RAP-
661 drug treatment also dramatically increased bone mass in the vertebra and 
cancellous tibial metaphysis along with increased strength in the vertebra, but had no 
effect at the femoral or cortical midshafts.  Our results are consistent with conditional 
BMPR1a knockout mouse models.   In mice with BMPR1a removed from postnatal 
osteoblasts, bone mass was decreased early in life but increased in adult animals 
compared to controls (27).  In mice with tamoxifen-induced osteoblast-specific 
ablation of BMPR1a, trabecular bone mass was increased at both 21 days and 22 
months of age, while femoral midshaft bone mass was not affected (37).  The 
differential effects of BMPR1a in corticocancellous sites compared to purely cortical 
sites could be due to a number of reasons.  If BMPR1a is mostly acting at the tissue 
surface, cancellous bone mass will be more easily increased due to its greater surface 
area.  In addition, BMP2 and BMP4, although very highly expressed in bone, are more 
highly expressed in cancellous bone than in mid-diaphyseal cortical bone, and 
therefore blocking BMP signaling through this pathway is likely to affect cancellous 
bone more than cortical bone (38).  In OVX mice, treatment with RAP-661 increased 
femoral maximum load and stiffness back to control animal levels, indicating that the 
drug can increase bone mass in the bone diaphysis although not observed in the 
current study (29).  However, these treatments were for longer time points (4 and 8 
weeks) at a higher dosage (10mg/kg vs. 5 mg/kg for the current study). 
In the vertebral cortical shell, pOC-ERαKO mice responded less to two weeks 
of RAP-661 treatment than LC animals, suggesting that ERα and BMP2/4 signaling in 
osteoblasts interact.  Absence of ERα partially blocked the mechanism that enhanced 
bone mass with drug treatment was partially blocked when ERα is removed.  One 
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possible explanation is through receptor activator of nuclear factor kappa-B ligand 
(RANKL), secreted by osteoblasts to regulate osteoclast differentiation and increase 
bone resorption (39).  Osteoprotegrin (OPG), also secreted by osteoblasts, prevents 
RANKL from binding to RANK to decrease bone resorption.  Denosumab, a current 
osteoporosis therapy, is a RANKL-antibody that reduces bone resorption. Estrogen 
deficiency also increases RANKL expression (40), which is one mechanism by which 
post-menopausal women lose bone mass, and therefore may be one mechanism for 
bone loss found in pOC-ERαKO animals.  In OVX mice, RAP-661 treatment 
decreased serum RANKL levels while increasing serum OPG levels (29).  By 
increasing serum RANKL levels, lack of ERα in osteoblasts could compete with the 
anabolic mechanism of RAP-661 and explain the reduced response to RAP-661 in the 
vertebral shell in pOC-ERαKO mice.  
Previous work has also shown direct and indirect crosstalk between the 
BMP2/4 and ER signaling pathways.  With estrogen treatment, Smad activity induced 
by BMP-2 was increased and decreased in mouse myoblasts and breast cancer cells, 
respectively (31, 32).  In mouse myoblastic cells, Smad1/5/8 phophorylation, induced 
by BMP-2, was enhanced with estrogen treatment (31).   On the other hand, BMP 
treatment increased the expression of both ERα and ERβ, while Smad4, downstream 
of BMP signaling, repressed estrogen-induced transcriptional activity (30, 32).  
Translating in vitro cell work in breast cancer and myoblasts cells to in vivo effects in 
bone is difficult, but it is possible propose that in osteoblasts, lack of ERα could have 
an impact on the effects of blocking signaling through BMPR1a, possibly by 
promoting signaling through another BMP receptor pair or through ERβ. 
Controlled in vivo loading models have been widely used to study bone 
adaptation to load (41-43).  Our loading model consistently has shown increased bone 
mass in the proximal tibia and tibial midshaft of growing, adult, male, female, and 
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genetically altered mice (17, 41, 44, 45).  In the current study, we found that mice 
treated with RAP-661 responded less to loading than placebo animals in the tibial 
metaphysis, but similarly at the tibial midshaft.  One possible explanation is that RAP-
661 increased cancellous BV/TV to such a large degree that any further loading-
induced increase would be swamped out.  A subsequent loading study with a lower 
drug dosage would help determine if the drug effect is masking the loading effect or 
attenuating the loading effect.  RAP-661 did not affect bone mass in the cortical shell 
metaphysis, which still responded less to loading in the drug-treated animals than 
placebo-treated animals.  During axial tibial compression at the metaphysis, the 
cortical shell and cancellous core share the load.  We cannot rule out the possibility 
that the increased cancellous bone mass carried more of the load in drug-treated 
animals, which resulted in stress shielding for the cortical metaphyseal shell and 
therefore could explain the shell’s decreased anabolic response to loading.  However, 
these results could also suggest that bone’s response to mechanical loading may be 
mediated through BMPR1a.  BMPs in general have been associated with bone’s 
response to mechanical loading previously.  Osteoblasts subjected to dynamic strain 
showed increased Smad1/5/8 expression, downstream of BMP signaling (46).  After 
exposure to loading, human fetal osteoblasts showed differential expression of many 
of the BMPs (47).  BMP2 and BMP4 expression were also upregulated after in vivo 
loading in rodents (26, 48). In support with our findings, osteoblast-like cells from 
C57Bl/6 mice increased expression of BMPR1a and BMPR1b after fluid shear 
mechanical stimulation (25).  Without BMPR1a, RAP-661-treated mice may not be 
able to fully convert a mechanical loading stimulus to an osteogenic response. 
RAP-661 treatment in LC and pOC-ERαKO mice increased bone mass 
markedly after two weeks of treatment compared to placebo controls in cortico-
cancellous sites but not in cortical diaphyses.  Because the greatest risks of 
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osteoporotic fracture are present in cortico-cancellous sites such as the vertebra or hip, 
inhibiting signaling through the BMPR1a receptor is a promising future drug treatment 
option for osteoporosis.  Future experiments should further investigate the signaling 
mechanisms involved, especially in the absence of estrogen, which is the case for 
many post-menopausal osteoporotic women.  Also, because BMPR1a is present in 
many cell types throughout the body, potential interactions and side effects of the 
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Chapter 5  
CONCLUSIONS AND DISCUSSION 
5.1 Summary 
The objective of this research was to elucidate the function of estrogen 
receptor alpha (ERα) signaling in osteoblasts. Because decreased circulating estrogen 
levels are associated with decreased bone mass, understanding estrogen signaling in 
bone is critical in osteoporosis pathology and developing potential new therapies.  
However, the roles of ERα and ERβ, the two main hormone receptors involved in 
estrogen signaling, are not well characterized and vary by cell type.  After generating 
an osteoblast-specific ERα knockout (pOC-ERαKO) mouse model, the role of ERα in 
osteoblasts in general bone phenotype (Aim 1), bone’s response to mechanical loading 
(Aim 2), and crosstalk with BMPR1a, a type I receptor in bone morphogenetic protein 
(BMP) signaling (Aim 3), were assessed.  In pOC-ERαKO females, bone mass was 
reduced and the response to mechanical loading was enhanced.  In pOC-ERαKO 
females, bone mass was increased and the response to mechanical loading was 
unaltered.  In females, ERα and BMPR1a were shown to interact in bone, and bone’s 
response to mechanical loading was partially mediated by BMPR1a.  This thesis 
shows that ERα has important, sex-specific roles in bone and bone 
mechanoadaptation, and that the receptor is involved in other important bone signaling 
networks.  Developing new drugs or technologies that can harness the signaling 
mechanisms of ERα in bone would advance the clinical field. 
 
Aim 1 
 Global ERαKO mice have systemic effects that interfere with interpreting the 
role of ERα in bone (1-4).  To combat these confounding effects, cell-specific 
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knockouts allow the receptor’s role to be examined at a particular point of interest in 
the cell lineage (5-11). An osteoblast-specific ERαKO mouse model was developed to 
eliminate systemic effects present in the global knockout.  We hypothesized that 
removing ERα at the osteoblast stage of lineage would decrease bone mass in females.  
Bone mass, architecture, and strength in female pOC-ERαKO and littermate control 
(LC) mice at 12 and 18 weeks of age were assessed.  At both ages, pOC-ERαKO mice 
had reduced bone volume fraction due to increased trabecular separation in the 
proximal tibia, L5 vertebra, and distal femur compared to LC.  In the vertebra, 
trabecular thickness was also decreased in knockouts, contributing to the overall 
decreased bone mass.  Osteoblast activity in knockouts was decreased in the 
cancellous proximal tibia, but osteoclast number was similar to LC.  At cortical sites 
in the tibial midshaft, L5 vertebra, and distal femur, cortical area was decreased in 
pOC-ERαKO mice at both ages, accompanied by overall decreased cortical thickness.  
The decreased cortical and cancellous bone mass corresponded to decreased whole 
bone strength in the femur and vertebra.  Osteoblastic ERα regulated both cortical and 
cancellous bone mass at multiple bone sites. 
 
Aim 2  
 Healthy bone has the ability to adapt to its mechanical requirements.  Increased 
dynamic mechanical loading, especially in younger populations, can promote bone 
formation (12, 13).  However, in older populations or in bone diseases such as 
osteoporosis, exercise programs have varied results on increasing bone mass (14-16).  
To study bone’s anabolic response to mechanical forces, controlled in vivo 
compression of rodent limbs are widely used models (10, 11, 17-19).  In global 
ERαKO mice, the response to loading was attenuated compared to controls, but in 
bone cell-specific knockouts, the loading response has not been well studied (11, 20, 
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21).  We hypothesized that pOC-ERαKO mice would have decreased bone mass and 
would respond less to mechanical loading.  We bred 10-week-old male and female 
pOC-ERαKO and LC mice to determine the role of ERα in osteoblasts in bone 
phenotype and mechanotransduction in both sexes.   After measuring bone stiffness at 
the tibial midshaft, all mice had their left tibiae loaded 5 days a week for 2 weeks with 
a peak load of –9.0N, which corresponded to 1200με at the midshaft.  Lack of ERα in 
osteoblasts had the opposite effect on bone mass in males than in females, compared 
to their respective LC.  Female pOC-ERαKO mice showed reduced cancellous bone 
volume fraction in the tibial metaphysis and L5 vertebral body and reduced cortical 
area in the vertebral cortical shell and femoral midshaft.  In contrast, male pOC-
ERαKO had increased bone volume fraction in the L5 vertebral body and increased 
cortical area at both the tibial and femoral midshafts.  Reflecting these bone mass 
changes, female knockouts had decreased whole bone vertebral strength, while males 
had increased whole bone femoral strength compared to their sex-matched controls.  
The response to mechanical loading in these animals was evaluated at both the tibial 
metaphysis and the tibial midshaft.  In female pOC-ERαKO mice, cancellous bone 
volume fraction increased more after 2 weeks of tibial loading than LC mice, while 
cortical area in the cortical shell of the metaphysis adapted similarly in both 
genotypes.  Furthermore, at the tibial midshaft, cortical area increased more in female 
knockouts.  In males, bone volume fraction did not increase with loading in either 
genotype, but in the cortical shell of the metaphysis and the cortical midshaft, cortical 
area and maximum moment of inertia increased similarly in pOC-ERαKO male and 
LC after loading.  ERα in osteoblasts affected bone mass and the response to 
mechanical loading differentially in males and females. 
 
Aim 3  
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 Cell signaling in bone is complex. Estrogen and its receptors interact with a 
variety of other signaling pathways.  Bone morphogenetic proteins (BMPs) and their 
signaling effectors have been shown to interact with ERα in non-bone cell types both 
in vitro and in vivo, and BMPs have also been implicated in bone adaptation (22-26).  
Throughout development, BMPs regulate a wide variety of cell processes, but BMP2 
and 4 have specific roles in bone.  Because BMP2 and BMP4 bind highly to the 
receptor BMPR1a, a soluble BMPR1a receptor, RAP-661, was created to block all 
signaling through BMPR1a (27).  We hypothesized that blocking BMP2/4 signaling 
would increase bone mass and reduce bone’s response to mechanical loading.  10-
week-old pOC-ERαKO and LC female mice were administered either RAP-661 or a 
IgG-matched placebo.  All animals underwent left tibial loading for 2 weeks with a 
peak load of -7.0N to eliminate woven bone that was induced at the tibial midshaft in 
female animals loaded at -9.0N in Aim 2.  RAP-661 treatment increased bone mass in 
the vertebra and cancellous tibial metaphysis, but not at the cortical shell of the tibial 
metaphysis, tibial midshaft, or femoral midshaft.  Furthermore, RAP-661 increased 
vertebral cortical area and cortical thickness to a lesser extent in pOC-ERαKO mice 
than in LC, and vertebral IMAX was only enhanced by RAP-661 in LC mice. In the 
tibial metaphysis, animals treated with RAP-661 showed a decreased anabolic 
response to 2 week of tibial loading compared to placebo animals.  In contrast, at the 
tibial midshaft both placebo and RAP-661-treated mice exhibited similar increases in 
cortical area, cortical thickness, and moments of inertia from loading.  In short, RAP-
661 treatment affected mostly cancellous regions and reduced bone’s response to 
mechanical loading only in the tibial metaphysis. 
 
5.2 Strengths 
 Knockout mouse models are valuable tools that allow researchers to study the 
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role of a particular gene/protein in cellular or whole body function.  The pOC- 
ERαKO mouse model, in which ERα is removed from mature osteoblasts and 
osteoctyes, is a major strength of this work.  Many other bone-cell-specific ERαKO 
mice have been developed, including those that target ERα deletion in osteoblast 
progenitors, osteoblasts precursors, committed osteoblasts, osteocytes, osteoclast 
precursors, and osteoclasts (5-11). To date, only one other group has developed the 
pOC-ERαKO thus far, and similar effects on male and female bone mass to this work 
have been reported (8). 
 The tibial compression model used in this work elicits a reliable, robust 
increase in bone mass in both cancellous and cortical bone.  Other rodent loading 
models exist that use rats, which cannot be genetically manipulated with the ease that 
mice can (28), or use the ulna instead of the tibia (19), which only allows for studying 
cortical bone’s adaptation to loading.  Although other mouse tibial compression 
models exist, a different waveform is often used.  Instead of loading the tibia 5 days a 
week, 1200 cycles per day, at a rate of 4Hz, with a 0.1-second rest between cycles 
(29), other groups may load the tibia 3 days a week, 60 cycles per day, at 2Hz, with 
10-second rest between cycles (30).  We have consistently shown an osteogenic 
response to our loading model in male and females, in growing and aged mice, in 
gonadectomized mice, and in genetically modified mice (17, 29, 31, 32).  In contrast, 
the loading waveform with longer rests and fewer cycles per day has actually been 
shown to decrease trabecular bone volume fraction in the cancellous metaphysis in 
aged mice and is not as osteogenic as the model used in the current work (33).   
 Another strength of this work is the ability to study signaling interactions of 
ERα in osteoblasts with other important bone pathways, including the BMP pathway 
using RAP-661, a soluble BMPR1a receptor that blocks signaling through BMP2/4.  
Currently, a number of osteoporosis drugs are FDA-approved, the majority of which 
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are classified as anti-resorptive agents.  Anti-resorptive agents include selective 
estrogen receptor modulators (SERMs), bisphosphonates, non-steroidal hormones, and 
antibodies.  The only anabolic agent available for osteoporosis treatment is teriparatide 
(rhPTH) that acts by increasing bone turnover so that osteoblasts are stimulated to a 
greater extent and thereby bone mass increases. RAP-661 is another potential anabolic 
osteoporosis treatment that increases bone mass and strength in mice by increasing 
osteoblast and osteoclast activity (27).  We have also contributed to the efficacy 
research of this drug through Aim 3, where we administered the drug or placebo to 
female pOC-ERαKO and LC mice concurrently with daily tibial compression.  This 
study was the first to examine the interactions of ERα in osteoblasts and mechanical 
loading with BMPR1a. 
 
5.3 Limitations 
 Every scientific model can only be examined in its specific context, which 
always introduces limitations.  One limitation with the pOC-ERαKO mouse model is 
the specificity of ERα deletion.  Breeding mice containing the osteocalcin-promoted 
cre recombinase (OC-Cre) (34) with mice that have exon 3 of the ERα gene floxed 
with loxP sites (3) should remove ERα from only mature osteoblasts and osteoctyes, 
because osteocalcin is specific to osteoblasts.  After OC-Cre mice were crossed with 
Rosa26-Cre reporter mice and tibia were fixed and embedded, longitudinal tibial 
sections were stained with X-Gal to detect β-galactosidase activity, which indicates 
the cre specificity (Figure 5.1).  We found distinct staining in osteoblasts and 
osteocytes, but also found β-galactosidase activity in hypertrophic chondroctyes, 
consistent with one previous report (35).  Although cellular organization appeared 
normal in pOC-ERαKO growth plates, and growth plate height and long bone lengths 
did not vary by genotype, if ERα is absent in some hypertrophic chondroctyes in our 
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model, then it is potentially also absent from osteoblast precursors, osteoblast 
progenitors, and committed osteoblasts.  The effects on endochondral ossification 
could be further explored.  In a chondrocyte-specific ERαKO mouse, growth plate 
heights and long bone lengths were not altered compared to controls (36).  However, 
the growth plate height in knockout mice did not decrease in response to estrogen 
treatment as wildtype mice did.  Furthermore, long bones continued to grow past 4 
months of age in the cartilage-specific ERαKOs.  Similar experiments could be 
performed on pOC-ERαKO mice to assess the possibility of ERα deletion in 
chondrocytes by aging the mice to assess long bone growth and treating mice with 
estrogen to examine growth plate height. 
 Although knockout mice, especially tissue-specific knockout mice, provide 
insight into the role of a particular gene in development and cellular processes, one 
drawback is the compensatory effects that arise from gene deficiency from birth or 
even in the womb.  Many knockout mice are embryonically lethal, including the 
Figure 5.1 Cre expression of OC-Cre mice was found not only in osteoblasts and 
osteocytes, but also in hypertrophic chondroctyes.  OC-Cre mice were crossed 
with Rosa26-Cre reporter mice, and then tibiae at 10 weeks were embedded, 
sectioned, and stained with LacZ to detect β-galactosidase activity. 
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global knockouts for BMP2, BMP4, BMPR1a, and Smad1, but other knockout models 
that are viable develop significant compensatory mechanisms due to the innate 
redundancy of biological systems (37).  For example, when both are present, ERα and 
ERβ repress functions of one another, but in the absence of ERα, ERβ may 
compensate and take over some of ERα’s functions (38).  If ERα were removed from 
osteoblasts but only in adult animals for a given amount of time, its effects on bone 
mass could be quite different than when it was removed in utero.  Developing a 
tamoxifen-induced, osteoblast-specific ERαKO mouse would provide interesting 
insight into the role of ERα in bone development and growth vs. bone maintenance.  
Tamoxifen-induced knockouts only activate cre recombinase in animals that harbor 
both a floxed gene and cre recombinase when tamoxifen is administered.  An 
inducible osteoblast-specific BMPR1a knockout mouse already exists that used a 
tamoxifen-induced OC-Cre mouse (39). 
 In vivo loading models provide controlled, non-invasive environments for 
studying bone adaptation.  Although these models control the magnitude of applied 
loads very well, the tissue-level strains are much more difficult to characterize, 
especially in the cancellous bone of the tibial metaphysis.  To conduct loading 
experiments, a peak load is chosen that matches strains experienced on the diaphyseal 
cortex, measured by strain gauging at the midshaft.  In Aim 2, bone stiffness was 
similar among male and female pOC-ERαKO and LC mice, and so all mice were 
loaded with a peak load of -9.0N.  However, microCT analysis revealed major cortical 
and cancellous bone differences between genotypes and sex.  At the tibial metaphysis, 
female pOC-ERαKO mice had decreased bone volume fraction than LC, and the 
knockouts responded more to mechanical loading.  This increased anabolic response 
could be due to higher strains experienced in the cancellous bone in pOC-ERαKO 
mice, as osteogenic responses have been correlated with bone strain magnitudes (40).  
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One approach to determine bone stiffness and engendered strains with loading would 
be to develop finite element models of whole bones in each genotype (29, 32).  
Another approach would be to design a loading experiment in which the female pOC-
ERαKO and LC mice each received a peak load proportional to their baseline bone 
volume fraction.  If the pOC-ERαKO mice still responded more to the loading than 
LC mice, then the increased response would be due to the genotype rather than 
different strain environments.  
 Although RAP-661, a soluble BMPR1a receptor, increased bone mass 
dramatically in mice, possible side effects on other body systems need further 
exploration and are a limitation to the possibility of this drug being used as an 
osteoporosis treatment.  BMPR1a, although highly implicated in bone, is widely 
expressed in many tissues throughout development (41).  Its importance is obvious by 
the embryonic lethality of a BMPR1a global KO mouse (42).  As with all drugs, side 
effects are inevitable, and the relative benefits and risks must be fully evaluated before 
a drug can be approved by the FDA.  Performing long-term drug treatment studies, 
toxicity studies, and full organ analysis studies would be next steps. 
 
5.4 Future Work 
 The pOC-ERαKO mouse model developed in this work showed an important 
role of ERα in bone mass and bone’s response to mechanical loading, while also 
beginning to delve into the signaling mechanisms of the receptor.  Future work would 
expand on ERα signaling knowledge to better understand osteoporosis pathology.  
Whether the bone phenotype or loading response in growing male and female pOC-
ERαKO mice is mirrored in aged mice needs to be determined.  Also, more work 
should focus on elucidating the cellular and molecular mechanisms that drive the 
genotype-specific responses seen in all three Aims.  Other potential future experiments 
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include performing ovariectomy on pOC-ERαKO female mice, administering RAP-
661 in aged mice, and exploring the signaling crosstalk between ERα in osteoblasts 
and other bone-specific pathways by administering additional signaling blocking 
agents. 
 
Effects of age in pOC-ERαKO mice 
 After generating a new knockout mouse model, its characteristics should be 
studied at multiple ages to determine if a phenomenon is age-specific or if it is 
consistent throughout the lifespan.  This information gives insight into the 
mechanisms behind the phenotype or response reported.  Furthermore, when bone is 
still modeling during growth, the skeleton behaves differently than when bone is only 
in the remodeling phase after peak bone mass is achieved, usually around 16 weeks in 
mice (43).  In Aim 1, pOC-ERαKO female mice were examined at 12 and 18 weeks of 
age.  In Aim 2, male and female pOC-ERαKO mice were examined at 12 weeks of 
age, both in bone phenotype and bone’s response to mechanical loading (10 weeks 
plus 2 weeks of loading).  For pOC-ERαKO, another group examined the bone 
phenotype of males and females at 3.5 and 6 months of age (8).  Although decreases in 
female bone mass similar to our results were reported at both ages, male pOC-ERαKO 
mice exhibited similar bone mass to controls at 3.5 months and decreased trabecular 
bone mass at 6 months of age.  Because of this discrepancy, a study utilizing aged 
pOC-ERαKO female and male mice from the current work would indicate if the 
decreased bone mass found in females and increased bone mass found in males 
continues with age.  Furthermore, in vivo tibial loading studies should be applied to 6-
month old pOC-ERαKO mice of both sexes. Our tibial loading model is anabolic in 
both growing and aged mice (17, 32); however, a loading model with a different 
waveform actually reduced bone mass in the tibial metaphysis in aged female mice 
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(33).  In humans, bone’s anabolic response to exercise decreases with age (14), and so 
determining if the controlled loading model can still stimulate bone formation in aged 
pOC-ERαKO mice, when bone is only remodeling, is a worthwhile endeavor.  
Furthermore, aged mice may be more relevant to human clinical data, as osteoporosis 
mostly affects the elderly and is especially present in estrogen-deplete post-
menopausal women. 
 
Cellular mechanisms driving the bone phenotype and response to loading in pOC-
ERαKO mice 
 Decreased estrogen levels are a major cause of bone loss in postmenopausal 
women (44).  During puberty, estrogen promotes bone growth, but it also contributes 
to growth plate closure and suppression of periosteal expansion, indicating multiple 
functions based on hormone levels, age, and other yet unknown factors (45).  Estrogen 
signaling can occur through classical pathways, involving estrogen’s activation of 
ERα or ERβ and subsequently gene transcription or repression events.  However, non-
genotropic pathways have also been recognized, which involve the ligand-binding 
domain of the ERs but are involved in other intracellular signaling pathways instead of 
direct gene regulation (46).  The signaling environments in which estrogens and ERs 
are involved are poorly understood due to the complexity.  In vitro, estrogen and ERα 
have been proposed to be involved in a number of signaling pathways important to 
bone, including the wnt/β-catenin pathway, IGF-1 signaling, BMP signaling, and PTH 
signaling (22, 23, 47).      
 This work has shown that in pOC-ERαKO female mice, bone mass is reduced 
and the response to mechanical loading is reduced.  In pOC-ERαKO male mice, bone 
mass is increased and the response to mechanical loading is unchanged.  However, by 
removing ERα from osteoblasts and osteocytes, the signaling environment is perturbed 
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from before birth.  By determining changes in gene expression of bone-related 
pathways, the in vivo interactions of ERα with other cell signaling systems can be 
determined.  RNAseq is a technique that determines the differential regulation of 
genes utilizing the entire mouse genome.  From this database, an abundant amount of 
information can be garnered.  By analyzing the cancellous compartment of the tibial 
metaphysis, the cortical shell of the tibial metaphysis, and the cortical diaphysis 
separately in male and female pOC-ERαKO and LC mice, genes that are affected by 
lack of ERα in osteoblasts and osteocytes could be determined.  For example, 
expression levels of ERβ may be highly increased in knockouts, as this receptor has 
been postulated to compensate for loss of ERα in vitro (38).   Another hypothesis 
would involve downregulation of wnt agonists, since ERs and wnts may cooperate 
with each other in bone (47, 48).   
 Determining the potential mechanisms behind why female pOC-ERαKO mice 
responded more to loading would expand on this work.  Similarly, RNAseq data could 
be obtained from cancellous and cortical bone of left, loaded tibia and right, control 
tibia to compare gene expression profile from both pOC-ERαKO and LC mice.  In 
Aim 2 and Aim 3, two weeks of in vivo tibial loading were used to assess whole tissue 
changes in bone mass and architecture.  The cellular mechanisms that drive tissue-
level changes occur on shorter time scales.  Some transcription factors can be targeted 
in under 30 minutes after a stimulus, but osteoblasts do not increase until 24-48 hours 
after a dynamic loading event, and mineralization does not begin for at least 3 days 
after the appropriate stimulus.  Therefore, obtaining samples for RNAseq data at time 
points that are 3 hours, 24 hours, and 3 days after single or multiple days of loading 
would provide much information about all of these processes.  Information gained 
from RNAseq experiments in pOC-ERαKO and LC mice with and without loading 
could generate ideas for future pathways to target for new drugs in osteoporosis 
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prevention and treatment. 
 
OVX response in pOC-ERαKO mice 
 As a model of estrogen deficiency such as with osteoporosis, ovariectomy 
(OVX) in the rat is the gold standard.  This surgery excises the estrogen-producing 
ovaries and therefore removes most circulating estrogen (49).  More recently, mouse 
OVX models have been frequently implemented due to the ability to manipulate the 
mouse genome through knockout models, but bone loss varies widely with bone site 
and mouse strain (50).  Bone loss with OVX and bone mass increase with estrogen 
treatment differ among ERαKO mouse models, indicating bone cell-specific 
mechanisms for each process.  In global ERαKO mice, estrogen treatment after OVX 
did not increase cortical area or trabecular bone mineral density to the same degree as 
in ERβKO or WT mice, indicating that estrogen’s bone-building effects may be 
mediated by ERα (51).  In mice with ERα removed at the osteoblast precursor or 
osteoblast progenitor stage which resulted in decreased cortical bone mass, OVX did 
not lose cortical bone after OVX as wildtype mice did (7).  In osteoclast-specific 
ERαKO mice that had decreased cancellous bone mass, OVX did not induce 
cancellous bone loss as it did in wildtype mice (5).  Our pOC-ERαKO female mice 
showed decreased cancellous and cortical bone mass, a different phenotype than the 
other cell-specific ERαKO models.  First, an OVX experiment on pOC-ERαKO mice 
would indicate if ERα in osteoblasts is required for further cancellous or cortical bone 
loss when all circulating estrogen is removed.  Next, estrogen replacement in these 
mice would show if estrogen can still increase bone mass without osteoblastic ERα, 
possibly through ERα in other cell types, or through compensatory action of ERβ.  
Some research has indicated that ERα and ERβ repress a subset of gene transcriptional 
activity of each other when both are present, but ERβ may take over some of the 
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activity of ERα in its absence (38, 52). 
 
RAP-661 effects in older animals of both sexes 
 Exercise programs to increase bone mass are not as effective in post-
menopausal women as in pre-menopausal women (14).  After menopause, estrogen 
levels in women decline, which contributes to bone mass and architecture changes, but 
men experience a decline in hormones with age as well (44, 53, 54).  Likewise, in vivo 
animal models of bone adaptation have been shown to be less responsive in older 
animals or even promoters of bone loss (32, 55).  Whether the reason is because the 
cells are not sensing the mechanical signal as well or because the cells cannot translate 
the signal into the correct cellular response is yet to be determined.  Other factors may 
contribute to this phenomenon in humans, including increased serum concentration of 
sclerostin, a wnt signaling inhibitor, and decreased OPG serum levels with age, which 
in turn increases osteoclast activity (56). 
 During bone’s modeling phase, the shape of bone is changing and bone mass 
in increasing during an animal’s growth.  Once peak bone mass is achieved, bone 
remodeling persists to delicately balance bone formation and bone resorption to 
maintain bone mass.  Aim 3 examined the effects of RAP-661, a BMPR1a receptor 
inhibitor, on bone mass in pOC-ERαKO and LC female mice, and in the response to 
loading in these animals.  However, at 10 weeks of age, mice are still rapidly growing 
and have not yet achieved peak bone mass.  Furthermore, only female mice were 
utilized.  To fully characterize the interactions among RAP-661, osteoblastic ERα, and 
loading, similar experiments should be repeated on older animals of both sexes that 
are at least skeletally mature or that are aged to 6 months.  Experiments on aged mice 
would give more relevance to the drug’s target demographic, as osteoporosis is most 
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In the field of bone metabolism, considerable interest exists in elucidating new 
anabolic pathways that can be targeted therapeutically to improve bone mass and 
strength.   The dysregulation of certain bone-active signaling pathways, manifest in 
numerous human diseases of bone metabolism as altered bone mass, size and strength, 
have shed light on the mechanisms of norma7l skeletal homeostasis.  More 
importantly, these observations provide insight into viable molecular targets that can 
be manipulated in otherwise healthy patients to achieve a therapeutic outcome.  Recent 
efforts in skeletal biology have been focused on uncovering new anabolic, rather than 
anti-catabolic, pathways that can be manipulated to improve bone mass in skeletally 
fragile individuals.  In addition, certain skeletal diseases have yielded targets for 
anabolic action in bone (e.g. hyperostosis corticalis, sclerosteosis).  However, a much 
more ubiquitous mechanism of bone formation and accrual, that is not based on 
disease yet is incredibly anabolic, is available for therapeutic discovery.  That 
mechanism is mechanotransduction, the process by which bone responds and adapts to 
its mechanical environment by adjusting tissue mass, architecture and material 
properties.   
Repeated increased loading, such as occurs with exercise, has the propensity to 
induce new bone formation.  Conversely, when loads are reduced during conditions 
such as bed rest, neuromuscular paralysis, and spaceflight, bone mass is lost in the 
weight-bearing bones.  Despite its anabolic potential, our understanding of the cellular 
and molecular mechanisms that govern this adaptive process is far from complete.  To 
systematically study this process, and eventually identify and clearly define the 
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anabolic mechanisms involved, reliable, meaningful, well-characterized, and 
reproducible physiologic models of mechanical loading are crucial, preferably in intact 
animals.  Towards this end, a number of animal loading models have been developed, 
including rodent exercise studies, rodent whole body vibration, and in vivo loading 
models such as tibial four-point bending, rodent ulnar axial loading, and mouse tibial 
axial loading (1-6).  An advantage of in vivo mechanical loading models is that 
controlled, repeated mechanical forces are applied to the skeletal site of interest.  In 
contrast, exercise studies are associated with a mechanical environment that is much 
more difficult to quantify and is less well-controlled.  
One in vivo loading model that has been met with broad appeal is the mouse tibial 
axial loading model.  This model applies cyclic, physiologically relevant loads to one 
tibia while using the contralateral tibia as an internal control (3, 7).  This model has 
several advantages, including the use of the mouse, and the presence of substantial 
volumes of cortical and cancellous bone. The mouse is a valuable animal model 
because of the opportunity to study genetic manipulations, including congenic, 
transgenic, knockout, and knock-in mice.  These genetic models can provide critical 
insights into the underlying mechanisms involved in mechanotransduction. The mouse 
tibia can provide information about the skeletal response to applied loads across 
several bone envelopes: cancellous, periosteal, and endocortical.   
This chapter describes general methods for cyclic loading of the mouse tibia.  The 
loading can be performed using a load-controlled mechanical testing system or a 
custom loading device with Labview software.  The basic protocol in our laboratories 
involves loading groups of mice under isoflurane anesthesia for multiple days, and the 
procedures described are generally applicable and can be modified to suit an 
investigator’s particular goals. Before beginning a loading experiment, a number of 
items must be considered.  Loading protocols reported in the literature use a variety of 
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different parameters including number of loading sessions per week, number of 
loading cycles per day, and characteristics of the load waveform including the loading 
frequency, loading rate, and inclusion of rest periods (8, 9).  Maximum or peak 
compressive load must also be determined prior to loading by using in vivo strain 
gauging techniques to measure bone stiffness at the tibial midshaft. Furthermore, 
before loading experiments are underway, a sham loading experiment must be 
performed to confirm the lack of systemic effects in any particular laboratory set-up.  
These considerations are first described, followed by a general outline of the strain 
gauging procedures and in vivo axial tibial loading methods. 
Although not the focus of this chapter, before beginning an experiment, relevant 
outcome measures must be chosen.  This choice will affect experimental design, 
number of animals, and experiment duration.  Common outcomes measures include 
gene expression via qPCR, bone geometry and morphology via micro-computed 
tomography, dynamic histomorphometry via injection of bone-seeking fluorescent 
labels prior to sacrifice, protein and/or RNA localization via immunohistochemistry or 
in situ hybridization, mechanical testing, serum measurements via ELISA or RIA, 




A.2.1 Animal Model Selection 
1. Select mouse strain.  The choice of background strain for mouse axial tibial 
loading will depend on a number of factors.  The amount of cancellous bone in 
the tibial metaphysis varies with mouse strain, as do cortical bone mass, bone 
mineral density, bone shape, and bone strength (10-14). Tibia length and 
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mouse size are also items to consider.  Furthermore, some mouse strains are 
more mechanoresponsive than others (15, 16). 
2. Select wild type or genetically modified mice.  Depending on the research 
question, genetically modified mice may help identify whether the response to 
loading depends on the absence, presence, overexpression or modification of a 
particular gene or set of genes.     
3. Select appropriate sex.  The research question being asked will guide the 
decision regarding the use of male or female mice (or both).  For example, 
models of post-menopausal osteoporosis are usually performed in female mice, 
particularly if ovariectomy will be used.  Models of osteoarthritis usually use 
male mice because of the chondroprotective effect of estrogen (17).  Many 
individual genes or larger quantitative trait loci (QTL) are associated with sex-
specific effects, so when dealing with a novel gene or pathway with no a priori 
knowledge of sex interaction, males and females should both be studied.    
4. Select mouse age.  Again, this choice depends on the research question.  
Growing animals are still accruing bone mass, until around 16-24 weeks of 
age, when peak bone mass is reached although the specific age varies with 
bone site and mouse strain (11, 14).  Aged mice are usually in a state of bone 
loss (18).  Mice that have just reached skeletal maturity (e.g., 16 wks of age) 
are often used for tibia loading because the skeleton is still young enough to 
elicit a robust anabolic response to mechanical stimulation, and at the same 
time, the appositional growth on the periosteal surfaces has dropped to very 
low levels.  This latter attribute allows for a less complicated interpretation of 
the load-induced bone formation effects observed in the loaded limb. At this 
age at this age the anabolic response is almost exclusively a result of loading, 
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rather than a combined function of growth and enhanced mechanical input (as 
occurs in loaded growing bone). 
 
A.2.2 Select appropriate controls.   
1. Sham controls.  A separate experiment must be performed to ensure that tibial 
loading does not cause systemic effects, which have been both confirmed and 
refuted in the literature (19, 20).  Confirm that paired contralateral control 
limbs from loaded mice are not different from control limbs obtained from 
separate nonloaded animals. This experiment should contain two groups of 
mice for an experimental duration corresponding to that of the planned in vivo 
tibial loading experiments.  The first group of mice should have one tibia 
loaded while the contralateral limb is used as an internal control.  The second 
group should be put under anesthesia and have one tibia placed in the loading 
device for the duration of loading just as the first group, but the tibia should 
not actually be loaded during the experiment (sham loading).  If the results 
from the two sets of control limbs are similar, then paired contralateral limbs 
are appropriate controls.   
2. Paired controls.  If no systemic effects are presents, the contralateral, unloaded 
limb is often used as the control tibia, to which all measurable outcomes will 
be compared in determining bone’s anabolic response to mechanical loading.  
 
A.2.3 Strain Gauging Materials (When not specified, materials can be ordered from 
Fisher Scientific or similar supplier) 
1. 60/40 tin/lead solder, 0.022 inch diameter (Multicore Solders, Westbury, NY) 
2. Three-conductor cable (Vishay Micro-Measurements, Wendell, NC, Cat# 336-
FTE) 
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3. Soldering iron (GC Electronics, Rockford, IL, Model# 12-070) 
4. Dissecting microscope with light source 
5. Dissecting curved jewelers microforceps (Fisher Scientific, Cat# 08-953F) 
6. Standard capacity wire stripping system (American Beauty, Clawson, MI, 
Model# 10503) 
7. Tip tinner (MG Chemicals, Burlington, Ontario, Cat# 4910-28G) 
8. Rosin Soldering Flux (Radio Shack) 
9. Single element strain gauges (Vishay Micro-Measurements, Cat# EA-06-
015LA-120) 
10. Scalpel holder and #15 scalpel blades 
11. Isopropyl alcohol 
12. Clear tape 
13. Index cards for gauge preparation 
14. 1st coat: M Bond Adhesive Resin Type AE (Vishay Micro-Measurements) 
15. Catalyst for 1st coat: M Bond Type 10 Curing Agent (Vishay Micro-
Measurements) 
16. 2nd coat: M Coat D (Vishay Micro-Measurements) (store in refrigerator) 
17. 3rd coat: M Coat A (Vishay Micro-Measurements) (store in refrigerator) 
18. Weigh boats in which to mix the first coat with the catalyst 
19. Cotton swabs to apply isopropyl alcohol 
20. Wooden applicator sticks to apply coat coverings 
21. Eye dropper or transfer pipettes 
22. Xylene, to thin 3rd coat if needed 
23. Toluene, to thin 2nd coat if needed 
24. Plugs for wires to connect gauge to computer or data acquisition device (Digi-
Key, Thief River Falls, MN, Part# A26528-40-ND) 
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25. 1-min, 3-min, or 5-min curing epoxy 
26. Digital multimeter 
27. Strain conditioning hardware including bridge excitation, Wheatstone bridge 
circuit, and signal amplification and filtering.  Integrated systems are produced 
by Vishay Micro-measurements and National Instruments LabView board 
(Part #’s 781156-01, 779521-01, 194738-01, 779012-01).   
 
A.2.4 Surgical Supplies  
1. Surgical tools including scissors, small scalpels and blades, jeweler’s forceps, 
periosteal elevator and small-tooth forceps 
2. Small gauze 
3. Small animal razor 
4. Calipers 
5. Cotton swabs 
6. Methyl ethyl ketone 
7. Cyanoacrylate tissue adhesive  
 
A.2.5 Loading Materials 
 
1. Loading device with actuator, calibrated load cell (or similar) 
2. Computer with connections for loading hardware and electronics  
3. If using custom loading device, signal conditioning hardware for data 
acquisition from load cell with Labview software for tibial loading (or similar) 
(see Note 1) 
4. Loading configuration files to input loading parameters 
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5. Wooden cylindrical rod (~17mm length) from long cotton swab handle (Fisher 
Scientific,  #23-400-118) for loading program test (see Note 2) 
 
A.2.6 Mouse Care Materials 
 
1. Rodent cages with food, enrichment (such as a shelter, PVC pipe, running 
wheel, or hard wood block), nesting material, and water. 
2. Rodent anesthesia induction chamber 
3. Mouse anesthesia nose cone 
4. Isoflurane anesthesia machine with tubing attached to anesthesia chamber and 
mouse nose cone simultaneously 
5. Oxygen tank connected to isoflurane machine 
6. Isoflurane 
7. Carbon cartridge halogen filters connected to tubing to scavenge isoflurane 
8. Sterile petroleum jelly eye ointment (Fisher Scientific, Cat# NC0138063) 
9. Extra mouse cage for anesthesia recovery 




All animal procedures should be reviewed and approved by your Institutional Animal 
Care and Use Committee. 
 
Prior to Loading Experiment: 
 
A.3.1 Loading Parameter Selection 
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1. Select peak or maximum compressive load.  Peak or maximum load is the load 
level that will be reached repeatedly during the cyclic loading.  This load can 
vary depending on age, sex, strain, and genotype.  To determine this load level, 
in vivo strain gaging at the tibial midshaft should be performed. (See 3.2 
“Determining in vivo stiffness using strain gauges” below.)  By determining 
tibial bone stiffness at the midshaft, the load to produce a desired strain at the 
tibial midshaft can be chosen. 
2. Select pre-load value.  The magnitude of the compressive pre-load should be a 
small percentage of the maximum or peak load.  For example, –0.5N is an 
appropriate pre-load for a -9.0N compressive peak load (see Note 3). 
3. Select frequency, loading rate, dwell time, and number of cycles for the 
loading waveform.  Triangle waves are generally used because the load is 
applied at a constant strain rate.  For a sinusoidal wave, the loading rate varies 
throughout the cycle. One commonly used in vivo compressive loading 
protocol for the mouse consists of 1200 cycles per day at 4 Hz, with a load-
unload ramp of 0.15 seconds and 0.1s dwell time (Figure A1) (8).  Another 
common protocol applies 60 cycles per day at 2Hz, with a load-unload ramp of 
0.15 seconds and 10s second dwell time (9). (see Note 4) 
4. Select pause insertion duration.  Bone formation is stimulated by inserting 
pauses in between load cycles, rather than continuous cyclic loading (21).  In 
axial tibial loading of mice, rest insertions have been short (0.1s) or long 
(10.0s) (8, 9). As described in Step (3) pauses also can be used to achieve the 
desired loading rate and frequency.  
5. Select loading duration.  A range of loading durations have been used.  
Loading 3 or 5 times per week is most common (8, 9).  The duration of loading 
experiments can last from 1 day to 6 weeks and will depend on the research 
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question and outcome measurements.  Shorter time frames are often used when 
the primary outcome measures are skeletal gene expression changes after 
mechanical loading.  Longer time frames are often used to detect changes in 
bone morphology, geometry, and cellular activity. 
 
Figure A.1 Common in vivo axial tibial loading triangular waveforms for mice with 
9.0N peak compressive load.  (A) This waveform is usually run 5 times per week, 
1200 cycles per day at a rate of 4Hz, with a 0.1s dwell period, and 113 N/s loading 
rate.  (B) This waveform is run 3 times per week, 60 cycles per day at a rate of 0.1Hz, 
with a 10.0s dwell period and a 48 N/s loading rate. 
 
A.3.2 Determining in vivo stiffness using strain gauges 
 
Strain gauges are electrical conductors that change resistance when deformed.  By 
rigidly attaching a gauge to the surface of the tibia, the deformation caused by loading 
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can be measured. Stiffness is then calculated as the applied load per deformation. In 
practice, the goal is to determine the load required to achieve a desired strain level on 
the bone surface. For a stiff bone, this load is higher than for a more compliant bone.  
 
Figure A.2 Trimmed strain gauge assembly.  (A) Top view of strain gauge 
preparation.  (B) Side-view schematic of strain gauge preparation.  The 1
st
 coat is 





 coats are applied to the entire gauge top surface.  Stripped wire should not be 
exposed and can be covered by the coats. 
 
A.3.2.1 Strain gauge preparation (Figure A.2) 
1. Trim the gauge of unnecessary material.  Place gauge on an index card and 
view using a dissecting microscope.  Using a scalpel, remove excess material 
by cutting just within alignment markings; be careful not to disturb strain-
sensitive grid.  Use rocking motions, not shearing motions, to trim.  Once 




2. Prepare lead wires. Trim two wires to 17cm in length and strip approximately 
0.5cm of insulation from one end of each wire.  Dip these ends in solder flux 
and touch the soldering iron to each wire.   
3. Prepare gauge terminals.  Apply a minimal amount of solder primer to the end 
of each wire, then use soldering iron to add tin.  Use the dissecting microscope, 
and be careful to ensure that the added tin is contained within each terminal to 
prevent a short circuit. 
4. Solder lead wires onto gauge terminals using the stripped and tinned ends. 
5. Remove tape, and clean gauge with isopropyl alcohol. 
6. Bend the gauge wires into an S-shape so that the gauge is slanted with the grid 
section at the highest point. 
7. Apply insulating coats (see Note 5).  
1. Mix up M-coat AE in a weigh boat 30 minutes before application to 
gauge leads.  Mix a dime-sized amount of resin and two medicine 
drops of catalyst.  After 30 minutes, apply only to the gauge terminals 
by dabbing small amounts of resin to the leads by touching with a 
wooden applicator stick. Make sure the resin does not touch the grid.  
Let the resin catalyze overnight at room temperature.  
2. The following day, apply M-coat D (white, store in refrigerator) with 
the supplied brush to the entire upper surface of the gauge. Cure 
overnight at room temperature, or at room temperature for 15minutes 
and then in an oven for 1hr at 65°C (see Note 6). 
8. The following day, apply M-coat A (clear, stored in refrigerator) to the entire 
top surface of the gauge using a wooden applicator stick by dab touching.  
Cure for 4-5 days at room temperature before applying the strain gauges to the 
bone (see Note 7). 
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9. Attach a plug to the wire ends.  First apply flux to both the wire tips and the 
plug leads.  Then, apply solder to the plug leads.  Last, place the wires on top 
of the solder-covered plugs and heat with the soldering iron until bonded. 
10. Coat plug/wire connections with epoxy. 
11. Check the resistance of the gauge.  Using a digital multimeter, touch the leads 
of the device to the ends of the plug.  The strain gauge should read 120.0 Ω, 
but an acceptable range is 118.5-121.5 Ω. 
 
A.3.2.2 In Vivo Load-Strain Calibration  
1. Prepare a working area in a fume hood or biosafety cabinet.  
2. Anesthetize the mouse using isoflurane (2.5% in 1 L/min O2). This procedure 
applies strain gauges as a non-survival surgery, and so the mouse is 
anesthetized throughout the surgery and data collection and then euthananized.  
3. Shave the mouse limb. Fur must be removed at the site of strain gauge 
application, which is the medial aspect of the hindlimb of interest. 
4. Measure the length of the tibia from ankle to knee using calipers.  Use the 
result to approximate the tibial midshaft and mark this location on the skin 
using a felt-tipped pen.  
5. Incise the hindlimb to expose tibia.  This exposure is most easily accomplished 
using scissors.  First, make an opening where the midshaft was approximated.  
Then, using blunt dissection techniques separate skin from underlying muscle 
working proximally toward the knee and distally toward the ankle.  The 
incision should be as small as possible, but will usually span from just 
proximal to the ankle joint to just distal to the knee joint.  Keep in mind that 
the knee and ankle will be contact points when load is applied, therefore skin 
in these areas should remain intact. 
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6. Retract muscle and skin from implantation site. Use blunt dissection 
techniques to expose the periosteal surface of the tibia. 
7. Prepare the tibial surface for adhesion. Gently scrape the bone with a periosteal 
elevator to remove the periosteum and debris.  Degrease the bone using a 
cotton swab saturated with methyl ethyl ketone or chloroform.  
8. Prepare strain gauge for adhesion. Using a cotton swab saturated with methyl 
ethyl ketone, degrease the gauge carefully using minimal pressure.  Then, 
grasp the wires with jeweler’s forceps just above the gauge. 
9. Apply a very small drop of cyanoacrylate adhesive to the back of the gauge 
and immediately adhere the gauge to the midshaft of the tibia, being sure to 
align it with the long axis of the diaphysis (Figure A.3).  Adhering the gauge 
works best when another laboratory member is firmly holding the tibia in 
place.  Apply gentle pressure for one minute to ensure secure attachment (see 
Note 8). 
10. Examine the gauge attachment.  The grid should be located at the midshaft of 
the tibia, aligned with the longitudinal axis of the tibia, and not be medial or 
lateral or rotated. 
11. Calibrate the strain gauge. Open Labview or similar data acquisition software.  
Insert the gauge lead wires into strain conditioner or similar to complete the 
Wheatstone bridge quarter-bridge.  Calibrate the gauge to zero while the 
mouse lies in a dorsal recumbent position.  If calibration fails, a new gauge 
must be prepared and attached. To do so, the bone must be re-cleaned and the 
Steps 7-11 repeated. 
12. Apply compressive load. Place animal in the loading device actuator and apply 
a voltage corresponding to approximately a 2N load (see Note 9).  Ascertain 
the viability of the attached gauge by determining if the results resemble 
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accurate strain patterns.  Apply mechanical loads for varying voltages to 
produce peak compressive loads from approximately 2.0N to 10.0N (see Note 
10).   
13. Once all data have been collected, cut off the wires very close to the gauge, but 
keep the gauge attached to the bone.  The tibia should be imaged using micro-
computed tomography to determine if gauge placement was accurate. Gauge 
positioning is very important to ensure that results are comparable across 
different animals and ages.   
14. Properly euthanize mouse once strain gauge data have been obtained for both 
limbs. 
15. From stiffness data of all animals in a group, calculate the load needed to apply 
a specific strain to the tibial midshaft.  The physiologic range of bone strain 
across multiple vertebrate species during normal activity is 1000-1500 µe in 
compression (22). 
16. If desired, the strain data measured at the gauge location can be combined with 
a finite element analysis to determine the peak strain within the cortical cross 
section (9, 23). The strains at the gauge location are generally not the 
maximum strains for the cortex. This analysis requires solving for the tibial 
strains using a computational model of the mouse tibia at the section of gauge 
attachment.   
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Figure A.3 Proper strain gauge placement at the tibial midshaft. (A) Schematic 
showing strain gauge positioned at the middiaphysis of tibia. (B) Photograph of 
surgically-implanted gauge attached to surface of mouse tibia.  
 
A.3.3 In Vivo Axial Tibial Loading Experimental Methods 
 
A.3.3.1 Set Up and Preparation for In Vivo Axial Tibial Loading  
1. Connect and power on all electronic signal conditioning components, including 
the loading device. 
2. Open LabView loading program and insert proper loading parameters. 
3. Zero the load cell.  Check load offset by reading load when load cell is resting 
without any item positioned in the loading fixtures.  Depending on your 
loading system, either enter the load offset in Newtons if an offset is entered 
directly or select the option to zero the load cell.  The load from load cell 
should now read 0.0N (see Note 11).   
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4. Position a wooden rod in the loading device.  Adjust and lock the horizontal 
position such that the rod is snug between the actuator and the load cell, but 
not so tight that the load cell is loaded beyond -1.0N. 
5. Open and appropriately name the data file.  
6. Run practice loading session with rod to warm up components and confirm the 
loading setup is working correctly and has no unforeseen issues. 
 
Figure A.4 Mouse situated in loading device, ready for in vivo axial loading to be 
applied to the left tibia. 
 
A.3.3.2 Application of In Vivo Axial Tibial Loading 
1. While rod is being loaded, turn on oxygen tank and isoflurane machine.  Set 
oxygen flow to 1L/min and isoflurane flow to 2%, or whatever levels have 
been established in your protocol and approved by your Institutional Animal 
Care and Use Committee. 
2. Place first mouse to be loaded into anesthesia chamber (Mouse A).  
3. When Mouse A is asleep, remove Mouse A from chamber and apply eye 




4. When test of wooden rod completes, promptly loosen fixtures and remove the 
rod. 
5. Immediately check the load cell offset and adjust offset value if necessary so 
that the resting load cell reads 0.0N. 
6. Remove Mouse A from the anesthesia chamber and place nose cone over nose. 
7. Position Mouse A in the loading device, and lock the device so that the left 
tibia is snug.  The left knee should be snug at the load cell cup and foot snug at 
the actuator (Figure A.4).  Once tibia is positioned and the device adjusted and 
locked, load cell should not read below -1.0N before loading begins or too 
much compressive preload is applied to the tibia (see Note 12).  
8. Open a new data file and name the file appropriately to identify experiment, 
mouse, and date.  
9. Begin the loading program when Mouse A’s breathing is slowed. 
10. Monitor Mouse A during loading to check for continued slow breathing and 
unconsciousness (see Note 13).  
11. Monitor the load cell and voltage outputs during the loading program (see 
Note 14). 
12. When 2 to 3 minutes remain in the loading program, place the next mouse 
(Mouse B) into the isoflurane chamber (see Note 15).  
13. When Mouse B is asleep, remove Mouse B from chamber and apply eye 
ointment to each eye to maintain hydration during anesthesia, loading and 
recovery. 
14. Once loading program finishes, promptly unlock the loading device, remove 
Mouse A, and place on balance. 
15. Check the load cell offset and adjust offset value if necessary so that the 
resting load cell reads 0.0N. 
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16. Record Mouse A body mass and place the animal into anesthesia recovery 
cage.  Use one recovery cage per cage of mice.  Once all mice from a single 
cage have been loaded, make sure all mice are awake and moving around 
before returning the animals to their original cage. 
17. Position Mouse B into loading device, and adjust and lock the device so that 
left tibia is snug. 
18. Repeat steps 7-17 for each subsequent mouse until all mice are loaded (Mouse 
B becomes Mouse A, and next mouse becomes Mouse B, etc.). 
19. If a mouse loses >10% body mass over the course of an experiment, then wet 
food should be placed in the cage containing that mouse.  If a mouse loses 20% 
body mass, that mouse should no longer be used for the experiment and should 
be appropriately euthanized.   
20. Repeat procedure for each day that mice are to be loaded.  Always load the 
same tibia for each mouse. 
 
A.3.3.3 Clean up 
1. Once final mouse is in recovery cage, turn off isoflurane and oxygen. 
2. Close loading program software. 
3. Turn off all electronic components. 
 
A.3.4 Potential Outcome Measures  
1. Cortical and cancellous morphology by microcomputed tomography 
2. Gene expression by qRT-PCR 
3. Dynamic histomorphometry using fluorochrome labeling 
4. Protein localization by immunohistochemistry 
5. Serum hormone assays by ELISA 
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6. Many others 
 
 Notes  A.4
 
1. The loads can be applied using a load-controlled mechanical testing system, 
such as the Bose Enduratec system or similar, or using a custom loading device 
with load cell and associated electronics signal conditioning hardware 
(National Instruments) and control software (Labview).  When using a 
mechanical testing system, the loading waveform needs to be programmed 
within the software interface. Portable systems allow loading to be performed 
in the animal facility; table top machines require transportation of the animals 
to the laboratory. Custom loading devices are portable and allow loading in the 
animal facility. The Labview software can be customized as desired.   
2. The practice rod does not have to be made of wood or be exactly 17mm in 
length.  Wooden handles removed from long cotton swabs work well, and 
approximate the length of a mouse tibia and are less stiff than metal.) 
3. A pre-load is required so that the actuator does not lift off at the beginning of 
loading or during the dwell phase of the cyclic loading. 
4. Several loading waveform parameters are coupled. For example, loading rate 
and frequency are related. However, if the loading rate results in a higher 
frequency than desired, a dwell period may be included to achieve the desired 
frequency.   
5. Insulating coats are applied to solidify solder bonds and to waterproof the 
gauge. 
6. Toluene may be added to thin M-coat D as necessary. 
7. Xylene may be added to thin M-coat A as necessary. 
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8. Attaching the strain gauge to bone in vivo is a difficult step, and practice runs 
are recommended. 
9. This voltage should be determined prior to beginning strain gauge surgery. By 
loading a wooden rod in the loading device, the voltage corresponding to 2, 4, 
6, 8, 10, and 12N can be determined.  These values can then be applied once 
the strain gauge is applied to the anesthetized mouse. 
10. During strain gaging, several items must be monitored:  1) Noise in data.  If 
the gauge is not attached properly or is misaligned, the data will be very noisy 
(Figure A.5).  Occasionally this noise will decrease at higher voltages. If the 
noise does not disappear, then a new gauge needs to be attached and data 
collection must be repeated.  2) Strain levels.  During loading, the bone strain 
should be approximated by determining the difference between the peak and 
valley of the strain read out. If the applied strain exceeds 2000 µe as the 
voltage increases, then the higher voltages should be excluded for this 
particular mouse/strain/limb.  At very high strain levels, the bone could 
fracture. 3) Mouse status.  Be sure that the mouse is in deep anesthesia and that 
its nose remains in the nose cone at all times. 
11. The offset load for the load cell should stay relatively constant throughout the 
day and throughout the entire experiment.  If large changes are noted, the load 
cell should be recalibrated or replaced.  The offset load value should also be 
relatively low compared to the peak load applied to the tibia, at least <10% but 
ideally <5%.) 
12. The tibia is positioned horizontally in our loading device at Cornell, and so the 
mouse will be positioned on its back. If the tibia is positioned vertically, the 
mouse will be positioned differently. 
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13. If the mouse’s breathing becomes rapid, quickly increase the isoflurane to 2.5-
3% for a period of about 20 seconds.  For the next mouse, be sure to wait 
longer for slower breathing before beginning the loading program. 
14. Both the voltage input and load output should be steady cyclic wave patterns.  
Make sure peak load is being reached consistently.  If using Labview and input 
and/or output are jumpy, Hardware Configuration PID settings may need to be 
altered.  If load cell is not reading, immediately stop program and check that 
all wires are connected. 
15. This time to start anesthesia may vary depending on how quickly anesthesia 
takes effect on mice and will differ by age, sex and genotype. 
 
Figure A.5 Sample strain gauge data.  (A) Clean data with clear values, indicating 
proper gauge attachment. (B) Data with high frequency noise evident likely because 
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the gauge is poorly attached or may be aligned off-axis.  A new gauge should be used.   
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Figure B.1 ERα deletion confirmation.  (A) LC mice have positively stained 
osteoblasts for ERα, while cKO mice do not. (B) Genomic femur DNA PCR 






Figure B.2 Unlike the global ERαKO, pOC-ERαKO female mice had normal body 







Figure B.3 Vertebral compressive strength correlated linearly with BV/TV for LC but 
not pOC-ERαKO mice through regression analysis.  BV/TV accounted for 43% of the 
variation in vertebral compressive strength for LC mice (p=0.0006) but BV/TV had no 
predictive value for vertebral strength in pOC-ERαKO mice. 
 
Table B.1: Phenotype measurements for female pOC-ERαKO and LC 
mice 
 
 12wk 18wk 
 LC cKO LC cKO 
Crown/Rump  
Length (mm) 
84.0 ± 4.2 85.0 ± 3.0 88.2 ± 3.7 90.0 ± 2.3 
Ovary  
Mass (mg) 
63.3 ± 17 61.4 ± 22 68.0 ± 22 80.0 ± 30 
Uterus  
Mass (mg) 
106 ± 39 111 ± 46 112 ± 37 102 ± 49 
Right Femur 
 Length (mm) 
17.8 ± 0.38 17.8 ± 0.46 18.3 ± 0.65 18.5 ± 0.39 
Right Tibia 
 Length (mm) 
15.4 ± 0.38 15.1 ± 0.66 15.7 ± 0.37 16.0 ± 0.43 





Table B.2 Indices of cancellous bone determined by microCT analysis of VOIs from 











15-02 16wk LC 0.1323 0.0581 0.3175 
 15-15 16wk LC 0.1139 0.0559 0.3581 
 16-03 16wk LC 0.1534 0.0641 0.3073 735.313 
17-11 16wk LC 0.1125 0.0606 0.3326 744.558 
17-02 16wk LC 0.1449 0.0721 0.4168 747.618 
17-03 16wk LC 0.1486 0.0748 0.48 751.46 
18-08 16wk LC 0.1175 0.059 0.3342 723.528 
19-06 16wk LC 0.1089 0.0621 0.3211 775.941 
20-03 16wk LC 0.1665 0.0694 0.3206 761.226 
21_04 16wk LC 0.1402 0.066 0.3321 758.231 
16-01 16wk cKO 0.1539 0.0715 0.4412 733.294 
16-02 16wk cKO 0.1181 0.0639 0.4056 744.754 
17-07 16wk cKO 0.1682 0.0762 0.432 711.026 
17-10 16wk cKO 0.136 0.0679 0.62 728.541 
18-02 16wk cKO 0.0719 0.061 0.7517 749.507 
19-04 16wk cKO 0.1096 0.0704 0.6239 753.804 
21-07 16wk cKO 0.1423 0.0718 0.5716 740.521 
18-04 16wk cKO 0.0609 0.0596 0.6602 730.885 
21-05 16wk cKO 0.1481 0.0721 0.4519 
 22-01 16wk cKO 0.1416 0.0707 0.6751 
 1203 12wk LC 0.0854 0.0494 0.334 761.974 
1205 12wk LC 0.0874 0.0496 0.2949 787.942 
1216 12wk LC 0.0983 0.0488 0.2971 765.504 
1304 12wk LC 0.0904 0.0499 0.3203 752.141 
1306 12wk LC 0.0773 0.0504 0.3668 803.132 
1410 12wk LC 0.0643 0.0445 0.34 774.454 
1201 12wk cKO 0.0508 0.049 0.3859 786.682 
1204 12wk cKO 0.0617 0.0506 0.5242 798.846 
1208 12wk cKO 0.0543 0.0467 0.4667 788.699 
804 12wk cKO 0.0583 0.0465 0.4771 771.996 
1107 12wk cKO 0.0362 0.0445 0.5281 782.711 
1301 12wk cKO 0.0566 0.0491 0.5422 804.771 
1403 12wk cKO 0.0304 0.0453 0.5299 761.281 
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A26-06 12wk LC 0.1277 0.0521 0.2714 766.826 
A27-07 12wk LC 0.1171 0.0558 0.3601 761.812 
A28-02 12wk LC 0.1321 0.056 0.2768 760.25 
A29-04 12wk LC 0.0571 0.0463 0.4388 757.189 
B31-04 12wk LC 0.0887 0.0483 0.3272 762.073 
B34-12 12wk LC 0.0985 0.0475 0.3323 770.277 
B33-07 12wk LC 0.0855 0.0517 0.363 748.074 
C34-11 12wk LC 0.13 0.0573 0.2794 790.265 
C32-07 12wk LC 0.0824 0.0546 0.3794 780.629 
C35-14 12wk LC 0.1196 0.0596 0.3511 798.665 
D27-03 12wk cKO 0.07 0.0546 0.4882 773.337 
D27-13 12wk cKO 0.0875 0.0562 0.4842 769.626 
D28-04 12wk cKO 0.0815 0.0506 0.4263 764.612 
D32-01 12wk cKO 0.0607 0.0492 0.4799 740.196 
E29-09 12wk cKO 0.0844 0.0503 0.4636 766.24 
E30-06 12wk cKO 0.0666 0.0485 0.4339 762.594 
E31-01 12wk cKO 0.0594 0.0507 0.5039 780.173 
F31-02 12wk cKO 0.0594 0.0518 0.5613 783.038 
F29-03 12wk cKO 0.0778 0.0504 0.5005 741.824 






Table B.3 Indices of cortical bone determined by microCT analysis of VOIs from the 



















15-02 16wk LC 0.06847 0.04026 0.63177 1038.791 
15-15 16wk LC 0.06999 0.04573 0.60843 1025.444 
16-03 16wk LC 0.11252 0.06485 0.7709 1032.866 
17-11 16wk LC 0.05921 0.04392 0.64991 1030.783 
17-02 16wk LC 0.0699 0.05407 0.68306 1050.837 
17-03 16wk LC 0.06537 0.0444 0.68001 1058.845 
18-08 16wk LC 0.07438 0.0508 0.65304 1040.875 
19-06 16wk LC 0.11552 0.0684 0.78482 1042.307 
20-03 16wk LC 0.07076 0.04665 0.62202 1019.258 
21_04 16wk LC 0.08952 0.05177 0.69098 1027.137 
16-01 16wk cKO 0.10778 0.06594 0.74552 1026.485 
16-02 16wk cKO 0.07439 0.04275 0.66412 1038.27 
17-07 16wk cKO 0.06508 0.04235 0.62457 1026.55 
17-10 16wk cKO 0.05394 0.02863 0.54642 1024.467 
18-02 16wk cKO 0.07106 0.04926 0.57425 1001.158 
19-04 16wk cKO 0.07077 0.04087 0.61317 1038.596 
21-07 16wk cKO 0.06927 0.03648 0.6037 1034.494 
18-04 16wk cKO 0.06633 0.03631 0.55627 1013.203 
21-05 16wk cKO 0.09809 0.05656 0.69015 1004.543 
22-01 16wk cKO 0.08759 0.03946 0.65746 1006.952 
1203 12wk LC 0.07441 0.05773 0.66708 1029.788 
1205 12wk LC 0.11077 0.06313 0.73495 1024.115 
1216 12wk LC 0.07463 0.05221 0.63534 1018.884 
1304 12wk LC 0.06415 0.04081 0.60024 1041.827 
1306 12wk LC 0.06724 0.0458 0.59784 1024.683 
1410 12wk LC 0.07785 0.04534 0.61215 1021.216 
1201 12wk cKO 0.07204 0.03624 0.57111 991.4658 
1204 12wk cKO 0.09218 0.0503 0.63899 994.7433 
1208 12wk cKO 0.07964 0.03981 0.59108 987.3689 
804 12wk cKO 0.07202 0.0452 0.58164 994.4282 
1107 12wk cKO 0.07103 0.03428 0.6007 1029.788 
1301 12wk cKO 0.07359 0.0441 0.5826 1013.589 
1403 12wk cKO 0.08152 0.04013 0.63131 1004.891 
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A26-06 12wk LC 0.08266 0.06087 0.66278 1009.557 
A27-07 12wk LC 0.07199 0.05427 0.65666 1017.305 
A28-02 12wk LC 0.08954 0.06929 0.7291 977.5226 
A29-04 12wk LC 0.07179 0.04314 0.58724 996.8603 
B31-04 12wk LC 0.09052 0.05577 0.7086 1026.876 
B34-12 12wk LC 0.05554 0.03922 0.58343 1026.42 
B33-07 12wk LC 0.06139 0.03971 0.59453 994.321 
C34-11 12wk LC 0.09904 0.05714 0.73524 1023.686 
C32-07 12wk LC 0.07562 0.04124 0.63462 
 C35-14 12wk LC 0.09791 0.05698 0.72146 993.2792 
D27-03 12wk cKO 0.05382 0.03555 0.54065 988.2658 
D27-13 12wk cKO 0.06361 0.03723 0.59139 988.2658 
D28-04 12wk cKO 0.07767 0.05596 0.60907 966.1934 
D32-01 12wk cKO 0.06399 0.03333 0.58976 997.7718 
E29-09 12wk cKO 0.06605 0.03542 0.57537 1008.059 
E30-06 12wk cKO 0.04475 0.02577 0.48159 
 E31-01 12wk cKO 0.0996 0.05219 0.68641 
 F31-02 12wk cKO 0.12201 0.06696 0.8173 1007.408 
F29-03 12wk cKO 0.06938 0.03359 0.5545 
 F33-01 12wk cKO 0.06699 0.0398 0.57519 
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15-02 16wk LC 0.84091 0.20914 0.75129 0.252 
15-15 16wk LC 0.88649 0.27806 0.68634 0.227 
16-03 16wk LC 1.08062 0.30972 0.71338 0.262 
17-11 16wk LC 0.81591 0.166 0.79654 0.273 
17-02 16wk LC 0.90806 0.225 0.75222 0.265 
17-03 16wk LC 0.83544 0.15543 0.81395 0.28 
18-08 16wk LC 0.91599 0.26295 0.71293 0.245 
19-06 16wk LC 1.10215 0.31733 0.71208 0.264 
20-03 16wk LC 0.88548 0.26346 0.70247 0.237 
21_04 16wk LC 0.95965 0.26867 0.72004 0.251 
16-01 16wk cKO 1.08159 0.33607 0.68929 0.251 
16-02 16wk cKO 0.8679 0.20378 0.7652 0.258 
17-07 16wk cKO 0.84244 0.21787 0.74138 0.251 
17-10 16wk cKO 0.72618 0.17976 0.75246 0.236 
18-02 16wk cKO 0.92579 0.35154 0.62028 0.203 
19-04 16wk cKO 0.85849 0.24532 0.71425 0.238 
21-07 16wk cKO 0.82775 0.22405 0.72933 0.236 
18-04 16wk cKO 0.83302 0.27675 0.66778 0.213 
21-05 16wk cKO 1.02086 0.33071 0.67605 0.24 
22-01 16wk cKO 0.88463 0.22717 0.7432 0.244 
1203 12wk LC 0.94704 0.27996 0.70439 0.247 
1205 12wk LC 1.07922 0.34427 0.681 0.243 
1216 12wk LC 0.93971 0.30437 0.6761 0.223 
1304 12wk LC 0.83842 0.23818 0.71591 0.235 
1306 12wk LC 0.88423 0.28639 0.67611 0.226 
1410 12wk LC 0.91441 0.30226 0.66945 0.221 
1201 12wk cKO 0.84716 0.27605 0.67415 0.216 
1204 12wk cKO 0.98451 0.34552 0.64904 0.22 
1208 12wk cKO 0.89489 0.30381 0.6605 0.217 
804 12wk cKO 0.90301 0.32137 0.64412 0.212 
1107 12wk cKO 0.82179 0.22109 0.73096 0.239 
1301 12wk cKO 0.91257 0.32997 0.63842 0.214 
1403 12wk cKO 0.88773 0.25642 0.71115 0.234 
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A26-06 12wk LC 0.99821 0.33543 0.66396 0.234 
A27-07 12wk LC 0.91786 0.2612 0.71542 0.245 
A28-02 12wk LC 1.03259 0.30349 0.70609 0.256 
A29-04 12wk LC 0.87744 0.2902 0.66926 0.217 
B31-04 12wk LC 0.98157 0.27297 0.72191 0.258 
B34-12 12wk LC 0.78732 0.20389 0.74103 0.236 
B33-07 12wk LC 0.81245 0.21792 0.73178 0.237 
C34-11 12wk LC 0.99386 0.25862 0.73978 0.265 
C32-07 12wk LC 0.85024 0.21562 0.7464 
 C35-14 12wk LC 1.00111 0.27965 0.72066 0.253 
D27-03 12wk cKO 0.77251 0.23186 0.69986 0.219 
D27-13 12wk cKO 0.80919 0.2178 0.73083 0.233 
D28-04 12wk cKO 0.98081 0.37174 0.62099 0.213 
D32-01 12wk cKO 0.77711 0.18735 0.75891 0.235 
E29-09 12wk cKO 0.80744 0.23207 0.71258 0.226 
E30-06 12wk cKO 0.67457 0.19298 0.71393 
 E31-01 12wk cKO 0.99247 0.30606 0.69161 
 F31-02 12wk cKO 1.08744 0.27014 0.75158 
 F29-03 12wk cKO 0.81295 0.25845 0.68209 
 F33-01 12wk cKO 0.83401 0.25882 0.68966 
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Table B.4 Indices of cancellous bone determined by microCT analysis of VOIs from 











15-02 16wk LC 0.297 0.0616 0.2177 649.172 
15-15 16wk LC 0.2262 0.0549 0.2649 652.297 
16-03 16wk LC 
    17-11 16wk LC 0.2028 0.0526 0.2473 639.861 
17-02 16wk LC 0.3154 0.0665 0.2787 682.378 
17-03 16wk LC 0.3288 0.0928 0.2268 719.0355 
18-08 16wk LC 0.3071 0.0615 0.2123 672.807 
19-06 16wk LC 0.2616 0.0637 0.2534 700.674 
20-03 16wk LC 
    21_04 16wk LC 0.2342 0.0572 0.2881 678.406 
16-01 16wk cKO 0.1315 0.0523 0.3781 682.834 
16-02 16wk cKO 0.1754 0.0503 0.2808 657.115 
17-07 16wk cKO 0.1578 0.0495 0.3248 646.893 
17-10 16wk cKO 0.1639 0.0509 0.2875 653.795 
18-02 16wk cKO 0.1185 0.0453 0.3061 645.07 
19-04 16wk cKO 0.1306 0.0492 0.3054 665.645 
21-07 16wk cKO 0.1753 0.0519 0.288 668.119 
18-04 16wk cKO 0.1247 0.05 0.3729 650.148 
21-05 16wk cKO 0.1812 0.0508 0.269 654.836 
22-01 16wk cKO 0.1771 0.0562 0.3011 679.578 
1203 12wk LC 0.2366 0.0507 0.2084 701.52 
1205 12wk LC 
    1216 12wk LC 
    1304 12wk LC 0.1985 0.0489 0.2478 714.412 
1306 12wk LC 0.2278 0.0508 0.1989 740.066 
1410 12wk LC 0.1517 0.0453 0.2503 710.766 
1201 12wk cKO 0.1161 0.043 0.3272 714.412 
1204 12wk cKO 0.1381 0.0432 0.2706 706.534 
1208 12wk cKO 0.1261 0.0432 0.2984 697.288 
804 12wk cKO 0.1234 0.0434 0.2934 721.965 
1107 12wk cKO 0.1439 0.0443 0.2505 706.208 
1301 12wk cKO 0.0923 0.0391 0.2829 696.181 
1403 12wk cKO 0.1505 0.0492 0.298 738.242 
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A26-06 12wk LC 0.2864 0.0558 0.2058 638.233 
A27-07 12wk LC 0.2541 0.0576 0.2536 643.637 
A28-02 12wk LC 0.3338 0.0668 0.2323 637.322 
A29-04 12wk LC 0.194 0.0535 0.2348 601.055 
B31-04 12wk LC 0.3053 0.0607 0.2177 647.479 
B34-12 12wk LC 0.1729 0.0503 0.3001 625.667 
B33-07 12wk LC 0.2514 0.059 0.296 620.003 
C34-11 12wk LC 0.2951 0.0599 0.2137 643.898 
C32-07 12wk LC 0.2343 0.0571 0.2446 664.408 
C35-14 12wk LC 0.2976 0.0587 0.1961 611.799 
D27-03 12wk cKO 0.1184 0.0443 0.2868 624.951 
D27-13 12wk cKO 0.1961 0.0514 0.243 643.898 
D28-04 12wk cKO 0.1956 0.0491 0.2384 620.523 
D32-01 12wk cKO 0.1958 0.0534 0.2445 649.758 
E29-09 12wk cKO 0.2419 0.0533 0.2134 633.611 
E30-06 12wk cKO 0.1586 0.0491 0.2915 632.829 
E31-01 12wk cKO 0.1672 0.0497 0.2571 636.801 
F31-02 12wk cKO 0.2052 0.0518 0.2328 640.382 
F29-03 12wk cKO 0.1338 0.0478 0.2975 618.57 
F33-01 12wk cKO 0.2094 0.0534 0.2488 655.748 
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Table B.5 Indices of cortical bone determined by microCT analysis of VOIs from the 



















15-02 16wk LC 0.14429 0.04228 0.41737 675.281 
15-15 16wk LC 0.18351 0.05935 0.46886 687.066 
16-03 16wk LC 
    17-11 16wk LC 0.26954 0.05635 0.52003 732.4481 
17-02 16wk LC 0.18454 0.06786 0.47931 732.969 
17-03 16wk LC 0.23372 0.06479 0.51822 711.2874 
18-08 16wk LC 0.20634 0.06288 0.50952 733.0341 
19-06 16wk LC 0.30799 0.07835 0.60089 771.5793 
20-03 16wk LC 
    21_04 16wk LC 0.22072 0.06514 0.49315 748.921 
16-01 16wk cKO 0.27194 0.07831 0.49666 735.247 
16-02 16wk cKO 0.21473 0.07129 0.46524 740.652 
17-07 16wk cKO 0.22104 0.08022 0.47007 699.502 
17-10 16wk cKO 0.2301 0.06604 0.48186 737.005 
18-02 16wk cKO 0.16063 0.05208 0.38773 706.013 
19-04 16wk cKO 0.18478 0.06004 0.42483 738.503 
21-07 16wk cKO 0.23081 0.05398 0.46968 745.665 
18-04 16wk cKO 0.16977 0.05041 0.38506 684.266 
21-05 16wk cKO 0.19299 0.05688 0.42155 725.351 
22-01 16wk cKO 0.21694 0.05828 0.45041 741.498 
1203 12wk LC 0.23139 0.06985 0.54893 725.6767 
1205 12wk LC 
    1216 12wk LC 
    1304 12wk LC 0.23676 0.09418 0.57687 733.555 
1306 12wk LC 0.19703 0.05131 0.46964 735.1827 
1410 12wk LC 0.20218 0.05332 0.4803 723.5931 
1201 12wk cKO 0.31721 0.08602 0.59337 707.315 
1204 12wk cKO 0.16176 0.05844 0.42405 701.651 
1208 12wk cKO 0.20507 0.08787 0.4945 709.854 
804 12wk cKO 0.18304 0.05576 0.42276 714.347 
1107 12wk cKO 0.1899 0.05635 0.43219 731.406 
1301 12wk cKO 0.22484 0.05328 0.47113 735.833 
1403 12wk cKO 0.19332 0.06458 0.48216 723.202 
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A26-06 12wk LC 0.20471 0.05657 0.44181 702.106 
A27-07 12wk LC 0.16019 0.05172 0.42843 715.259 
A28-02 12wk LC 0.24584 0.09944 0.60734 744.9493 
A29-04 12wk LC 0.09925 0.05111 0.35761 640.838 
B31-04 12wk LC 0.18097 0.05348 0.44502 682.118 
B34-12 12wk LC 0.22282 0.07841 0.49859 721.5096 
B33-07 12wk LC 0.18644 0.04264 0.43935 692.665 
C34-11 12wk LC 0.19473 0.06444 0.48328 721.705 
C32-07 12wk LC 0.19921 0.04356 0.42743 723.9187 
C35-14 12wk LC 0.20962 0.04888 0.47919 709.0085 
D27-03 12wk cKO 0.14813 0.03908 0.36838 683.159 
D27-13 12wk cKO 0.2728 0.05912 0.53092 702.432 
D28-04 12wk cKO 0.25132 0.04774 0.50024 708.031 
D32-01 12wk cKO 0.23109 0.04652 0.46545 729.843 
E29-09 12wk cKO 0.15297 0.03882 0.38658 673.132 
E30-06 12wk cKO 0.23398 0.05567 0.46359 694.814 
E31-01 12wk cKO 0.25294 0.05907 0.47871 707.38 
F31-02 12wk cKO 0.15821 0.04191 0.37708 675.802 
F29-03 12wk cKO 0.24822 0.07284 0.49796 714.022 
F33-01 12wk cKO 0.18981 0.05452 0.43189 711.482 
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15-02 16wk LC 0.81274 0.51354 0.089 
15-15 16wk LC 1.0235 0.45809 0.088 
16-03 16wk LC 
   17-11 16wk LC 1.11058 0.46825 0.096 
17-02 16wk LC 0.94279 0.50839 0.097 
17-03 16wk LC 1.10616 0.46848 0.097 
18-08 16wk LC 1.03733 0.49118 0.093 
19-06 16wk LC 1.16024 0.5179 0.104 
20-03 16wk LC 
   21_04 16wk LC 
  
0.094 
16-01 16wk cKO 
  
0.085 
16-02 16wk cKO 1.06589 0.43648 0.082 
17-07 16wk cKO 1.15495 0.40701 0.079 
17-10 16wk cKO 1.22556 0.39317 0.086 
18-02 16wk cKO 0.97832 0.39632 0.075 
19-04 16wk cKO 0.95407 0.44528 0.082 
21-07 16wk cKO 
  
0.088 
18-04 16wk cKO 0.98036 0.39277 0.073 
21-05 16wk cKO 1.02796 0.41008 0.081 
22-01 16wk cKO 1.0462 0.43052 0.085 
1203 12wk LC 1.04104 0.52729 0.102 
1205 12wk LC 
   1216 12wk LC 
   1304 12wk LC 1.18473 0.48692 0.1 
1306 12wk LC 0.91607 0.51267 0.095 
1410 12wk LC 0.98318 0.48852 0.093 
1201 12wk cKO 1.27599 0.46503 0.085 
1204 12wk cKO 0.98543 0.43032 0.08 
1208 12wk cKO 1.09165 0.45299 0.084 
804 12wk cKO 0.9556 0.4424 0.082 
1107 12wk cKO 0.92525 0.46711 0.082 
1301 12wk cKO 1.1063 0.42587 0.086 
1403 12wk cKO 1.01346 0.47576 0.089 
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A26-06 12wk LC 0.994 0.44448 0.084 
A27-07 12wk LC 0.95887 0.44681 0.09 
A28-02 12wk LC 1.20574 0.50371 0.112 
A29-04 12wk LC 0.96039 0.37236 0.072 
B31-04 12wk LC 1.07941 0.41228 0.086 
B34-12 12wk LC 1.12616 0.44274 0.09 
B33-07 12wk LC 1.17111 0.37515 0.085 
C34-11 12wk LC 1.09002 0.44337 0.094 
C32-07 12wk LC 1.11008 0.38505 0.078 
C35-14 12wk LC 1.0572 0.45326 0.091 
D27-03 12wk cKO 1.09307 0.33701 0.073 
D27-13 12wk cKO 1.09551 0.48463 0.094 
D28-04 12wk cKO 1.12973 0.44279 0.084 
D32-01 12wk cKO 1.09447 0.42528 0.082 
E29-09 12wk cKO 0.95339 0.40548 0.075 
E30-06 12wk cKO 1.27044 0.36491 0.08 
E31-01 12wk cKO 
  
0.081 
F31-02 12wk cKO 1.08269 0.34828 0.071 
F29-03 12wk cKO 
  
0.083 
F33-01 12wk cKO 1.17535 0.36746 0.078 
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15-02 16wk LC 0.64162 0.30152 1.22466 909.5477 
15-15 16wk LC 0.56416 0.31608 1.07306 858.2408 
16-03 16wk LC 0.7635 0.39455 1.27132 899.5858 
17-11 16wk LC 0.54662 0.25603 1.1785 920.6815 
17-02 16wk LC 0.63703 0.29757 1.24998 893.791 
17-03 16wk LC 0.66353 0.34139 1.2784 889.7542 
18-08 16wk LC 0.65774 0.30612 1.19553 912.5427 
19-06 16wk LC 0.76157 0.41478 1.32699 904.4691 
20-03 16wk LC 0.56116 0.28626 1.07574 888.452 
21_04 16wk LC 0.6336 0.30195 1.19324 914.8867 
16-01 16wk cKO 0.75379 0.373 1.1733 871.1326 
16-02 16wk cKO 0.5158 0.27288 0.97678 894.1817 
17-07 16wk cKO 0.6499 0.31147 1.13601 865.6634 
17-10 16wk cKO 0.52161 0.2378 1.00472 884.2849 
18-02 16wk cKO 0.44002 0.24414 0.84817 846.4559 
19-04 16wk cKO 0.59157 0.29265 1.06602 875.3648 
21-07 16wk cKO 0.54313 0.25651 1.00654 867.0307 
18-04 16wk cKO 0.46669 0.23333 0.93283 880.2481 
21-05 16wk cKO 0.67451 0.29953 1.1587 888.6473 
22-01 16wk cKO 0.57097 0.32545 1.08628 879.2714 
1203 12wk LC 0.61655 0.24506 1.17409 913.7147 
1205 12wk LC 0.67736 0.25043 1.22117 925.4996 
1216 12wk LC 0.50093 0.20047 1.01734 881.6805 
1304 12wk LC 0.45755 0.19578 1.00913 923.2208 
1306 12wk LC 0.48048 0.21548 1.00847 909.2872 
1410 12wk LC 0.44295 0.20589 0.97205 920.8768 
1201 12wk cKO 0.4841 0.20133 0.96687 878.5552 
1204 12wk cKO 0.52005 0.21602 0.9624 879.7923 
1208 12wk cKO 0.43853 0.15718 0.95259 883.4384 
804 12wk cKO 0.50865 0.23083 1.03966 910.0034 
1107 12wk cKO 0.39661 0.19155 0.97875 937.7403 
1301 12wk cKO 0.63766 0.27046 1.22135 905.055 
1403 12wk cKO 0.31813 0.1651 0.85515 928.1691 
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A26-06 12wk LC 0.59063 0.33478 1.12329 838.7729 
A27-07 12wk LC 0.50503 0.26509 1.0412 877.7739 
A28-02 12wk LC 0.73055 0.38119 1.30273 855.2458 
A29-04 12wk LC 0.40862 0.22949 0.90521 864.8821 
B31-04 12wk LC 0.62473 0.38995 1.16253 870.6769 
B34-12 12wk LC 0.44902 0.24973 0.92818 847.6279 
B33-07 12wk LC 0.50727 0.3263 1.11291 881.4201 
C34-11 12wk LC 0.71039 0.3976 1.26025 858.3711 
C32-07 12wk LC 0.5169 0.24707 1.05445 894.4421 
C35-14 12wk LC 0.63791 0.30324 1.13154 849.1254 
D27-03 12wk cKO 
    D27-13 12wk cKO 0.37839 0.19075 0.80423 837.3405 
D28-04 12wk cKO 0.54754 0.2779 0.99996 830.504 
D32-01 12wk cKO 0.40489 0.21152 0.89364 854.0087 
E29-09 12wk cKO 0.39266 0.26572 0.86041 836.6894 
E30-06 12wk cKO 0.35114 0.20788 0.82928 825.7509 
E31-01 12wk cKO 0.57063 0.29255 1.01599 855.1156 
F31-02 12wk cKO 0.64635 0.34277 1.02458 820.1514 
F29-03 12wk cKO 0.39311 0.22121 0.83868 836.1035 
F33-01 12wk cKO 0.44511 0.24652 0.91841 867.3563 
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15-02 16wk LC 1.81194 0.67588 0.183 
15-15 16wk LC 1.71274 0.62652 0.152 
16-03 16wk LC 
  
0.17 
17-11 16wk LC 1.85138 0.63655 0.183 
17-02 16wk LC 1.82486 0.68497 0.191 
17-03 16wk LC 1.93686 0.66003 0.186 
18-08 16wk LC 1.81877 0.65733 0.174 
19-06 16wk LC 1.99529 0.66506 0.184 
20-03 16wk LC 1.76785 0.6085 0.153 
21_04 16wk LC 1.81029 0.65914 0.178 
16-01 16wk cKO 1.93865 0.60521 0.156 
16-02 16wk cKO 1.56682 0.62341 0.146 
17-07 16wk cKO 1.8064 0.62888 0.155 
17-10 16wk cKO 
  
0.152 
18-02 16wk cKO 1.56305 0.54264 0.128 
19-04 16wk cKO 1.67579 0.63613 0.154 
21-07 16wk cKO 1.60399 0.62753 0.146 
18-04 16wk cKO 1.62155 0.57527 0.147 
21-05 16wk cKO 
  
0.163 
22-01 16wk cKO 1.79717 0.60444 0.155 
1203 12wk LC 1.69319 0.69342 0.186 
1205 12wk LC 1.69914 0.7187 0.192 
1216 12wk LC 1.44241 0.7053 0.173 
1304 12wk LC 1.37536 0.73372 0.179 
1306 12wk LC 1.41741 0.71149 0.167 
1410 12wk LC 1.45601 0.66762 0.171 
1201 12wk cKO 1.71204 0.56475 0.166 
1204 12wk cKO 1.61779 0.59489 0.162 
1208 12wk cKO 1.49177 0.63856 0.175 
804 12wk cKO 1.51987 0.68405 0.176 
1107 12wk cKO 1.42524 0.68672 0.183 
1301 12wk cKO 1.77951 0.68634 0.202 
1403 12wk cKO 1.37777 0.62068 0.172 
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A26-06 12wk LC 1.86567 0.60209 0.153 
A27-07 12wk LC 1.73823 0.599 0.159 
A28-02 12wk LC 2.04498 0.63704 0.181 
A29-04 12wk LC 1.56739 0.57753 0.145 
B31-04 12wk LC 1.90014 0.61181 0.163 
B34-12 12wk LC 1.57254 0.59024 0.143 
B33-07 12wk LC 1.86643 0.59627 0.168 
C34-11 12wk LC 1.91904 0.65671 0.174 
C32-07 12wk LC 1.68237 0.62677 0.164 
C35-14 12wk LC 1.7871 0.63317 0.162 
D27-03 12wk cKO 
   D27-13 12wk cKO 1.47523 0.54515 0.126 
D28-04 12wk cKO 
  
0.147 
D32-01 12wk cKO 1.51812 0.58865 0.144 
E29-09 12wk cKO 1.51831 0.56669 0.129 
E30-06 12wk cKO 1.35701 0.61111 0.135 
E31-01 12wk cKO 1.65133 0.61525 0.148 
F31-02 12wk cKO 1.81934 0.56316 0.133 
F29-03 12wk cKO 
  
0.129 
F33-01 12wk cKO 1.5591 0.58907 0.14 
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Table B.7 Indices of cancellous bone determined by microCT analysis of VOIs from 











15-02 16wk LC 0.0932 0.0501 0.2991 733.945 
15-15 16wk LC 0.0908 0.0524 0.352 741.889 
16-03 16wk LC 0.0855 0.0518 0.2999 732.643 
17-11 16wk LC 0.0903 0.048 0.2667 721.249 
17-02 16wk LC 0.1225 0.0602 0.2845 728.997 
17-03 16wk LC 0.1658 0.0702 0.3063 758.947 
18-08 16wk LC 0.0932 0.0497 0.2772 721.053 
19-06 16wk LC 0.1063 0.0586 0.2945 716.821 
20-03 16wk LC 0.0608 0.0464 0.3323 718.709 
21_04 16wk LC 0.0592 0.0496 0.3654 745.144 
16-01 16wk cKO 0.0777 0.0546 0.4438 717.993 
16-02 16wk cKO 0.0669 0.0529 0.3944 736.81 
17-07 16wk cKO 0.0839 0.0527 0.3949 715.91 
17-10 16wk cKO 0.0678 0.0512 0.636 714.217 
18-02 16wk cKO 0.0378 0.0507 0.7385 708.617 
19-04 16wk cKO 0.0488 0.0524 0.5998 705.492 
21-07 16wk cKO 0.0801 0.0563 
 
738.633 
18-04 16wk cKO 0.0248 0.0424 0.5895 703.018 
21-05 16wk cKO 0.097 0.0637 0.4631 760.38 
22-01 16wk cKO 0.0636 0.0551 0.6209 721.249 
1203 12wk LC 0.1529 0.0614 0.227 688.824 
1205 12wk LC 0.1663 0.0597 0.2308 701.651 
1216 12wk LC 0.13 0.0583 0.2584 675.997 
1304 12wk LC 0.1338 0.0515 0.2434 759.664 
1306 12wk LC 0.0992 0.0515 0.2708 724.7 
1410 12wk LC 0.0971 0.0561 0.2942 701.976 
1201 12wk cKO 0.0654 0.0451 0.3656 714.673 
1204 12wk cKO 0.0804 0.0492 0.4094 717.537 
1208 12wk cKO 0.0716 0.0484 0.364 700.348 
804 12wk cKO 0.1083 0.0556 0.2649 724.765 
1107 12wk cKO 0.0879 0.052 0.2729 753.739 
1301 12wk cKO 0.1341 0.0534 0.2182 712.459 
1403 12wk cKO 0.063 0.0569 0.3529 739.675 
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A26-06 12wk LC 0.1279 0.0577 0.2509 698.2 
A27-07 12wk LC 0.1052 0.0538 0.2611 726.783 
A28-02 12wk LC 0.1578 0.0568 0.2095 688.889 
A29-04 12wk LC 0.0747 0.0588 0.3242 717.993 
B31-04 12wk LC 0.1016 0.0512 0.2769 684.527 
B34-12 12wk LC 0.0965 0.0517 0.2756 691.819 
B33-07 12wk LC 0.091 0.0546 0.2995 693.968 
C34-11 12wk LC 0.1541 0.0598 0.2316 710.961 
C32-07 12wk LC 0.09 0.0541 0.3037 727.304 
C35-14 12wk LC 0.1049 0.057 0.2595 700.869 
D27-03 12wk cKO 
    D27-13 12wk cKO 0.0667 0.0543 0.4392 687.066 
D28-04 12wk cKO 0.0799 0.052 0.3512 691.884 
D32-01 12wk cKO 0.0792 0.0541 0.4044 724.179 
E29-09 12wk cKO 0.088 0.0546 0.4169 697.418 
E30-06 12wk cKO 0.0666 0.0533 0.4087 685.438 
E31-01 12wk cKO 0.075 0.0539 0.4013 706.339 
F31-02 12wk cKO 0.074 0.053 0.4856 697.418 
F29-03 12wk cKO 0.066 0.0495 0.4793 682.508 
F33-01 12wk cKO 0.1049 0.057 0.2595 700.869 
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Table B.8 Indices of serum makers determined by ELISAs for female pOC-ERαKO 













15-02 16wk LC 49.8 187 49.8  
15-15 16wk LC 35.2 231 35.2  
16-03 16wk LC 32.5 220 32.5  
17-11 16wk LC 20.9 242 20.9  
17-02 16wk LC 52.7 236 52.7  
17-03 16wk LC 59.8 242 59.8  
18-08 16wk LC 39.8 230 39.8  
19-06 16wk LC 28.4 224 28.4  
20-03 16wk LC 27.8 234 27.8  
21_04 16wk LC 33.3 213 33.3  
16-01 16wk cKO 15.6 266 15.6  
16-02 16wk cKO 16.1 222 16.1  
17-07 16wk cKO 59.7 291 59.7  
17-10 16wk cKO 22.6 253 22.6  
18-02 16wk cKO 32.3 243 32.3  
19-04 16wk cKO 22.3 260 22.3  
21-07 16wk cKO 14.3 225 14.3  
18-04 16wk cKO 17 218 17  
21-05 16wk cKO 21.3 141 21.3  
22-01 16wk cKO 19.1 315 19.1  
1203 12wk LC    6.9645 
1205 12wk LC    12.696 
1216 12wk LC    6.416 
1304 12wk LC    7.593 
1306 12wk LC    9.341 
1410 12wk LC    7.573 
1201 12wk cKO    6.669 
1204 12wk cKO    10.256 
1208 12wk cKO    9.918 
804 12wk cKO    9.634 
1107 12wk cKO    9.719 
1301 12wk cKO    9.391 
1403 12wk cKO    15.717 
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A26-06 12wk LC 20 378 121  
A27-07 12wk LC 23.7 353 120  
A28-02 12wk LC 19.2 429 93  
A29-04 12wk LC 14.2 334 132  
B31-04 12wk LC 27.5 349 81  
B34-12 12wk LC 18.1 288 91  
B33-07 12wk LC 17.7 398 110  
C34-11 12wk LC 17.8 313 111  
C32-07 12wk LC 23.8 409 126  
C35-14 12wk LC 
 
394 105  
D27-03 12wk cKO 8 309 83  
D27-13 12wk cKO 
 
384 75  
D28-04 12wk cKO 16.1 306 89  
D32-01 12wk cKO 12.5 373 139  
E29-09 12wk cKO 15.9 236 111  
E30-06 12wk cKO 12 390 104  
E31-01 12wk cKO 10.5 265 86  
F31-02 12wk cKO 29.1 395 85  
F29-03 12wk cKO 15.2 427 133  
F33-01 12wk cKO 10.4 318 98  
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15-02 16wk LC 22.52 0.0559 0.0711 
15-15 16wk LC 23.8 0.0875 0.1075 
16-03 16wk LC 26.78 0.0775 0.0956 
17-11 16wk LC 21.44 0.0448 0.078 
17-02 16wk LC 24.51 0.0754 0.1225 
17-03 16wk LC 22.57 0.0332 0.1473 
18-08 16wk LC 23.41 0.0942 0.0866 
19-06 16wk LC 26.03 0.0894 0.1854 
20-03 16wk LC 21.33 0.0448 0.0817 
21_04 16wk LC 24.73 0.0769 0.143 
16-01 16wk cKO 27.07 0.1244 0.0765 
16-02 16wk cKO 24.88 0.0629 0.067 
17-07 16wk cKO 24.7 0.0445 0.2217 
17-10 16wk cKO 22.98 0.0708 0.069 
18-02 16wk cKO 20.03 0.0431 0.077 
19-04 16wk cKO 25.07 0.0836 0.1271 
21-07 16wk cKO 23.56 0.0546 0.0948 
18-04 16wk cKO 23.82 0.0886 0.0516 
21-05 16wk cKO 26.16 0.1026 0.1187 
22-01 16wk cKO 25.99 0.1217 0.1157 
1203 12wk LC 21.59 0.044 0.075 
1205 12wk LC 21.6 0.072 0.169 
1216 12wk LC 21.65 0.094 0.109 
1304 12wk LC 22.3 0.083 0.089 
1306 12wk LC 20.93 0.051 0.101 
1410 12wk LC 21.6 0.068 0.07 
1201 12wk cKO 22.03 0.048 0.14 
1204 12wk cKO 22.56 0.064 0.13 
1208 12wk cKO 21.9 0.057 0.108 
804 12wk cKO 21.56 0.06 0.128 
1107 12wk cKO 20.79 0.076 0.24 
1301 12wk cKO 22.14 0.084 0.085 
1403 12wk cKO 23.95 0.055 0.124 
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A26-06 12wk LC 22.04 0.05 0.06 
A27-07 12wk LC 20.04 0.04 0.06 
A28-02 12wk LC 24.45 0.07 0.07 
A29-04 12wk LC 19.69 0.05 0.12 
B31-04 12wk LC 26.31 0.09 0.14 
B34-12 12wk LC 20.15 0.08 0.1 
B33-07 12wk LC 21.39 0.05 0.17 
C34-11 12wk LC 23.2 0.06 0.18 
C32-07 12wk LC 22.42 0.05 0.1 
C35-14 12wk LC 23.21 0.06 0.09 
D27-03 12wk cKO 18.47 0.04 0.11 
D27-13 12wk cKO 19.39 0.04 0.16 
D28-04 12wk cKO 21.77 0.06 0.07 
D32-01 12wk cKO 20.81 0.04 0.08 
E29-09 12wk cKO 19.77 0.05 0.15 
E30-06 12wk cKO 19.57 0.03 0.08 
E31-01 12wk cKO 23.27 0.09 0.07 
F31-02 12wk cKO 24.52 0.09 0.07 
F29-03 12wk cKO 19.87 0.05 0.07 
F33-01 12wk cKO 23.53 0.11 0.06 
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15-02 16wk LC 89.5 15.87 19.5 
15-15 16wk LC 85.8 15.62 18.24 
16-03 16wk LC 89.6 15.74 18.69 
17-11 16wk LC 81.7 15.34 17.34 
17-02 16wk LC 87.5 15.8 18.09 
17-03 16wk LC 89.1 15.74 18.06 
18-08 16wk LC 88.9 15.52 18 
19-06 16wk LC 93.9 16.28 19.11 
20-03 16wk LC 83.9 14.98 17.7 
21_04 16wk LC 92.2 16.07 18.51 
16-01 16wk cKO 92 16.69 19.14 
16-02 16wk cKO 89.1 16.07 18.42 
17-07 16wk cKO 89.2 16.32 18.84 
17-10 16wk cKO 91 16.16 18.42 
18-02 16wk cKO 84.6 15.43 17.91 
19-04 16wk cKO 89.1 16.36 18.9 
21-07 16wk cKO 91.8 15.85 18.27 
18-04 16wk cKO 89.4 15.35 18.18 
21-05 16wk cKO 92.4 15.63 18.12 
22-01 16wk cKO 91.3 15.91 18.45 
1203 12wk LC  15.39 17.73 
1205 12wk LC  15.93 18.27 
1216 12wk LC  15.82 18.15 
1304 12wk LC  15.2 17.55 
1306 12wk LC  15.38 17.97 
1410 12wk LC  15.23 18.21 
1201 12wk cKO  15.53 17.88 
1204 12wk cKO  16.12 18.72 
1208 12wk cKO  15.44 17.88 
804 12wk cKO  15.78 18.15 
1107 12wk cKO  15.63 17.52 
1301 12wk cKO  15.1 18.06 
1403 12wk cKO  15.39 18.57 
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A26-06 12wk LC 88.82 15.41 18.06 
A27-07 12wk LC 80.62 15.52 17.7 
A28-02 12wk LC 85.97 15.63 17.82 
A29-04 12wk LC 76.42 15.07 17.58 
B31-04 12wk LC 89.76 15.45 17.94 
B34-12 12wk LC 79.9 14.69 17.4 
B33-07 12wk LC 82.27 14.81 17.64 
C34-11 12wk LC 84.93 15.72 18.03 
C32-07 12wk LC 84.76 14.83 16.86 
C35-14 12wk LC 86.5 15.81 18.39 
D27-03 12wk cKO 82.24 13.48 17.16 
D27-13 12wk cKO 83.58 14.38 17.55 
D28-04 12wk cKO 86.37 15.29 17.37 
D32-01 12wk cKO 80.79 14.37 17.16 
E29-09 12wk cKO 86.04 14.8 17.49 
E30-06 12wk cKO 83.22 15.42 18.15 
E31-01 12wk cKO 84.56 15.36 18.06 
F31-02 12wk cKO 91.89 15.5 18.18 
F29-03 12wk cKO 84.56 15.18 17.67 
F33-01 12wk cKO 86.43 14.28 17.34 
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15-02 16wk LC 2.36 2.867448 0.10563 
15-15 16wk LC 1.08 1.382762 0.09245 
16-03 16wk LC 
  
 
17-11 16wk LC 
  
 
17-02 16wk LC 
  
 
17-03 16wk LC 0.98 2.495536 0.12852 
18-08 16wk LC 2.86 2.702598 0.110413 
19-06 16wk LC 
  
 
20-03 16wk LC 3.05 1.476561 0.10653 
21_04 16wk LC 2.52 1.751456 0.08962 
16-01 16wk cKO 0.55 
 
0.086463 
16-02 16wk cKO 
  
0.0907 
17-07 16wk cKO 
  
 
17-10 16wk cKO 
  
 
18-02 16wk cKO 0.22 
 
0.0862 
19-04 16wk cKO 
  
 
21-07 16wk cKO 2.74 1.712516 0.12894 
18-04 16wk cKO 2.09 1.670796 0.13898 
21-05 16wk cKO 1.2 0.902501 0.09701 
22-01 16wk cKO 
  
 
1203 12wk LC   0.12057 
1205 12wk LC 5.33 3.533224 0.11778 
1216 12wk LC 2.46  0.10797 
1304 12wk LC 1.53 3.584055 0.11948 
1306 12wk LC 4.44 3.203233 0.11882 
1410 12wk LC   
 1201 12wk cKO 2.99 3.029201 0.11506 
1204 12wk cKO 0.911 3.409571 0.11934 
1208 12wk cKO 1.63 3.660773 0.11422 
804 12wk cKO 2.81 2.618107 0.11719 
1107 12wk cKO  3.745557 0.10848 
1301 12wk cKO   




Table B.12 Indices of femur and vertebra mechanical testing data for female pOC-

















15-02 16wk LC 28.578 103.8904 33.678 1074.243 
15-15 16wk LC 18.697 305.3106 24.78 699.83 
16-03 16wk LC 
  
38.214 1083.659 
17-11 16wk LC 22.739 373.2911 35.143 1111.282 
17-02 16wk LC 30.093 421.6552 39.084 1200.667 
17-03 16wk LC 30.333 479.2656 42.296 1193.437 
18-08 16wk LC 30.24 511.8893 33.088 1038.062 
19-06 16wk LC 36.065 399.4248 38.232 1255.336 
20-03 16wk LC 24.049 248.9949 22.704 836.328 
21_04 16wk LC 31.788 536.362 32.713 1132.686 
16-01 16wk cKO 20.012 274.2806 35.358 777.816 
16-02 16wk cKO 20.431 377.0363 29.756 871.938 
17-07 16wk cKO 23.113 398.924 36.604 1114.085 
17-10 16wk cKO 19.594 178.0772 28.582 983.447 
18-02 16wk cKO 17.526 291.137 26.498 694.513 
19-04 16wk cKO 19.256 345.072 30.216 1025.179 
21-07 16wk cKO 19.332 392.6172 29.297 992.692 
18-04 16wk cKO 
  
27.567 713.822 
21-05 16wk cKO 19.354 177.4108 28.842 958.379 
22-01 16wk cKO 30.121 433.449 32.329 949.633 
1203 12wk LC 20.219 327.3722 29.852 850.369 
1205 12wk LC   33.01 820.189 
1216 12wk LC 24.013 379.507 25.39 758.404 
1304 12wk LC 24.567 495.1576 28.23 873.911 
1306 12wk LC 18.039 584.3264 24.383 721.598 
1410 12wk LC 22.819 325.4188 21.926 701.304 
1201 12wk cKO 17.416 201.7724 25.511 716.661 
1204 12wk cKO 20.119 140.1533 26.524 721.101 
1208 12wk cKO 20.23 632.702 27.171 759.793 
804 12wk cKO 23.755 288.4784 27.718 773.605 
1107 12wk cKO 20.549 364.4803 21.371 645.551 
1301 12wk cKO 17.025 205.215 27.482 684.986 
1403 12wk cKO 22.686 252.1339 25.163 703.881 
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A26-06 12wk LC 28.655 329.133 24.632 697.853 
A27-07 12wk LC 26.817 191.4022 23.824 774.6 
A28-02 12wk LC 26.7 182.1428 36.46 821.303 
A29-04 12wk LC 17.386 146.5738 19.635 595.092 
B31-04 12wk LC 26.713 224.2436 30.204 625.039 
B34-12 12wk LC 18.036 106.2432 22.684 608.673 
B33-07 12wk LC 26.599 194.148 23.962 667.121 
C34-11 12wk LC 26.67 199.4929 30.73 877.487 
C32-07 12wk LC 24.121 230.216 26.579 756.158 
C35-14 12wk LC 25.459 296.3981 30.126 802.994 
D27-03 12wk cKO 11.711 61.53558 19.961 543.797 
D27-13 12wk cKO 14.105 101.8058 22.943 548.801 
D28-04 12wk cKO 18.012 163.0534 25.376 595.605 
D32-01 12wk cKO 19.392 294.4854 25.503 559.089 
E29-09 12wk cKO 16.515 78.80144 21.876 618.729 
E30-06 12wk cKO 15.253 255.1193 19.117 559.196 
E31-01 12wk cKO 18.669 221.999 26.048 806.559 
F31-02 12wk cKO 23.847 291.5137 24.702 574.879 
F29-03 12wk cKO 12.588 83.62522 19.689 564.95 






 CHAPTER 3 SUPPLEMENTARY FIGURES AND DATA APPENDIX C.
Figure C.1 Serum marker measurements in male and female LC and pOC-ERαKO 
mice.  Female pOC-ERαKO mice had similar levels of osteocalcin, IGF-1, estrogen, 
and P1NP as LC, but TRAP5b serum levels were lower.  Male pOC-ERαKO mice had 
decreased serum osteocalcin levels but similar IGF-1, P1NP, and TRAP5b levels to 
LC. 
 
Table C.1 Length and mass measurements for female and male LC and pOC-ERαKO 
mice.  Data are mean ± SD.  n=6-14 per group. *pOC-ERαKO different from LC, 
p<0.05 by one-way ANOVA for each sex. 
 Female Male 
 LC pOC-ERαKO LC pOC-ERαKO 
Crown/Rump 
Length (mm) 
82.4 ± 1.8 81.8 ± 1.6 89.4 ± 1.9 90.1 ± 2.5 
Body mass  
(g) 
18.8 ± 0.82 19.0 ± 0.79 25.0 ± 1.0 25.9 ± 1.4 
Loaded tibia 
length (mm) 
17.4 ± 0.19 17.4 ± 0.18 18.0 ± 0.16 17.9 ± 0.13 
Control tibia 
length (mm) 
17.3 ± 0.30 17.4 ± 0.26 18.1 ± 0.11 18.1 ± 0.13 
Right femur 
length (mm) 
15.0 ±0.29 15.0 ± 0.29 15.5 ± 0.30 15.8 ± 0.21* 
Ovarian mass 
(mg) 
154 ± 47 168 ± 48 N/A N/A 
Uterine mass 
(mg) 





Table C.2 Indices of cancellous bone determined by microCT analysis of VOIs from 
loaded left (L) and control right (R) proximal tibial metaphysis of 12-week-old female 












H1314 F LC 0.0975 0.0922 0.0618 0.0488 
H1411 F LC 0.0845 0.0587 0.0629 0.0476 
H1504 F LC 0.1043 0.0639 0.0644 0.0499 
H1708 F LC 0.116 0.1196 0.0628 0.0491 
I1710 F LC 0.1175 0.0712 0.0694 0.0456 
I2007 F LC 0.0849 0.0535 0.0622 0.0467 
I2205 F LC 0.114 0.0778 0.0694 0.0519 
I2209 F LC 0.1252 0.081 0.072 0.0514 
J2304 F LC 0.1237 0.0819 0.0672 0.0476 
J2306 F LC 0.1066 0.0622 0.0761 0.0449 
J2413 F LC 0.1328 0.1001 0.0648 0.0482 
K2501 F LC 0.1175 0.0526 0.0723 0.0451 
K2503 F LC 0.1221 0.0866 0.0707 0.0519 
K2606 F LC 0.1118 0.0899 0.0659 0.049 
L1707 F cKO 0.1152 0.0623 0.0725 0.0438 
L1804 F cKO 0.1151 0.0554 0.0772 0.047 
L1808 F cKO 0.1214 0.0598 0.0741 0.0477 
L1813 F cKO 0.1332 0.073 0.0699 0.0476 
M2113 F cKO 0.093 0.0591 0.0717 0.0473 
M2216 F cKO 0.1203 0.071 0.073 0.0463 
M2303 F cKO 0.1047 0.046 0.0735 0.0446 
M2310 F cKO 0.1484 0.0417 0.0737 0.0415 
N2311 F cKO 0.1034 0.0586 0.0719 0.0489 
N2404 F cKO 0.1089 0.0669 0.0693 0.0489 
N2406 F cKO 0.1139 0.0487 0.0796 0.0477 
N2410 F cKO 0.1063 0.0585 0.0842 0.0459 
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O1412 M LC 0.1607 0.1705 0.0573 0.0536 
O1507 M LC 0.1651 0.1361 0.0633 0.0476 
O1610 M LC 0.1717 0.1652 0.0562 0.0486 
O1701 M LC 0.1515 0.1797 0.0585 0.0541 
P1801 M LC 0.1734 0.1293 0.0583 0.0492 
P1910 M LC 0.1255 0.1043 0.0557 0.0413 
P2003 M LC 
    P2117 M LC 
    Q2202 M LC 0.0944 0.0673 0.0538 0.0401 
Q2309 M LC 0.1043 0.0562 0.0593 0.0394 
Q2403 M LC 0.1535 0.1145 0.0594 0.0429 
R2412 M LC 0.0948 0.0651 0.0637 0.0406 
R2506 M LC 0.1535 0.1329 0.0623 0.0493 
R2611 M LC 0.1679 0.1307 0.0571 0.0449 
S1306 M cKO 0.1473 0.1207 0.0644 0.0475 
S1307 M cKO 0.1541 0.154 0.0548 0.0483 
S1401 M cKO 0.1843 0.1543 0.0614 0.0481 
S1805 M cKO 0.1305 0.0913 0.0683 0.0488 
T1607 M cKO 0.1583 0.2072 0.0584 0.0581 
T1806 M cKO 0.1707 0.2102 0.062 0.062 
T1811 M cKO 0.1698 0.2001 0.054 0.0526 
T2101 M cKO 0.1421 0.1911 0.0588 0.0587 
U2108 M cKO 0.1564 0.1342 0.056 0.0457 
U2402 M cKO 0.1381 0.1443 0.0558 0.0471 
U2505 M cKO 0.1711 0.1562 0.0675 0.0536 
V2507 M cKO 0.1552 0.1815 0.0707 0.0587 
V2602 M cKO 
    V2608 M cKO 
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H1314 F LC 0.3054 0.2983 781.866 753.869 
H1411 F LC 0.3892 0.3379 793.195 769.3 
H1504 F LC 0.2978 0.3744 801.725 786.684 
H1708 F LC 0.3203 0.2543 780.304 750.158 
I1710 F LC 0.2858 0.3088 809.799 762.529 
I2007 F LC 0.365 0.3484 786.88 773.011 
I2205 F LC 0.3528 0.3247 788.638 787.791 
I2209 F LC 0.2959 0.3122 803.353 762.463 
J2304 F LC 0.3235 0.3225 807.715 777.048 
J2306 F LC 0.3221 0.3364 800.683 753.022 
J2413 F LC 0.2929 0.2746 787.27 748.53 
K2501 F LC 0.35 0.3715 815.658 755.822 
K2503 F LC 0.3648 0.3548 813.249 782.713 
K2606 F LC 0.3121 0.3022 798.404 777.634 
L1707 F cKO 0.3784 0.3595 765.003 737.591 
L1804 F cKO 0.4747 0.4777 805.762 768.909 
L1808 F cKO 0.4009 0.4299 790.135 759.599 
L1813 F cKO 0.4087 0.3781 798.404 768.909 
M2113 F cKO 0.4535 0.3788 799.12 758.557 
M2216 F cKO 0.3665 0.4206 797.948 754.715 
M2303 F cKO 0.4523 0.4499 782.973 767.672 
M2310 F cKO 0.3774 0.3745 769.821 750.613 
N2311 F cKO 0.4553 0.4351 806.087 751.59 
N2404 F cKO 0.4237 0.3716 807.455 782.582 
N2406 F cKO 0.5034 0.4765 797.493 740 
N2410 F cKO 0.5321 0.4097 770.016 739.87 
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LC Tb.Sp.L Tb.Sp R cn.TMD.L cn.TMD.R 
O1412 M LC 0.2279 0.2067 798.665 765.393 
O1507 M LC 0.2218 0.2127 798.209 776.918 
O1610 M LC 0.1876 0.2001 790.982 765.133 
O1701 M LC 0.2276 0.2262 812.468 776.462 
P1801 M LC 0.1886 0.2176 787.856 764.742 
P1910 M LC 0.2172 0.2034 790.331 771.123 
P2003 M LC 
    P2117 M LC 
    Q2202 M LC 0.2605 0.2605 791.698 764.221 
Q2309 M LC 0.253 0.2675 795.735 768.063 
Q2403 M LC 0.1945 0.2029 794.693 764.742 
R2412 M LC 0.2893 0.2814 820.086 764.156 
R2506 M LC 0.2284 0.2332 791.893 762.463 
R2611 M LC 0.1978 0.2074 775.941 740.717 
S1306 M cKO 0.2561 0.2681 798.404 781.541 
S1307 M cKO 0.1986 0.1972 781.606 759.403 
S1401 M cKO 0.1936 0.1909 800.097 758.166 
S1805 M cKO 0.3083 0.2909 810.45 805.501 
T1607 M cKO 0.2208 0.2043 788.377 782.387 
T1806 M cKO 0.2367 0.2376 800.944 790.786 
T1811 M cKO 0.1907 0.1914 776.006 764.677 
T2101 M cKO 0.2615 0.2699 777.113 773.728 
U2108 M cKO 0.1951 0.1976 792.284 755.041 
U2402 M cKO 0.2225 0.1958 779.718 765.133 
U2505 M cKO 0.2121 0.2056 808.952 768.909 
V2507 M cKO 0.2615 0.2532 810.58 782.127 
V2602 M cKO 
    V2608 M cKO 
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Table C.3 Indices of cortical bone determined by microCT analysis of VOIs from 
loaded left (L) and control right (R) tibial midshaft of 12-week-old female and male 
















H1314 F LC 0.09647 0.05995 0.06344 0.05181 
H1411 F LC 0.0722 0.05977 0.0545 0.05064 
H1504 F LC 0.08801 0.06697 0.06235 0.04923 
H1708 F LC 0.07719 0.05276 0.0606 0.0462 
I1710 F LC 0.08574 0.05325 0.05396 0.04449 
I2007 F LC 0.09717 0.06048 0.06796 0.05286 
I2205 F LC 
    I2209 F LC 0.10162 0.06108 0.07811 0.05594 
J2304 F LC 0.09608 0.05239 0.0661 0.04642 
J2306 F LC 0.09626 0.07 0.06252 0.0531 
J2413 F LC 0.08858 0.05848 0.06849 0.04841 
K2501 F LC 0.10658 0.06021 0.06858 0.05027 
K2503 F LC 0.10068 0.06238 0.06949 0.0545 
K2606 F LC 0.0966 0.06647 0.06424 0.05197 
L1707 F cKO 0.09298 0.05238 0.06225 0.04354 
L1804 F cKO 0.1083 0.05679 0.07276 0.04868 
L1808 F cKO 0.09682 0.06321 0.06194 0.04453 





M2113 F cKO 0.11851 0.05908 0.07309 0.04491 
M2216 F cKO 0.09614 0.06272 0.06032 0.04628 
M2303 F cKO 0.11756 0.04817 0.07466 0.04249 
M2310 F cKO 0.10734 0.05678 0.07237 0.04183 
N2311 F cKO 0.09849 0.07031 0.0652 0.05082 
N2404 F cKO 0.10735 0.06514 0.07091 0.05343 
N2406 F cKO 0.0996 0.05726 0.06627 0.04562 
N2410 F cKO 0.11366 0.05738 0.07604 0.04511 
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O1412 M LC 0.12617 0.11634 0.08948 0.08733 
O1507 M LC 0.13942 0.12962 0.09474 0.08379 
O1610 M LC 0.13251 0.14426 0.0975 0.10701 
O1701 M LC 0.14357 0.14495 0.09945 0.10315 
P1801 M LC 0.12454 0.1199 0.08375 0.08282 
P1910 M LC 0.11093 0.12456 0.07822 0.08466 
P2003 M LC 0.14377 0.13826 0.08833 0.09529 
P2117 M LC 0.13808 0.14168 0.10428 0.09663 
Q2202 M LC 0.13063 0.09848 0.08508 0.06852 
Q2309 M LC 0.09368 0.0772 0.07059 0.06026 
Q2403 M LC 0.12299 0.12696 0.08965 0.08873 
R2412 M LC 0.10443 0.08228 0.07183 0.06478 
R2506 M LC 0.11783 0.12524 0.08335 0.07984 
R2611 M LC 0.15439 0.13115 0.09954 0.08611 
S1306 M cKO 0.14111 0.15141 0.09106 0.08569 
S1307 M cKO 0.18662 0.16167 0.10825 0.08958 
S1401 M cKO 0.14223 0.15312 0.09885 0.09768 
S1805 M cKO 0.13376 0.13952 0.08172 0.09561 
T1607 M cKO 0.14149 0.14429 0.11186 0.10581 
T1806 M cKO 0.16421 0.16911 0.10399 0.11046 
T1811 M cKO 0.17147 0.14641 0.11484 0.10043 
T2101 M cKO 0.16086 0.13504 0.10249 0.09322 
U2108 M cKO 0.13737 0.13265 0.09775 0.09257 
U2402 M cKO 0.15639 0.15125 0.1099 0.10329 
U2505 M cKO 0.14981 0.13213 0.10008 0.09111 
V2507 M cKO 0.12179 0.12028 0.09205 0.0816 
V2602 M cKO 0.10884 0.10252 0.07021 0.07004 
V2608 M cKO 0.14811 0.13789 0.09646 0.09307 
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H1314 F LC 0.72629 0.56607 1009.166 1022.904 
H1411 F LC 0.65553 0.56859 1015.938 1016.003 
H1504 F LC 0.677 0.57549 1027.722 1018.086 
H1708 F LC 0.66011 0.50429 974.3322 990.6749 
I1710 F LC 0.71031 0.52449 1023.556 1018.802 
I2007 F LC 0.73966 0.57546 1012.226 1029.285 
I2205 F LC 
    I2209 F LC 0.74972 0.57748 1014.505 1029.22 
J2304 F LC 0.7244 0.52613 997.5114 1015.677 
J2306 F LC 0.70094 0.59131 1009.817 1022.774 
J2413 F LC 0.73273 0.53151 1009.036 1005.194 
K2501 F LC 0.75772 0.56373 1020.886 1033.322 
K2503 F LC 0.75355 0.57058 1023.165 1030.848 
K2606 F LC 0.73238 0.60161 1053.441 1057.608 
L1707 F cKO 0.71827 0.50818 1001.548 1018.672 
L1804 F cKO 0.77843 0.5251 1011.054 1017.891 
L1808 F cKO 0.72437 0.53545 1007.018 1021.928 





M2113 F cKO 0.81455 0.54376 1004.804 1027.657 
M2216 F cKO 0.72057 0.54895 1012.357 1023.49 
M2303 F cKO 0.82934 0.49464 993.0187 1031.238 
M2310 F cKO 0.74387 0.49986 993.4745 1000.897 
N2311 F cKO 0.71226 0.56958 1026.03 1024.793 
N2404 F cKO 0.72339 0.56505 1031.694 1022.318 
N2406 F cKO 0.74325 0.52153 1006.562 1011.185 
N2410 F cKO 0.79538 0.52701 996.4697 1010.989 
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O1412 M LC 0.78024 0.77414 1044.651 1055.264 
O1507 M LC 0.83357 0.78705 1045.042 1050.511 
O1610 M LC 0.82751 0.85469 1057.543 1038.335 
O1701 M LC 0.84272 0.87523 1040.94 1055.85 
P1801 M LC 0.76538 0.73595 1048.818 1029.741 
P1910 M LC 0.7429 0.75633 1040.744 1032.671 
P2003 M LC 0.82669 0.85087 1039.703 1046.604 
P2117 M LC 0.83599 0.84284 1023.36 1034.168 
Q2202 M LC 0.76651 0.66826 1016.979 1024.402 
Q2309 M LC 0.70693 0.62194 1034.364 1027.788 
Q2403 M LC 0.79971 0.78398 1042.828 1041.265 
R2412 M LC 0.71203 0.63316 1028.634 1020.756 
R2506 M LC 0.77521 0.79321 1047.581 1056.566 
R2611 M LC 0.86051 0.79424 1040.549 1044.391 
S1306 M cKO 0.83093 0.83869 1049.73 1046.344 
S1307 M cKO 0.91831 0.85328 1039.573 1045.758 
S1401 M cKO 0.83175 0.82829 1049.209 1034.689 
S1805 M cKO 0.78077 0.80608 1045.888 1044.846 
T1607 M cKO 0.84464 0.86271 1058.129 1060.473 
T1806 M cKO 0.87855 0.92101 1058.129 1064.119 
T1811 M cKO 0.89452 0.85995 1048.232 1073.104 
T2101 M cKO 0.8512 0.81242 1039.377 1044.846 
U2108 M cKO 0.81914 0.78113 1052.399 1039.377 
U2402 M cKO 0.85718 0.8561 1039.247 1048.102 
U2505 M cKO 0.84451 0.81876 1053.311 1055.199 
V2507 M cKO 0.78013 0.7542 1042.242 1049.013 
V2602 M cKO 0.71181 0.70156 1020.235 998.9438 
V2608 M cKO 0.83609 0.82369 1037.294 1041.786 
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H1314 F LC 0.254 0.207 0.31538 0.32459 
H1411 F LC 0.246 0.21 0.27414 0.31902 
H1504 F LC 0.235 0.209 0.33606 0.32942 
H1708 F LC 0.235 0.184 0.32566 0.35499 
I1710 F LC 0.267 0.197 0.25268 0.31666 
I2007 F LC 0.263 0.211 0.3193 0.32191 
I2205 F LC 
    I2209 F LC 0.251 0.211 0.36623 0.34554 
J2304 F LC 0.252 0.198 0.32857 0.32131 
J2306 F LC 0.24 0.209 0.33405 0.344 
J2413 F LC 0.259 0.192 0.30749 0.36132 
K2501 F LC 0.26 0.207 0.32909 0.32815 
K2503 F LC 0.268 0.205 0.32236 0.35275 
K2606 F LC 0.257 0.22 0.30444 0.30877 
L1707 F cKO 0.254 0.19 0.30635 0.33054 
L1804 F cKO 0.266 0.189 0.3299 0.36158 
L1808 F cKO 0.254 0.194 0.30835 0.34505 





M2113 F cKO 0.274 0.203 0.30353 0.31792 
M2216 F cKO 0.256 0.201 0.30894 0.33611 
M2303 F cKO 0.281 0.188 0.29678 0.32569 
M2310 F cKO 0.246 0.183 0.3524 0.35603 
N2311 F cKO 0.243 0.2 0.34129 0.36185 
N2404 F cKO 0.238 0.2 0.38523 0.35906 
N2406 F cKO 0.258 0.19 0.313 0.34905 
N2410 F cKO 0.266 0.194 0.33436 0.33932 
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O1412 M LC 0.238 0.246 0.44124 0.42179 
O1507 M LC 0.256 0.247 0.42981 0.4233 
O1610 M LC 0.253 0.253 0.42247 0.4568 
O1701 M LC 0.254 0.266 0.44593 0.4232 
P1801 M LC 0.238 0.227 0.43453 0.47111 
P1910 M LC 0.24 0.231 0.39815 0.45037 
P2003 M LC 0.253 0.262 0.41672 0.40345 
P2117 M LC 0.246 0.258 0.45853 0.43637 
Q2202 M LC 0.235 0.217 0.4422 0.42149 
Q2309 M LC 0.239 0.215 0.34519 0.36611 
Q2403 M LC 0.252 0.235 0.40745 0.43949 
R2412 M LC 0.233 0.213 0.38877 0.39871 
R2506 M LC 0.247 0.254 0.39958 0.38075 
R2611 M LC 0.257 0.244 0.44447 0.43025 
S1306 M cKO 0.255 0.259 0.39703 0.41635 
S1307 M cKO 0.259 0.257 0.47196 0.43495 
S1401 M cKO 0.248 0.24 0.46451 0.49194 
S1805 M cKO 0.242 0.24 0.4356 0.48156 
T1607 M cKO 0.247 0.257 0.48768 0.44261 
T1806 M cKO 0.257 0.27 0.47088 0.44939 
T1811 M cKO 0.251 0.26 0.50874 0.44194 
T2101 M cKO 0.246 0.249 0.48665 0.44663 
U2108 M cKO 0.245 0.233 0.45601 0.47438 
U2402 M cKO 0.246 0.252 0.49972 0.46585 
U2505 M cKO 0.251 0.255 0.46313 0.42175 
V2507 M cKO 0.24 0.235 0.43475 0.42912 
V2602 M cKO 0.231 0.231 
  V2608 M cKO 0.25 0.253 
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Table C.4 Indices of cortical bone determined by microCT analysis of VOIs from 
loaded left (L) and control right (R) tibial metaphyseal cortical shell of 12-week-old 
















H1314 F LC 0.57359 0.32878 0.44911 0.25657 
H1411 F LC 0.51219 0.36795 0.40061 0.27276 
H1504 F LC 0.50291 0.34614 0.37988 0.27035 
H1708 F LC 0.42567 0.28728 0.32648 0.22976 
I1710 F LC 0.41664 0.33107 0.34874 0.28633 
I2007 F LC 0.49526 0.4088 0.40883 0.34163 
I2205 F LC 0.56225 0.42348 0.45574 0.33683 
I2209 F LC 0.59722 0.39047 0.50905 0.33781 
J2304 F LC 0.51779 0.33194 0.43504 0.28143 
J2306 F LC 0.50904 0.34181 0.42391 0.28619 
J2413 F LC 0.50649 0.35117 0.41288 0.3029 
K2501 F LC 0.67133 0.36821 0.54306 0.29178 
K2503 F LC 0.56751 0.50031 0.47631 0.36604 
K2606 F LC 0.61455 0.44076 0.49907 0.35653 
L1707 F cKO 0.52075 0.32361 0.4085 0.26 
L1804 F cKO 0.61293 0.33886 0.48187 0.25965 
L1808 F cKO 0.50702 0.34045 0.41831 0.24684 
L1813 F cKO 0.598 0.38121 0.48934 0.33032 
M2113 F cKO 0.5357 0.3458 0.42933 0.27037 
M2216 F cKO 0.53159 0.36688 0.42241 0.27818 
M2303 F cKO 0.5093 0.28829 0.40294 0.2115 
M2310 F cKO 0.51133 0.30318 0.41132 0.23405 
N2311 F cKO 0.49477 0.33532 0.41845 0.29395 
N2404 F cKO 0.63298 0.39581 0.48813 0.29929 
N2406 F cKO 0.51793 0.34188 0.38695 0.2293 
N2410 F cKO 0.51098 0.30075 0.39227 0.22785 
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O1412 M LC 0.66493 0.59319 0.52239 0.44572 
O1507 M LC 0.6776 0.53349 0.52996 0.42294 
O1610 M LC 0.70305 0.57387 0.57859 0.43031 
O1701 M LC 0.70228 0.63236 0.5529 0.47034 
P1801 M LC 0.61714 0.5974 0.48387 0.3903 
P1910 M LC 0.66092 0.49858 0.49654 0.40133 
P2003 M LC 0.767 0.68585 0.61828 0.57444 
P2117 M LC 0.72984 0.66952 0.58568 0.42463 
Q2202 M LC 0.58799 0.4198 0.4149 0.35455 
Q2309 M LC 0.53522 0.41842 0.41402 0.32538 
Q2403 M LC 0.68857 0.52809 0.54015 0.39098 
R2412 M LC 0.61392 0.44391 0.501 0.3565 
R2506 M LC 0.72174 0.53762 0.61364 0.43244 
R2611 M LC 0.71661 0.61214 0.56626 0.46745 
S1306 M cKO 0.63754 0.49085 0.46876 0.3424 
S1307 M cKO 0.79347 0.57638 0.62135 0.40546 
S1401 M cKO 0.73987 0.60811 0.59074 0.42608 
S1805 M cKO 0.69332 0.47215 0.55421 0.37936 
T1607 M cKO 0.84467 0.7649 0.65139 0.56008 
T1806 M cKO 1.05651 0.78747 0.79125 0.53589 
T1811 M cKO 0.84393 0.65226 0.67676 0.46565 
T2101 M cKO 0.88742 0.79133 0.6575 0.50722 
U2108 M cKO 0.65356 0.53871 0.52029 0.43032 
U2402 M cKO 0.77898 0.52505 0.6318 0.40316 
U2505 M cKO 0.79574 0.66302 0.58972 0.46773 
V2507 M cKO 0.73819 0.58173 0.59525 0.39781 
V2602 M cKO 0.72907 0.57578 0.56404 0.44528 
V2608 M cKO 0.60402 0.55442 0.46251 0.39984 
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H1314 F LC 1.28537 0.90588 1.81258 1.31204 
H1411 F LC 1.25535 0.94869 1.76172 1.48042 
H1504 F LC 1.2209 0.89409 1.63005 1.35724 
H1708 F LC 1.11363 0.80816 1.57935 1.30491 
I1710 F LC 1.14391 0.91536 1.47666 1.37854 
I2007 F LC 1.28217 1.05066 1.82107 1.681 
I2205 F LC 1.3723 1.05903 2.16429 1.81098 
I2209 F LC 1.39062 1.02918 2.23547 1.80653 
J2304 F LC 1.28429 0.9192 2.06701 1.61957 
J2306 F LC 1.28222 0.93065 2.08891 1.612 
J2413 F LC 1.15407 0.86418 1.79973 1.43346 
K2501 F LC 1.42173 0.9652 1.99868 1.56539 
K2503 F LC 1.36287 1.1221 2.13231 1.92811 
K2606 F LC 1.36568 1.08793 2.24392 1.88868 
L1707 F cKO 1.287 0.86942 2.18722 1.68859 
L1804 F cKO 1.37102 0.86386 2.36889 1.73989 
L1808 F cKO 1.17182 0.8367 2.33303 1.87888 
L1813 F cKO 1.31356 0.93236 2.34444 2.0739 
M2113 F cKO 1.31744 0.891 2.01309 1.59248 
M2216 F cKO 1.27969 0.92345 2.05297 1.66322 
M2303 F cKO 1.25569 0.78995 1.96529 1.40003 
M2310 F cKO 1.28612 0.78701 1.98796 1.46447 
N2311 F cKO 1.23474 0.88407 1.92446 1.66017 
N2404 F cKO 1.27355 0.93424 2.25259 1.81014 
N2406 F cKO 1.25433 0.84785 1.85662 1.42551 
N2410 F cKO 1.24248 0.83235 1.82539 1.42101 
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O1412 M LC 1.33529 1.21426   
O1507 M LC 1.33187 1.1153   
O1610 M LC 1.36541 1.19876 
  O1701 M LC 1.36123 1.2445 
  P1801 M LC 1.25308 1.09968 
  P1910 M LC 1.25881 1.0378 
  P2003 M LC 1.41538 1.32636 
  P2117 M LC 1.35615 1.20298 
  Q2202 M LC 1.20311 0.94107 
  Q2309 M LC 1.12699 0.90789 
  Q2403 M LC 1.27135 1.06541 
  R2412 M LC 1.2283 0.97985 
  R2506 M LC 1.41122 1.12315 
  R2611 M LC 1.36739 1.13505 
  S1306 M cKO 1.26785 1.03303 
  S1307 M cKO 1.3619 1.08136 
  S1401 M cKO 1.33563 1.10263 
  S1805 M cKO 1.38011 0.98856 
  T1607 M cKO 1.4634 1.38642 
  T1806 M cKO 1.65962 1.43201 
  T1811 M cKO 1.44696 1.27471 
  T2101 M cKO 1.4736 1.36656 
  U2108 M cKO 1.26754 1.08839 
  U2402 M cKO 1.37946 1.05454 
  U2505 M cKO 1.41302 1.21701 
  V2507 M cKO 1.43739 1.17058 
  V2602 M cKO 1.34455 1.17504 
  V2608 M cKO 1.23305 1.11136 
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H1314 F LC 0.168 0.138 823.0163 825.816 
H1411 F LC 0.185 0.147 846.9117 824.1883 
H1504 F LC 0.181 0.138 856.6131 849.1906 
H1708 F LC 0.172 0.125 844.8933 800.4882 
I1710 F LC 0.177 0.138 882.5921 834.2803 
I2007 F LC 0.196 0.151 864.4914 840.9216 
I2205 F LC 0.192 0.151 846.4559 833.8246 
I2209 F LC 0.179 
 
819.1097 872.3204 
J2304 F LC 0.173 0.135 837.0801 838.187 
J2306 F LC 0.186 0.143 854.0087 833.1083 
J2413 F LC 0.154 0.118 800.8788 774.5743 
K2501 F LC 0.182 0.147 827.6391 840.8564 
K2503 F LC 0.185 0.147 849.3208 844.8282 
K2606 F LC 0.17 0.15 843.7864 847.2372 
L1707 F cKO 0.179 0.128 819.891 792.8703 
L1804 F cKO 0.173 0.125 828.6808 820.6723 
L1808 F cKO 0.16 0.124 821.5187 825.23 
L1813 F cKO 0.17 0.128 841.3773 816.6355 
M2113 F cKO 0.186 0.128 839.424 807.5852 
M2216 F cKO 0.181 0.136 840.8564 820.3468 
M2303 F cKO 0.178 0.124 846.2606 842.8749 
M2310 F cKO 0.173 0.118 805.0459 778.0903 
N2311 F cKO 0.178 0.125 838.1218 836.6894 
N2404 F cKO 0.155 0.129 837.2754 830.8295 
N2406 F cKO 0.18 0.13 837.8614 801.0742 
N2410 F cKO 0.179 0.135 842.4191 821.7792 
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O1412 M LC 0.153 0.141 826.6625 820.477 
O1507 M LC 0.158 0.135 831.2202 819.6306 
O1610 M LC 0.16 0.14 839.6194 826.7927 
O1701 M LC 
 
0.148 872.3204 840.5309 
P1801 M LC 0.151 0.131 835.6476 807.3899 
P1910 M LC 0.15 0.13 814.4869 820.2166 
P2003 M LC 0.168 0.154 826.6625 825.8812 
P2117 M LC 0.168 0.157 815.9193 824.9045 
Q2202 M LC 0.157 0.122 829.4622 803.6786 
Q2309 M LC 0.145 0.117 818.5237 804.9157 
Q2403 M LC 0.148 0.116 820.477 821.5839 
R2412 M LC 0.147 0.121 827.7042 813.7056 
R2506 M LC 0.163 0.132 814.6171 801.9206 
R2611 M LC 0.155 0.125 799.9673 808.8223 
S1306 M cKO 0.155 0.13 828.6158 818.0028 
S1307 M cKO 0.149 0.13 814.2264 807.8456 
S1401 M cKO 0.15 0.128 816.5053 801.8555 
S1805 M cKO 0.164 0.12 830.6342 812.1429 
T1607 M cKO 0.166 0.157 815.4635 818.9144 
T1806 M cKO 0.171 0.173 814.9426 839.0334 
T1811 M cKO 0.158 0.151 806.4132 829.5924 
T2101 M cKO 0.168 0.16 816.0495 830.6993 
U2108 M cKO 0.145 0.125 808.8223 801.5951 
U2402 M cKO 0.155 0.132 808.9525 808.9525 
U2505 M cKO 0.157 0.135 821.5839 811.3616 
V2507 M cKO 0.166 0.149 815.5938 825.0998 
V2602 M cKO 0.158 0.145 812.9243 812.8591 
V2608 M cKO 0.148 0.133 802.116 786.7499 
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Table C.5 Indices of cancellous bone from microCT analysis of L5 vertebral body of 














H1314 F LC 0.1941 0.0479 0.227 612.84 
H1411 F LC 0.171 0.0471 0.2432 629.639 
H1504 F LC 
    H1708 F LC 0.2464 0.053 0.195 644.419 
I1710 F LC 0.2022 0.0463 0.1974 626.969 
I2007 F LC 0.1843 0.0487 0.2385 639.21 
I2205 F LC 0.1697 0.0469 0.2397 641.749 
I2209 F LC 0.1495 0.0452 0.2471 630.681 
J2304 F LC 
    J2306 F LC 
    J2413 F LC 
    K2501 F LC 
    K2503 F LC 0.1957 0.0515 0.2156 632.178 
K2606 F LC 
    L1707 F cKO 
    L1804 F cKO 
    L1808 F cKO 0.1427 0.0443 0.2256 653.99 
L1813 F cKO 0.1543 0.046 0.2401 641.424 
M2113 F cKO 0.1727 0.0456 0.2116 638.168 
M2216 F cKO 0.181 0.0459 0.2154 629.574 
M2303 F cKO 
    M2310 F cKO 
    N2311 F cKO 
    N2404 F cKO 0.1437 0.0457 0.2468 638.559 
N2406 F cKO 0.1689 0.0458 0.2095 634.327 
N2410 F cKO 0.1552 0.0439 0.2434 637.647 
 
 198 














O1412 M LC 0.2741 0.0542 0.1671 664.343 
O1507 M LC     
O1610 M LC 0.2558 0.0506 0.1712 644.875 
O1701 M LC 
    P1801 M LC 
    P1910 M LC 0.2185 0.0467 0.1872 629.834 
P2003 M LC 0.3025 0.058 0.1591 679.253 
P2117 M LC 0.2654 0.0525 0.1654 656.529 
Q2202 M LC 0.1859 0.0438 0.1923 631.462 
Q2309 M LC 0.2014 0.0458 0.1834 618.635 
Q2403 M LC 
    R2412 M LC 
    R2506 M LC 
    R2611 M LC 
    S1306 M cKO 
    S1307 M cKO 0.266 0.0509 0.158 647.479 
S1401 M cKO 
    S1805 M cKO 0.2124 0.0459 0.1666 638.168 
T1607 M cKO 0.331 0.0603 0.1615 674.955 
T1806 M cKO 
    T1811 M cKO 0.3102 0.0546 0.146 652.232 
T2101 M cKO 0.3466 0.0606 0.1401 680.425 
U2108 M cKO 0.2803 0.051 0.154 635.043 
U2402 M cKO 
    U2505 M cKO 
    V2507 M cKO 0.2882 0.0559 0.1677 656.529 
V2602 M cKO 
    V2608 M cKO 0.2707 0.0517 0.1679 642.596 
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Table C.6 Indices of cortical bone from microCT analysis of L5 cortical vertebral 
























H1314 F LC 0.13658 0.02985 0.31723 0.86805 
H1411 F LC 0.14528 0.02941 0.32793 0.83764 
H1504 F LC 
    H1708 F LC 0.1498 0.031 0.33396 0.90138 
I1710 F LC 0.15246 0.03507 0.33806 0.86011 
I2007 F LC 0.12518 0.02653 0.31715 0.79824 
I2205 F LC 0.14054 0.02948 0.32907 0.94037 
I2209 F LC 0.14059 0.02872 0.32651 0.89089 
J2304 F LC 
    J2306 F LC 
    J2413 F LC 
    K2501 F LC 
    K2503 F LC 0.14857 0.02712 0.33918 0.92831 
K2606 F LC 
    L1707 F cKO 
    L1804 F cKO 
    L1808 F cKO 0.12517 0.0247 0.27646 0.83946 
L1813 F cKO 0.15817 0.03115 0.29619 0.91385 
M2113 F cKO 0.13044 0.02963 0.29314 0.87508 
M2216 F cKO 0.15025 0.03071 0.31722 0.93925 
M2303 F cKO 
    M2310 F cKO 
    N2311 F cKO 0.1457 0.02903 0.30141 0.89386 
N2404 F cKO 0.11959 0.02528 0.26487 0.79025 
N2406 F cKO 
    N2410 F cKO 0.14108 0.0283 0.29683 0.84429 
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O1412 M LC 0.16991 0.04364 0.38706 0.88151 
O1507 M LC     
O1610 M LC 0.12998 0.03248 0.31724 0.84998 
O1701 M LC 
    P1801 M LC 
    P1910 M LC 0.12451 0.02851 0.29031 0.85824 
P2003 M LC 0.13775 0.03893 0.35583 0.91451 
P2117 M LC 0.15298 0.03897 0.34399 0.90543 
Q2202 M LC 0.12067 0.02641 0.28047 0.72351 
Q2309 M LC 0.11669 0.02436 0.27425 0.79627 
Q2403 M LC 
    R2412 M LC 
    R2506 M LC 
    R2611 M LC 
    S1306 M cKO 
    S1307 M cKO 0.13641 0.03212 0.31698 0.7995 
S1401 M cKO 
    S1805 M cKO 0.11409 0.02955 0.28478 0.85277 
T1607 M cKO 0.17668 0.04296 0.36066 0.93344 
T1806 M cKO 
    T1811 M cKO 0.13704 0.03354 0.32638 0.8027 
T2101 M cKO 0.1629 0.0376 0.3805 0.9643 
U2108 M cKO 0.12942 0.03104 0.31716 0.89323 
U2402 M cKO 
    U2505 M cKO 
    V2507 M cKO 0.13541 0.03229 0.32073 0.81465 
V2602 M cKO 
    V2608 M cKO 0.1369 0.03156 0.32411 0.85734 
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H1314 F LC 0.36545 0.062 774.574 
H1411 F LC 0.39149 0.068 798.925 
H1504 F LC 
   H1708 F LC 0.3705 0.064 793.586 
I1710 F LC 0.39305 0.061 791.763 
I2007 F LC 0.39731 0.069 795.67 
I2205 F LC 0.34994 0.065 790.656 
I2209 F LC 0.3665 0.067 788.963 
J2304 F LC 
   J2306 F LC 
   J2413 F LC 
   K2501 F LC 
   K2503 F LC 0.36537 0.068 795.8 
K2606 F LC 
   L1707 F cKO 
   L1804 F cKO 
   L1808 F cKO 0.32933 0.057 801.79 
L1813 F cKO 0.32411 0.058 791.698 
M2113 F cKO 0.33499 0.059 788.638 
M2216 F cKO 0.33774 0.059 777.048 
M2303 F cKO 
   M2310 F cKO 
   N2311 F cKO 0.3372 0.06 786.88 
N2404 F cKO 0.33518 0.054 779.783 
N2406 F cKO 
   N2410 F cKO 0.35157 0.059 786.489 
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O1412 M LC 0.43909 0.069 798.99 
O1507 M LC    
O1610 M LC 0.37323 0.063 796.776 
O1701 M LC 
   P1801 M LC 
   P1910 M LC 0.33827 0.057 791.112 
P2003 M LC 0.38909 0.068 805.176 
P2117 M LC 0.37992 0.062 791.568 
Q2202 M LC 0.38765 0.059 785.773 
Q2309 M LC 0.34442 0.057 792.87 
Q2403 M LC 
   R2412 M LC 
   R2506 M LC 
   R2611 M LC 
   S1306 M cKO 
   S1307 M cKO 0.39648 0.063 798.73 
S1401 M cKO 
   S1805 M cKO 0.33394 0.056 787.921 
T1607 M cKO 0.38638 0.066 805.762 
T1806 M cKO 
   T1811 M cKO 0.4066 0.065 805.436 
T2101 M cKO 0.39459 0.07 812.012 
U2108 M cKO 0.35507 0.062 790.331 
U2402 M cKO 
   U2505 M cKO 
   V2507 M cKO 0.3937 0.064 790.135 
V2602 M cKO 
   V2608 M cKO 0.37804 0.063 792.675 
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Table C.7 Indices of cortical bone from microCT analysis of femoral midshaft in 12-
























H1314 F LC 
    H1411 F LC 0.20554 0.1078 0.73707 1.64374 
H1504 F LC 
    H1708 F LC 
    I1710 F LC 0.18875 0.09982 0.7176 1.56852 
I2007 F LC 
    I2205 F LC 0.18427 0.10503 0.7257 1.57486 
I2209 F LC 0.22747 0.11149 0.76358 1.69098 
J2304 F LC 0.16089 0.09425 0.6755 1.49048 
J2306 F LC 
    J2413 F LC 
    K2501 F LC 0.18592 0.10753 0.7092 1.61537 
K2503 F LC 0.20099 0.10899 0.72732 1.64662 
K2606 F LC 0.20812 0.12013 0.75252 1.699 
L1707 F cKO 
    L1804 F cKO 
    L1808 F cKO 0.16229 0.10588 0.66771 1.57536 
L1813 F cKO 0.19192 0.11394 0.71074 1.67157 
M2113 F cKO 0.1538 0.09657 0.65532 1.50025 
M2216 F cKO 
    M2303 F cKO 0.16969 0.09542 0.6721 1.53472 
M2310 F cKO 0.17473 0.09919 0.67914 1.56418 
N2311 F cKO 
    N2404 F cKO 0.19918 0.11264 0.7005 1.70093 
N2406 F cKO 0.17482 0.09822 0.64796 1.52265 
N2410 F cKO 0.17586 0.10155 0.66817 1.59634 
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O1412 M LC 0.38018 0.17477 0.99391 2.14234 
O1507 M LC 0.32796 0.17206 0.94187 2.07344 
O1610 M LC 
    O1701 M LC 
    P1801 M LC 0.31672 0.14607 0.86047 2.01197 
P1910 M LC 0.32654 0.16579 0.89962 2.08083 
P2003 M LC 
    P2117 M LC 0.48215 0.21835 1.09071 2.44105 
Q2202 M LC 
    Q2309 M LC 
    Q2403 M LC 
    R2412 M LC 0.27373 0.11929 0.80844 1.81559 
R2506 M LC 0.32406 0.15278 0.89257 2.02434 
R2611 M LC 0.37527 0.18801 0.98292 2.20117 
S1306 M cKO 0.40187 0.17208 1.04793 2.1204 
S1307 M cKO 0.42396 0.21136 1.03238 2.36015 
S1401 M cKO 
    S1805 M cKO 
    T1607 M cKO 0.43891 0.24014 1.08811 2.44166 
T1806 M cKO 0.5603 0.25639 1.22987 2.57149 
T1811 M cKO 0.43499 0.21962 1.06601 2.38652 
T2101 M cKO 0.486 0.22883 1.14984 2.41592 
U2108 M cKO 
    U2402 M cKO 
    U2505 M cKO 
    V2507 M cKO 
    V2602 M cKO 0.32178 0.13796 0.91304 1.92117 
V2608 M cKO 0.37422 0.1849 0.98119 2.18814 
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H1314 F LC 
    H1411 F LC 0.44841 0.18 956.492 0.90667 
H1504 F LC 
    H1708 F LC 
    I1710 F LC 0.4575 0.179 945.1629 0.85092 
I2007 F LC 
    I2205 F LC 0.4608 0.185 955.32 0.84916 
I2209 F LC 0.45156 0.184 951.9343 0.9274 
J2304 F LC 0.45321 0.173 932.7269 0.81498 
J2306 F LC 
    J2413 F LC 
    K2501 F LC 0.43903 0.176 936.2427 0.90617 
K2503 F LC 0.4417 0.178 938.6518 0.9193 
K2606 F LC 0.44292 0.182 943.6653 0.94648 
L1707 F cKO 
    L1804 F cKO 
    L1808 F cKO 0.42385 0.169 942.2328 0.90765 
L1813 F cKO 0.4252 0.174 934.4197 0.96083 
M2113 F cKO 0.43681 0.17 937.8054 0.84493 
M2216 F cKO 
    M2303 F cKO 0.43793 0.171 937.4799 0.86262 
M2310 F cKO 0.43418 0.171 924.6531 0.88504 
N2311 F cKO 
    N2404 F cKO 0.41183 0.168 914.6262 1.00043 
N2406 F cKO 0.42555 0.144 929.862 0.87469 
N2410 F cKO 0.41857 0.165 938.9774 0.92817 
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O1412 M LC 0.46394 0.201 929.4714 1.14843 
O1507 M LC 0.45426 0.201 932.3361 1.13157 
O1610 M LC 
    O1701 M LC 
    P1801 M LC 0.42767 0.185 940.0191 1.1515 
P1910 M LC 0.43234 0.189 915.7982 1.18121 
P2003 M LC 
    P2117 M LC 0.44682 0.194 921.5279 1.35034 
Q2202 M LC 
    Q2309 M LC 
    Q2403 M LC 
    R2412 M LC 0.44528 0.182 917.8166 1.00715 
R2506 M LC 0.44092 0.192 925.3694 1.13177 
R2611 M LC 0.44654 0.202 920.0303 1.21825 
S1306 M cKO 0.49422 0.203 928.9505 1.07247 
S1307 M cKO 0.43742 0.188 933.6384 1.32777 
S1401 M cKO 
    S1805 M cKO 
    T1607 M cKO 0.44565 0.204 937.9356 1.35355 
T1806 M cKO 0.47827 0.211 933.2477 1.34162 
T1811 M cKO 0.44668 0.196 934.4197 1.32051 
T2101 M cKO 0.47594 0.221 934.5499 1.26608 
U2108 M cKO 
    U2402 M cKO 
    U2505 M cKO 
    V2507 M cKO 
    V2602 M cKO 0.47525 0.192 921.2674 1.00813 
V2608 M cKO 0.44842 0.198 919.1188 1.20695 
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Table C.8 Indices of serum markers in 12-week-old female and male pOC-ERαKO 


















H1314 F LC 
   
108.4487 
 H1411 F LC 6.2 244 55  3.448049 
H1504 F LC 
   
116.7179 
 H1708 F LC 5.9 192 54  3.271478 
I1710 F LC 
   
99.28205 
 I2007 F LC 6.4 255 95  3.549684 
I2205 F LC 
   
96.84615 
 I2209 F LC 7.2 301 91  2.487657 
J2304 F LC 
   
97.35897 
 J2306 F LC 7.1 282 111  2.419775 
J2413 F LC 9.4 245 56  6.004602 
K2501 F LC 6.2 250 65  3.574322 
K2503 F LC 
   
123.7692 
 K2606 F LC 8 237 64  3.59913 
L1707 F cKO 
   
117.9359 
 L1804 F cKO 
   
105.1795 
 L1808 F cKO 5.4 255 61  3.285083 
L1813 F cKO 5.9 341 76  6.515233 
M2113 F cKO 
   
84.79487 
 M2216 F cKO 5.7 297 71  3.358604 
M2303 F cKO 5.7 254 85  2.669501 
M2310 F cKO 5.9 231 65 145.8205 3.830296 
N2311 F cKO 6.5 290 56  2.896515 
N2404 F cKO 
   
92.16667 
 N2406 F cKO 5.6 315 65 122.0385 2.721704 
N2410 F cKO 6.3 268 71  3.195441 
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O1412 M LC 5.9 270 73  
 O1507 M LC 6 264 55 113.1923 
 O1610 M LC 6.3 261 59  
 O1701 M LC 6.5 251 66  
 P1801 M LC 6.1 297 54  
 P1910 M LC 6 262 57  
 P2003 M LC 
   
92.87179 
 P2117 M LC 
   
91.97436 
 Q2202 M LC 
   
139.6667 
 Q2309 M LC 
   
95.5641 
 Q2403 M LC 
   
120.1795 
 R2412 M LC 
   
108.4487 
 R2506 M LC 7.3 264 55  
 R2611 M LC 5.6 251 55  
 S1306 M cKO 5.2 285 54  
 S1307 M cKO 6.6 287 43 101.2051 
 S1401 M cKO 6.2 294 50  
 S1805 M cKO 6.4 295 58 94.47436 
 T1607 M cKO 6.1 283 47  
 T1806 M cKO 6.2 279 45  
 T1811 M cKO 
   
96.39744 
 T2101 M cKO 
   
136.9744 
 U2108 M cKO 
   
134.9872 
 U2402 M cKO    144.859  
U2505 M cKO 5.2 249 48   
V2507 M cKO 6.1 248 56  
 V2602 M cKO 
   
128.1923 
 V2608 M cKO 




Table C.9 Indices of body, ovarian, and uterine masses in 12-week-old female and 














H1314 F LC 18.66 147 486 
H1411 F LC 19.07 
 
458 
H1504 F LC 
 
112 850 
H1708 F LC 19.18 179 511 
I1710 F LC 17.45 122 480 
I2007 F LC 18.89 138 473 
I2205 F LC 19.28 246 912 
I2209 F LC 19.39 238 721 
J2304 F LC 17.49 164 578 
J2306 F LC 19.19 95 822 
J2413 F LC 20.55 
 
578 
K2501 F LC 18.47 132 561 
K2503 F LC 18.28 140 500 
K2606 F LC 18.64 132 429 
L1707 F cKO 17.47 148 602 
L1804 F cKO 19.54 248 997 
L1808 F cKO 18.41 132 505 
L1813 F cKO 20.55 167 1090 
M2113 F cKO 18.44 241 811 
M2216 F cKO 19.14 120 878 
M2303 F cKO 18.71 185 507 
M2310 F cKO 18.8 124 1272 
N2311 F cKO 19.67 229 458 
N2404 F cKO 19.61 154 913 
N2406 F cKO 19.25 150 444 
N2410 F cKO 18.66 113 455 
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O1412 M LC 24.59 N/A N/A 
O1507 M LC 24.36 N/A N/A 
O1610 M LC 25.35 N/A N/A 
O1701 M LC 26.36 N/A N/A 
P1801 M LC 24.6 N/A N/A 
P1910 M LC 25.7 N/A N/A 
P2003 M LC 25.8 N/A N/A 
P2117 M LC 26.56 N/A N/A 
Q2202 M LC 23.79 N/A N/A 
Q2309 M LC 23.17 N/A N/A 
Q2403 M LC 26.18 N/A N/A 
R2412 M LC 24.41 N/A N/A 
R2506 M LC 24.2 N/A N/A 
R2611 M LC 25.3 N/A N/A 
S1306 M cKO 24.9 N/A N/A 
S1307 M cKO 26.14 N/A N/A 
S1401 M cKO 25.5 N/A N/A 
S1805 M cKO 26.02 N/A N/A 
T1607 M cKO 26.87 N/A N/A 
T1806 M cKO 28.72 N/A N/A 
T1811 M cKO 27.28 N/A N/A 
T2101 M cKO 26.73 N/A N/A 
U2108 M cKO 25.07 N/A N/A 
U2402 M cKO 27.19 N/A N/A 
U2505 M cKO 25.18 N/A N/A 
V2507 M cKO 23.25 N/A N/A 
V2602 M cKO 24.61 N/A N/A 
V2608 M cKO 24.86 N/A N/A 
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Table C.10 Indices of crown/rump and long bone lengths in 12-week-old female and 


















H1314 F LC 81.34 17.58 17.46 14.97 
H1411 F LC 80.81 17.55 17.61 15.12 
H1504 F LC 80.59 17.25 16.92 14.59 
H1708 F LC 81.17 17.4 17.61 
 I1710 F LC 82.52 17.13 17.01 14.86 
I2007 F LC 80.4  17.19 14.86 
I2205 F LC 83.81  
 
15.21 
I2209 F LC 85.14  
 
15.12 





J2306 F LC 80.58  
 
14.74 
J2413 F LC 85.95  
 
15.4 
K2501 F LC 83.04  
 
15.18 
K2503 F LC 82.86  
 
15.02 
K2606 F LC 83.25  
 
15.04 
L1707 F cKO 79.23 17.16 17.25 14.77 
L1804 F cKO 80.4 17.55 17.46 14.97 
L1808 F cKO 81.83 17.46 17.07 14.88 
L1813 F cKO 82.08  17.82 15.54 
M2113 F cKO 81.48 17.52 17.61 15.03 
M2216 F cKO 83.69 17.49 17.4 15.29 
M2303 F cKO 78.53  
 
15.2 
M2310 F cKO 81.95  
 
14.81 
N2311 F cKO 83.22  
  N2404 F cKO 83.31  
 
14.96 
N2406 F cKO 82.36  
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O1412 M LC 88.53 17.67 17.7 15.62 
O1507 M LC 89.37 18 17.97 15.53 
O1610 M LC 90.52 17.94 17.82 15.79 
O1701 M LC 92.18 18.12 18.03 15.52 
P1801 M LC 88.7 18.06 17.97 15.52 
P1910 M LC 90.92 18.06 18 16.02 
P2003 M LC 92.34   15.41 
P2117 M LC 89.86   15.06 
Q2202 M LC 86.55   14.89 
Q2309 M LC 86.2    
Q2403 M LC 91.77   15.3 
R2412 M LC 88.11   15.38 
R2506 M LC 89.35   15.75 
R2611 M LC 87.96   15.66 
S1306 M cKO 88.25 18.09 18.09  
S1307 M cKO 94.42 18.18 18.03 15.91 
S1401 M cKO 91.86 18.03 17.88 15.58 
S1805 M cKO 91.03 18.15 18.18  
T1607 M cKO 91.79 17.88 18 16.12 
T1806 M cKO 91.12 18.15 18.24 15.95 
T1811 M cKO 89.71   15.85 
T2101 M cKO 90.84   15.97 
U2108 M cKO 86.46   16.03 
U2402 M cKO 93.18   15.71 
U2505 M cKO 91.57   15.68 
V2507 M cKO 86.47   15.61 
V2602 M cKO 88.71   15.68 
V2608 M cKO 86.47   15.39 
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Table C.11 Indices of L5 vertebral geometries in 12-week-old female and male pOC-














H1314 F LC 3.05 2.09 1.17 
H1411 F LC 3.51 2.1 1.29 
H1504 F LC 3.09 2.04 1.16 
H1708 F LC 
 
 
 I1710 F LC 2.56 2.13 
 I2007 F LC 3.11 1.93 1.11 
I2205 F LC 3.46 2.28 1.14 
I2209 F LC 2.55 2.12 1.05 
J2304 F LC 3.27 1.72 1.09 
J2306 F LC 2.64 2.11 1.18 
J2413 F LC 3.13 2.09 1.37 
K2501 F LC 3.03 2.14 1.11 
K2503 F LC 3.16 1.93 1.13 
K2606 F LC 2.81 2.16 1.08 
L1707 F cKO 3.44 2.5 1.24 
L1804 F cKO 2.29  
 L1808 F cKO 
 
 
 L1813 F cKO 3.6 2.09 1.24 
M2113 F cKO 3.03 2.03 1.37 
M2216 F cKO 
 
 
 M2303 F cKO 2.9 2 1.36 
M2310 F cKO 2.96 1.84 1.34 
N2311 F cKO 3.22 2 1.13 
N2404 F cKO 
 
 
 N2406 F cKO 3.53 2.17 1.08 
N2410 F cKO 3.15 2.01 1.22 
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O1412 M LC 3.33   
O1507 M LC 3.19 2.12 1.25 
O1610 M LC 3.47 2.29 1.16 
O1701 M LC 
 
  
P1801 M LC 
 
  
P1910 M LC 3.13 2.1 1.23 
P2003 M LC 3.06 1.88 1.39 
P2117 M LC 3.16 2.1 1.23 
Q2202 M LC 3.14 1.97 1.22 
Q2309 M LC 2.96 2.15 1.23 
Q2403 M LC 
 
  
R2412 M LC 
 
  
R2506 M LC 
 
  
R2611 M LC 3.1 2.24 1.1 
S1306 M cKO 
 
  
S1307 M cKO 3.41 2.1 1.26 
S1401 M cKO 3.37   
S1805 M cKO 3.14 2.16 1.27 
T1607 M cKO 
 
  
T1806 M cKO 
 
  
T1811 M cKO 3.18 2.26 1.33 
T2101 M cKO 3.36 2.21 1.27 
U2108 M cKO 3.2   
U2402 M cKO 
 
  
U2505 M cKO 
 
  
V2507 M cKO 3.34   
V2602 M cKO 
 
  
V2608 M cKO 3.04 2.16 1.34 
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Table C.12 Indices of mechanical testing data in right femur and L5 vertebra in 12-




















H1314 F LC 21.3 150.6544 26.45956 47.82056 
H1411 F LC 20.766 109.4184 25.74407 43.95674 
H1504 F LC 18.134 82.10611 27.89319 81.61951 
H1708 F LC     
I1710 F LC 26.93 252.5554 21.09659 29.34121 
I2007 F LC   22.28689 25.30023 
I2205 F LC 21.272 122.2372 26.32479 33.80898 
I2209 F LC 20.483 274.5931 24.28274 42.12473 
J2304 F LC 20.585 85.57881 23.32698 26.60421 
J2306 F LC 18.736 165.7116 20.4339 32.82371 
J2413 F LC 22.007 113.9209 21.21159 21.70257 
K2501 F LC 25.11 80.60002 24.7689 53.47599 
K2503 F LC 27.897 305.9099 22.47223 29.29675 
K2606 F LC 17.712 112.9539 27.0933 48.04753 
L1707 F cKO 18.221 91.96649 25.44859 84.99117 
L1804 F cKO 15.156 64.02484 22.76094 41.17293 
L1808 F cKO 19.767  22.8981 25.30077 
L1813 F cKO 19.915 201.664 22.8981 25.30077 
M2113 F cKO 20.068 176.0935 21.7013 30.49013 
M2216 F cKO 17.899  23.44835 46.86691 
M2303 F cKO 15.319 85.21682 25.27342 23.90771 
M2310 F cKO 12.911 56.38142 20.66681 47.71993 
N2311 F cKO 17.072 97.98532   
N2404 F cKO 18.929  22.5519 49.52684 
N2406 F cKO 18.65 120.9425 25.73869 34.59623 
N2410 F cKO 19.75 71.8018 22.15127 71.86923 
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O1412 M LC 24.867 220.4127 38.07199 209.9159 
O1507 M LC 17.817 227.6033 38.55323 217.3116 
O1610 M LC 26.674 149.6611 34.91419 79.94756 
O1701 M LC     
P1801 M LC   28.06262 172.7391 
P1910 M LC 20.376 213.3878 30.12318 48.3166 
P2003 M LC 29.249 248.2333 38.12461 43.45768 
P2117 M LC 29.432 532.1187 39.20994 83.67157 
Q2202 M LC 18.686 128.5139 28.64428 78.05465 
Q2309 M LC 26.619 115.955 25.56948 87.14018 
Q2403 M LC   32.64057 47.16066 
R2412 M LC   25.56114 23.12665 
R2506 M LC   35.86112 29.42739 
R2611 M LC 21.46 366.5595 37.82316 136.8459 
S1306 M cKO   34.92784 86.85404 
S1307 M cKO 22.451 159.9802 36.12844 97.87588 
S1401 M cKO 21.626 147.1915 32.50593 65.07007 
S1805 M cKO 17.645 157.9703   
T1607 M cKO 38.346 301.7728 40.69047 101.328 
T1806 M cKO   44.81976 206.1935 
T1811 M cKO 25.315 264.9894 43.57968 228.4519 
T2101 M cKO 34.458 389.7634 42.58247 151.7351 
U2108 M cKO 22.737 254.0512 37.19725 96.73706 
U2402 M cKO   38.98755 63.46775 
U2505 M cKO   38.56435 129.4197 
V2507 M cKO 26.402 177.5177 41.05285 31.21829 
V2602 M cKO   30.67679 35.12127 
V2608 M cKO   38.22918 261.5301 
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Table C.13 Indices of histology and IHC in the left loaded (L) and right control (R) 
















) Oc.S/BS.L Oc.S/BS.L 
H1314 F LC 3.306435 1.625295 0.062143 0.02833 
H1411 F LC 1.396418 2.626927 0.025033 0.055065 
H1504 F LC 2.718334  0.05735  
H1708 F LC 1.00334 1.382218 0.016908 0.025269 
I1710 F LC 2.837096 4.478723 0.059442 0.11618 
I2007 F LC 2.520633 1.19772 0.045665 0.025919 
I2205 F LC 3.063762 3.545493 0.073225 0.094126 
I2209 F LC     
J2304 F LC     
J2306 F LC     
J2413 F LC     
K2501 F LC     
K2503 F LC     
K2606 F LC     
L1707 F cKO 2.857316 0.63389 0.076545 0.012516 
L1804 F cKO 3.044763 2.611393 0.062592 0.043461 
L1808 F cKO 2.397827 1.120268 0.045548 0.018749 
L1813 F cKO 1.180976 2.824179 0.022639 0.061743 
M2113 F cKO 3.321339 2.994283 0.06272 0.059232 
M2216 F cKO 1.316706 1.65151 0.021361 0.02745 
M2303 F cKO     
M2310 F cKO     
N2311 F cKO     
N2404 F cKO     
N2406 F cKO     
N2410 F cKO     
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) Oc.S/BS.L Oc.S/BS.L 
O1412 M LC 4.413818 1.519655 0.102097 0.023419 
O1507 M LC 2.714064 3.401465 0.054702 0.069983 
O1610 M LC 4.840309 2.636878 0.112848 0.055795 
O1701 M LC 5.009117 3.217296 0.113281 0.063754 
P1801 M LC 5.535407 4.042086 0.122497 0.080494 
P1910 M LC 2.007029 3.585239 0.03893 0.075761 
P2003 M LC 2.433492 1.868339 0.056071 0.036255 
P2117 M LC     
Q2202 M LC     
Q2309 M LC     
Q2403 M LC     
R2412 M LC     
R2506 M LC     
R2611 M LC     
S1306 M cKO 4.321684 5.231241 0.110984 0.113817 
S1307 M cKO     
S1401 M cKO     
S1805 M cKO 3.851248 3.145757 0.079168 0.062854 
T1607 M cKO 3.912146 2.684461 0.070692 0.064413 
T1806 M cKO     
T1811 M cKO 4.608856 3.363916 0.10483 0.069227 
T2101 M cKO     
U2108 M cKO     
U2402 M cKO     
U2505 M cKO     
V2507 M cKO     
V2602 M cKO 3.991309 2.95816 0.094434 0.062854 
V2608 M cKO 5.583881 3.460954 0.142686 0.08068 
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H1314 F LC 2.13716 0.927 0.18175 0.10051 
H1411 F LC 2.60249 1.6907 0.18295 0.11383 
H1504 F LC 2.51905  0.1731  
H1708 F LC 3.96817 3.51719 0.17581 0.11314 
I1710 F LC 1.82915 0.98188 0.18441 0.0922 
I2007 F LC 3.61003 2.45755 0.17195 0.10997 
I2205 F LC 4.48204 2.67077 0.17652 0.11025 
I2209 F LC     
J2304 F LC     
J2306 F LC     
J2413 F LC     
K2501 F LC     
K2503 F LC     
K2606 F LC     
L1707 F cKO 2.89942 1.23876 0.22718 0.11614 
L1804 F cKO 2.54611 1.40857 0.1742 0.11754 
L1808 F cKO 2.43955 1.17164 0.1963 0.11643 
L1813 F cKO 2.44367 1.10779 0.19482 0.12271 
M2113 F cKO 4.20884 1.66701 0.203 0.11756 
M2216 F cKO 2.5242 1.0485 0.19229 0.12101 
M2303 F cKO     
M2310 F cKO     
N2311 F cKO     
N2404 F cKO     
N2406 F cKO     
N2410 F cKO     
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O1412 M LC 4.413818 1.519655 0.102097 0.023419 
O1507 M LC 2.714064 3.401465 0.054702 0.069983 
O1610 M LC 4.840309 2.636878 0.112848 0.055795 
O1701 M LC 5.009117 3.217296 0.113281 0.063754 
P1801 M LC 5.535407 4.042086 0.122497 0.080494 
P1910 M LC 2.007029 3.585239 0.03893 0.075761 
P2003 M LC 2.433492 1.868339 0.056071 0.036255 
P2117 M LC     
Q2202 M LC     
Q2309 M LC     
Q2403 M LC     
R2412 M LC     
R2506 M LC     
R2611 M LC     
S1306 M cKO 4.321684 5.231241 0.110984 0.113817 
S1307 M cKO     
S1401 M cKO     
S1805 M cKO 3.851248 3.145757 0.079168 0.062854 
T1607 M cKO 3.912146 2.684461 0.070692 0.064413 
T1806 M cKO     
T1811 M cKO 4.608856 3.363916 0.10483 0.069227 
T2101 M cKO     
U2108 M cKO     
U2402 M cKO     
U2505 M cKO     
V2507 M cKO     
V2602 M cKO 3.991309 2.95816 0.094434 0.062854 
V2608 M cKO 5.583881 3.460954 0.142686 0.08068 
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Table C.14 Indices of dynamic histomorphometry measurements in the left loaded (L) 
and right control (R) cancellous tibial metaphysis of 12-week-old female and male 
















H1314 F LC     
H1411 F LC     
H1504 F LC     
H1708 F LC     
I1710 F LC     
I2007 F LC     
I2205 F LC     
I2209 F LC     
J2304 F LC 0.36814 0.17952 1.66825 1.34253 
J2306 F LC 0.2711 0.20297 2.31127 1.44191 
J2413 F LC 0.29248 0.19234 1.49875 1.64009 
K2501 F LC 0.34931 0.20789 2.04939 1.43749 
K2503 F LC 0.34405 0.26526 1.73354 1.66952 
K2606 F LC     
L1707 F cKO     
L1804 F cKO     
L1808 F cKO     
L1813 F cKO     
M2113 F cKO     
M2216 F cKO     
M2303 F cKO 0.28104 0.17665 1.85725 1.06099 
M2310 F cKO  0.28374  1.11657 
N2311 F cKO 0.27266 0.20494 2.03331 1.06495 
N2404 F cKO 0.3012 0.26762 1.79311 1.33764 
N2406 F cKO 0.31534 0.22273 2.47846 1.25661 
N2410 F cKO 0.22565 0.2292 2.39834 1.2479 
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O1412 M LC     
O1507 M LC     
O1610 M LC     
O1701 M LC     
P1801 M LC     
P1910 M LC     
P2003 M LC     
P2117 M LC     
Q2202 M LC 0.32247 0.29417 1.45196 1.24966 
Q2309 M LC 0.33269 0.31072 1.24601 1.177 
Q2403 M LC 0.34949 0.20056 1.13762 0.91171 
R2412 M LC 0.31561 0.26573 1.14046 1.09377 
R2506 M LC     
R2611 M LC 0.28149 0.30917 0.97261 1.03749 
S1306 M cKO     
S1307 M cKO 0.22169 0.22382 1.10307 1.03546 
S1401 M cKO     
S1805 M cKO     
T1607 M cKO     
T1806 M cKO 0.31743 0.30816 1.13217 1.37931 
T1811 M cKO     
T2101 M cKO     
U2108 M cKO 0.13779 0.14226 0.40597 0 
U2402 M cKO 0.37353 0.27162 1.1498 0.92006 
U2505 M cKO 0.28728 0.26711 1.28026 1.30245 
V2507 M cKO 0.33851 0.28514 1.54796 1.42769 
V2602 M cKO     
V2608 M cKO     
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H1314 F LC   
H1411 F LC   
H1504 F LC   
H1708 F LC   
I1710 F LC   
I2007 F LC   
I2205 F LC   
I2209 F LC   
J2304 F LC 0.09684 0.05675 
J2306 F LC 0.07645 0.03718 
J2413 F LC 0.04506 0.03953 
K2501 F LC 0.15581 0.06204 
K2503 F LC 0.07456 0.07931 
K2606 F LC   
L1707 F cKO   
L1804 F cKO   
L1808 F cKO   
L1813 F cKO   
M2113 F cKO   
M2216 F cKO   
M2303 F cKO 0.08833 0.03194 
M2310 F cKO  0.05321 
N2311 F cKO 0.06534 0.04746 
N2404 F cKO 0.09562 0.08144 
N2406 F cKO 0.09422 0.04214 
N2410 F cKO 0.06884 0.04472 
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O1412 M LC   
O1507 M LC   
O1610 M LC   
O1701 M LC   
P1801 M LC   
P1910 M LC   
P2003 M LC   
P2117 M LC   
Q2202 M LC 0.04972 0.04065 
Q2309 M LC 0.0545 0.05559 
Q2403 M LC 0.03057 0.01539 
R2412 M LC 0.04354 0.02996 
R2506 M LC   
R2611 M LC 0.01959 0.02366 
S1306 M cKO   
S1307 M cKO 0.0221 0.01955 
S1401 M cKO   
S1805 M cKO   
T1607 M cKO   
T1806 M cKO 0.02657 0.03841 
T1811 M cKO   
T2101 M cKO   
U2108 M cKO 0.0042 0 
U2402 M cKO 0.03147 0.02285 
U2505 M cKO 0.03528 0.0272 
V2507 M cKO 0.04265 0.05175 
V2602 M cKO   
V2608 M cKO   
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Table C.15 Indices of dynamic histomorphometry measurements in the left loaded (L) 
and right control (R) endosteal tibial midshaft of 12-week-old female and male pOC-
















H1314 F LC     
H1411 F LC     
H1504 F LC     
H1708 F LC     
I1710 F LC     
I2007 F LC     
I2205 F LC     
I2209 F LC     
J2304 F LC 0.74158 0.62317 2.06334 0.62317 
J2306 F LC 0.57502 0.56692 1.45973 0.56692 
J2413 F LC 0.66269 0.61338 2.77227 0.61338 
K2501 F LC 0.46109 0.56907 2.53442 0.56907 
K2503 F LC 0.34209 0.56066 1.57995 0.56066 
K2606 F LC     
L1707 F cKO     
L1804 F cKO     
L1808 F cKO     
L1813 F cKO     
M2113 F cKO     
M2216 F cKO     
M2303 F cKO 0.33789 0.6252 1.80393 0.6252 
M2310 F cKO 0.42726 0.73957 0.99638 0.73957 
N2311 F cKO 0.56091 0.30863 1.40117 0.30863 
N2404 F cKO 0.34655 0.63301 1.61171 0.63301 
N2406 F cKO 0.32133 0.32533 0.98014 0.32533 
N2410 F cKO 0.28444 0.67411 2.03405 0.67411 
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O1412 M LC     
O1507 M LC     
O1610 M LC     
O1701 M LC     
P1801 M LC     
P1910 M LC     
P2003 M LC     
P2117 M LC     
Q2202 M LC 0.40617 0.53644 1.30601 0.68835 
Q2309 M LC 0.46877 0.5127 1.33834 0.48391 
Q2403 M LC 0.2012 0.34364 0 0.5355 
R2412 M LC 0.45123 0.45681 0 0 
R2506 M LC  0.05235  0 
R2611 M LC 0.03225 0.23777 0 0.92234 
S1306 M cKO     
S1307 M cKO 0.22764 0.27243 0.85997 0.55954 
S1401 M cKO     
S1805 M cKO     
T1607 M cKO     
T1806 M cKO 0.05634 0.14543 0 0 
T1811 M cKO     
T2101 M cKO     
U2108 M cKO 0.09989 0.05609 0 0 
U2402 M cKO 0.12076 0.15321 0 0.50896 
U2505 M cKO 0.16582 0.14199 0 0 
V2507 M cKO 0.1541 0.39863 0 0.85279 
V2602 M cKO     
V2608 M cKO     
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H1314 F LC     
H1411 F LC     
H1504 F LC     
H1708 F LC     
I1710 F LC     
I2007 F LC     
I2205 F LC     
I2209 F LC     
J2304 F LC 0.63796 0.22393 0 0 
J2306 F LC 0.32024 0.14427 0 0 
J2413 F LC 0.83405 0.21079 0 0 
K2501 F LC 0.55813 0.14335 0.02007 0 
K2503 F LC 0.36691 0.19464 0.03255 0 
K2606 F LC     
L1707 F cKO     
L1804 F cKO     
L1808 F cKO     
L1813 F cKO     
M2113 F cKO     
M2216 F cKO     
M2303 F cKO 0.35209 0.21735 0.04524 0 
M2310 F cKO 0.18316 0.26836 0.01437 0 
N2311 F cKO 0.32695 0.08164 0.01119 0 
N2404 F cKO 0.20391 0.25185 0.0108 0 
N2406 F cKO 0.21358 0 0.02212 0 
N2410 F cKO 0.43818 0.17609 0.03057 0 
 
 228 
























O1412 M LC     
O1507 M LC     
O1610 M LC     
O1701 M LC     
P1801 M LC     
P1910 M LC     
P2003 M LC     
P2117 M LC     
Q2202 M LC 0.19287 0.1275 0 0 
Q2309 M LC 0.25025 0.08698 0 0 
Q2403 M LC 0 0.05483 0 0 
R2412 M LC 0 0 0 0 
R2506 M LC  0  0 
R2611 M LC 0 0.06133 0 0 
S1306 M cKO     
S1307 M cKO 0.0464 0.04971 0 0 
S1401 M cKO     
S1805 M cKO     
T1607 M cKO     
T1806 M cKO 0 0 0 0 
T1811 M cKO     
T2101 M cKO     
U2108 M cKO 0 0 0 0 
U2402 M cKO 0 0.0242 0 0 
U2505 M cKO 0 0 0 0 
V2507 M cKO 0 0.10072 0 0 
V2602 M cKO     
V2608 M cKO     
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Table C.16 Indices of dynamic histomorphometry measurements in the left loaded (L) 
and right control (R) periosteal tibial midshaft of 12-week-old female and male pOC-
















H1314 F LC     
H1411 F LC     
H1504 F LC     
H1708 F LC     
I1710 F LC     
I2007 F LC     
I2205 F LC     
I2209 F LC     
J2304 F LC 0.32211 0.04132 2.37324 0 
J2306 F LC 0.10212 0.15179 2.61944 0 
J2413 F LC 0.20765 0.12335 2.3402 0 
K2501 F LC 0.25128 0.16569 2.11839 0 
K2503 F LC 0.24823 0.04073 2.22811 0 
K2606 F LC     
L1707 F cKO     
L1804 F cKO     
L1808 F cKO     
L1813 F cKO     
M2113 F cKO     
M2216 F cKO     
M2303 F cKO 0.09287 0.06929 0 0 
M2310 F cKO 0.31946 0.03921 1.91439 0 
N2311 F cKO 0.38956 0.07851 1.5714 0 
N2404 F cKO 0.32679 0.11145 2.7089 0 
N2406 F cKO 0.22034 0.12717 2.11904 0 
N2410 F cKO 0.21226 0.07056 1.88384 0 
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O1412 M LC     
O1507 M LC     
O1610 M LC     
O1701 M LC     
P1801 M LC     
P1910 M LC     
P2003 M LC     
P2117 M LC     
Q2202 M LC 0.55087 0.08429 1.43845 0 
Q2309 M LC 0.51949 0.13136 1.91359 0 
Q2403 M LC 0.22665 0.0662 0 0 
R2412 M LC 0.69662 0.14282 1.7518 0 
R2506 M LC  0.04827  0 
R2611 M LC 0.16264 0.0304 0 0 
S1306 M cKO     
S1307 M cKO 0.54829 0.1373 1.17717 0 
S1401 M cKO     
S1805 M cKO     
T1607 M cKO     
T1806 M cKO 0.46807 0.54246 0.79333 0.88301 
T1811 M cKO     
T2101 M cKO     
U2108 M cKO 0.1884 0.1065 0 0 
U2402 M cKO 0.29555 0.14247 0.4237 0 
U2505 M cKO 0.57935 0.19892 1.10236 0 
V2507 M cKO 0.39777 0.13925 1.15115 0 
V2602 M cKO     
V2608 M cKO     
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H1314 F LC     
H1411 F LC     
H1504 F LC     
H1708 F LC     
I1710 F LC     
I2007 F LC     
I2205 F LC     
I2209 F LC     
J2304 F LC 0.34195 0 0.11831 0 
J2306 F LC 0.19643 0 0.15287 0 
J2413 F LC 0.27022 0 0.1087 0 
K2501 F LC 0.24548 0 0.17849 0 
K2503 F LC 0.26639 0 0.1423 0 
K2606 F LC     
L1707 F cKO     
L1804 F cKO     
L1808 F cKO     
L1813 F cKO     
M2113 F cKO     
M2216 F cKO     
M2303 F cKO 0 0 0.25725 0 
M2310 F cKO 0.28681 0 0.16585 0 
N2311 F cKO 0.20206 0 0.13243 0 
N2404 F cKO 0.27638 0 0.11363 0 
N2406 F cKO 0.27855 0 0.16307 0 
N2410 F cKO 0.22883 0 0.162 0 
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O1412 M LC     
O1507 M LC     
O1610 M LC     
O1701 M LC     
P1801 M LC     
P1910 M LC     
P2003 M LC     
P2117 M LC     
Q2202 M LC 0.1828 0 0 0 
Q2309 M LC 0.30253 0 0.02625 0 
Q2403 M LC 0 0 0 0 
R2412 M LC 0.27055 0 0 0 
R2506 M LC  0  0 
R2611 M LC 0 0 0 0 
S1306 M cKO     
S1307 M cKO 0.09763 0 0 0 
S1401 M cKO     
S1805 M cKO     
T1607 M cKO     
T1806 M cKO 0.07874 0.09804 0 0 
T1811 M cKO     
T2101 M cKO     
U2108 M cKO 0 0 0 0 
U2402 M cKO 0.0276 0 0 0 
U2505 M cKO 0.13621 0 0 0 
V2507 M cKO 0.10311 0 0 0 
V2602 M cKO     
V2608 M cKO     
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Table C.17 Indices of bone stiffness from strain gauge data in left and right tibia of 








L and R 
average 
KOF1 N/A -0.00781 -0.00781 
KOF2 -0.00832 -0.00552 -0.00692 
KOF3 -0.00683 -0.00777 -0.0073 
KOF4 -0.00763 -0.00934 -0.00849 
LCF1 -0.00777 -0.0064 -0.00708 
LCF2 -0.00775 -0.00535 -0.00655 
LCF3 -0.00571 -0.00538 -0.00555 
LCF4 -0.01179 -0.00509 -0.00844 
LCF5 -0.00709 -0.00662 -0.00686 
LCF6 -0.006 -0.0056 -0.0058 
KOM1 -0.00555 -0.01237 -0.00896 
KOM2 -0.00668 -0.00635 -0.00651 
KOM3 -0.00796 -0.01031 -0.00914 
KOM4 -0.00536 -0.00555 -0.00545 
KOM5 -0.00908 -0.00746 -0.00827 
LCM1 -0.00552 -0.00566 -0.00559 
LCM2 -0.01629 -0.00945 -0.01287 
LCM3 -0.00575 -0.00668 -0.00621 
LCM4 -0.00539 -0.00408 -0.00474 
LCM5 -0.00935 -0.00785 -0.0086 





 CHAPTER 4 DATA APPENDIX D.
Table D.1 Indices of cancellous bone from microCT analysis of tibial metaphysis in 
















A4204 LC placebo 0.0636 0.0482 0.3855 678.341 
A4406 LC placebo 0.1173 0.0537 0.3159 685.308 
A4415 LC placebo 0.0831 0.05 0.3661 647.805 
A4502 LC placebo 0.0586 0.0486 0.4159 686.024 
A4508 LC placebo 0.0688 0.0502 0.4413 692.991 
B4807 LC placebo 0.0749 0.0516 0.3747 706.729 
B5012 LC placebo 0.0953 0.0512 0.2814 695.4 
B5108 LC placebo 0.0883 0.0496 0.3605 677.169 
B5110 LC placebo 0.1023 0.0498 0.2896 695.075 
B5302 LC placebo 0.1122 0.049 0.2766 676.323 
C5203 LC drug 0.103 0.0581 0.3187 718.514 
C5605 LC drug 0.1158 0.0588 0.3006 712.068 
C5702 LC drug 0.1429 0.0617 0.3006 717.537 
C5915 LC drug 0.1369 0.0579 0.263 712.068 
C6010 LC drug 0.1416 0.0632 0.2817 715.259 
D6105 LC drug 0.1308 0.0581 0.2962 697.288 
D6312 LC drug 0.1682 0.06 0.2279 702.562 
D6407 LC drug 0.1935 0.0625 0.2456 702.041 
D6509 LC drug 0.1138 0.0576 0.2841 726.848 
D6603 LC drug 0.1323 0.0605 0.2897 728.736 
E4112 cKO placebo 0.0985 0.0503 0.327 692.47 
E4209 cKO placebo 0.0582 0.0453 0.3989 678.797 
E4213 cKO placebo 0.0715 0.0491 0.3922 682.378 
E4301 cKO placebo 0.0644 0.0513 0.4883 712.003 
E4307 cKO placebo 0.0734 0.0482 0.4262 680.034 
F4409 cKO placebo 0.0941 0.0533 0.303 698.525 
F4512 cKO placebo 0.0555 0.0494 0.4531 693.512 
F4901 cKO placebo 0.0724 0.0495 0.3199 702.497 
F4904 cKO placebo 0.0762 0.0515 0.3518 703.409 
F5008 cKO placebo 0.0772 0.051 0.3932 698.525 
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G5013 cKO drug 0.1015 0.0591 0.3687 709.529 
G5502 cKO drug 0.1436 0.0597 0.2861 686.35 
G5504 cKO drug 0.1318 0.0574 0.2982 694.033 
G5601 cKO drug 0.1146 0.0609 0.3818 708.227 
G5709 cKO drug 0.1335 0.06 0.2945 720.663 
H5812 cKO drug 0.1051 0.0561 0.3555 703.213 
H6007 cKO drug 0.1534 0.0554 0.2756 672.937 
H6415 cKO drug 0.109 0.0586 0.4072 713.175 
H6503 cKO drug 0.114 0.0592 0.354 705.297 
H6608 cKO drug 0.1406 0.0613 0.3882 705.622 
 
















A4204 LC placebo 0.0824 0.0591 0.3415 711.157 
A4406 LC placebo 0.12 0.0599 0.26 708.943 
A4415 LC placebo 0.1021 0.0622 0.3187 704.906 
A4502 LC placebo 0.079 0.0578 0.4043 698.851 
A4508 LC placebo 0.0591 0.0601 0.4468 715.389 
B4807 LC placebo 0.0884 0.0616 0.3497 724.114 
B5012 LC placebo 0.0949 0.0579 0.2912 709.399 
B5108 LC placebo 0.094 0.0572 0.3475 677.234 
B5110 LC placebo     
B5302 LC placebo 0.1072 0.0559 0.2923 684.657 
C5203 LC drug 0.0892 0.0632 0.3818 730.95 
C5605 LC drug 0.1175 0.0591 0.2925 725.806 
C5702 LC drug 0.1191 0.0592 0.2782 716.821 
C5915 LC drug 0.1456 0.0624 0.2494 729.778 
C6010 LC drug 0.1282 0.0635 0.2795 725.611 
D6105 LC drug 0.1336 0.0629 0.2769 714.608 
D6312 LC drug 0.1717 0.0627 0.2405 715.128 
D6407 LC drug 0.1602 0.0623 0.2681 710.44 
D6509 LC drug 0.1069 0.062 0.2903 729.843 
D6603 LC drug 0.1259 0.0613 0.3399 718.449 
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E4112 cKO placebo 0.1177 0.0616 0.3367 709.985 
E4209 cKO placebo 0.0828 0.0674 0.3883 733.424 
E4213 cKO placebo 0.0788 0.0652 0.4391 714.152 
E4301 cKO placebo 0.082 0.0679 0.5091 750.418 
E4307 cKO placebo 0.1001 0.0666 0.4396 728.346 
F4409 cKO placebo 0.0945 0.0647 0.326 717.993 
F4512 cKO placebo 0.0737 0.0664 0.45 712.719 
F4901 cKO placebo 0.0815 0.0581 0.3475 715.91 
F4904 cKO placebo 0.0974 0.0632 0.3273 727.89 
F5008 cKO placebo 0.0862 0.0609 0.3563 718.123 
G5013 cKO drug 0.1315 0.0693 0.3053 721.77 
G5502 cKO drug     
G5504 cKO drug 0.1163 0.0647 0.324 727.499 
G5601 cKO drug 0.1119 0.0674 0.3442 712.133 
G5709 cKO drug 0.1391 0.0634 0.2829 720.533 
H5812 cKO drug 0.1234 0.0609 0.3488 705.036 
H6007 cKO drug 0.1525 0.0605 0.2674 700.739 
H6415 cKO drug 0.1054 0.059 0.3168 720.402 
H6503 cKO drug 0.1206 0.063 0.3248 714.998 
H6608 cKO drug 0.1349 0.0681 0.4008 723.723 
 
Table D.2 Indices of cortical bone from microCT analysis of tibial metaphysis in 12-



























A4204 LC placebo 0.36455 0.28647 0.93021 0.136 768.715 
A4406 LC placebo 0.51052 0.32993 1.1096 0.146 799.121 
A4415 LC placebo 0.33987 0.28156 0.93631 0.136 781.671 
A4502 LC placebo 0.38646 0.32148 0.9605 0.135 779.458 
A4508 LC placebo 0.40699 0.33749 0.99686 0.137 787.596 
B4807 LC placebo 0.31619 0.25253 0.86214 0.127 773.272 
B5012 LC placebo 0.32786 0.28524 0.93958 0.14 775.551 
B5108 LC placebo 0.38996 0.33555 1.01485 0.144 798.275 
B5110 LC placebo 0.3393 0.27045 0.93999 0.14 782.908 
B5302 LC placebo 0.3337 0.27023 0.87545 0.121 753.348 
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C5203 LC drug 0.3734 0.32412 1.02452 0.148 801.27 
C5605 LC drug 0.28518 0.24921 0.91506 0.145 783.299 
C5702 LC drug 0.37148 0.28679 1.01891 0.149 796.061 
C5915 LC drug 0.40015 0.34707 1.0355 0.139 775.551 
C6010 LC drug 0.36772 0.29337 1.01803 0.152 776.398 
D6105 LC drug 0.39867 0.32377 1.05918 0.153 796.061 
D6312 LC drug 0.33193 0.28562 0.89438 0.122 738.113 
D6407 LC drug 0.29725 0.24449 0.86791 0.122 743.842 
D6509 LC drug 0.41171 0.35293 1.04615 0.141 792.349 
D6603 LC drug 0.35387 0.28852 1.01712 0.152 786.75 
E4112 cKO placebo 0.35417 0.27332 0.98737 0.149 791.829 
E4209 cKO placebo 0.34564 0.29201 0.88313 0.122 762.92 
E4213 cKO placebo 0.34111 0.30208 0.91589 0.127 777.374 
E4301 cKO placebo 0.35274 0.28332 0.90036 0.125 785.383 
E4307 cKO placebo 0.28535 0.23974 0.82319 0.123 780.955 
F4409 cKO placebo 0.42642 0.35802 1.05352 0.141 785.057 
F4512 cKO placebo 0.32827 0.27554 0.87006 0.123 769.105 
F4901 cKO placebo 0.38276 0.31834 0.99413 0.137 800.098 
F4904 cKO placebo 0.40518 0.35106 0.98897 0.129 777.049 
F5008 cKO placebo 0.35486 0.29783 0.91694 0.125 775.551 
G5013 cKO drug 0.32409 0.25647 0.92812 0.142 781.151 
G5502 cKO drug 0.27578 0.2219 0.87525 0.135 776.072 
G5504 cKO drug 0.35365 0.29013 0.96814 0.134 772.296 
G5601 cKO drug 0.30134 0.2554 0.83306 0.126 766.826 
G5709 cKO drug 0.37269 0.30276 0.94001 0.125 757.385 
H5812 cKO drug 0.29584 0.24979 0.86608 0.129 754.846 
H6007 cKO drug 0.3392 0.24225 0.82357 0.109 720.924 
H6415 cKO drug 0.3339 0.2877 0.95501 0.14 772.491 
H6503 cKO drug 0.33168 0.28321 0.89979 0.124 764.157 
H6608 cKO drug 0.31732 0.24231 0.88369 0.128 762.269 
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A4204 LC placebo 0.47391 0.36975 1.10116 0.149 782.453 
A4406 LC placebo 0.53998 0.43276 1.22484 0.159 783.95 
A4415 LC placebo 0.47644 0.35069 1.10555 0.15 777.7 
A4502 LC placebo 0.47999 0.39456 1.09159 0.145 779.002 
A4508 LC placebo 0.47459 0.36561 1.07318 0.149 784.927 
B4807 LC placebo 0.41395 0.33223 1.05043 0.146 768.649 
B5012 LC placebo 0.43331 0.35126 1.05334 0.143 763.05 
B5108 LC placebo 0.48232 0.38999 1.13433 0.153 783.494 
B5110 LC placebo 0.49607 0.40923 1.19092 0.162 779.653 
B5302 LC placebo 0.44539 0.34792 1.06947 0.144 770.407 
C5203 LC drug 0.47335 0.36961 1.1425 0.158 808.953 
C5605 LC drug 0.40741 0.33825 1.11173 0.158 798.795 
C5702 LC drug 0.43466 0.32952 1.08938 0.152 797.754 
C5915 LC drug 0.46359 0.37418 1.13685 0.149 786.88 
C6010 LC drug 0.42511 0.32757 1.09346 0.158 794.889 
D6105 LC drug 0.4682 0.38122 1.19795 0.17 808.887 
D6312 LC drug 0.4313 0.32456 1.03197 0.136 760.185 
D6407 LC drug 0.35202 0.26837 0.92438 0.129 754.065 
D6509 LC drug 0.45204 0.37347 1.13378 0.162 801.53 
D6603 LC drug 0.4283 0.33914 1.13407 0.161 798.34 
E4112 cKO placebo 0.48679 0.38883 1.20284 0.166 776.267 
E4209 cKO placebo 0.49835 0.37871 1.08608 0.14 762.659 
E4213 cKO placebo 0.44116 0.35947 1.05158 0.142 765.264 
E4301 cKO placebo 0.53848 0.41742 1.20528 0.159 787.01 
E4307 cKO placebo 0.43562 0.33056 1.10991 0.156 781.151 
F4409 cKO placebo 0.53759 0.42574 1.20796 0.155 772.361 
F4512 cKO placebo 0.44052 0.3536 1.07708 0.146 773.142 
F4901 cKO placebo 0.45565 0.34876 1.10683 0.154 795.084 
F4904 cKO placebo 0.49849 0.38928 1.13045 0.146 775.616 
F5008 cKO placebo 0.45796 0.37703 1.09225 0.143 768.129 
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A4204 LC placebo 0.42883 0.31373 1.11308 0.16 792.545 
A4406 LC placebo      
A4415 LC placebo 0.41868 0.32468 1.06545 0.148 779.197 
A4502 LC placebo 0.4032 0.31097 1.0042 0.14 784.146 
A4508 LC placebo 0.39956 0.31825 1.01348 0.137 764.938 
B4807 LC placebo 0.40767 0.32325 1.05129 0.141 764.092 
B5012 LC placebo 0.41864 0.30497 0.95962 0.122 748.596 
B5108 LC placebo 0.36895 0.30845 0.98244 0.139 777.635 
B5110 LC placebo 0.39292 0.30282 0.97616 0.132 769.821 
B5302 LC placebo 0.33203 0.25637 0.9282 0.134 774.249 
 



























C5203 LC drug 0.47335 0.36961 1.1425 0.158 808.953 
C5605 LC drug 0.40741 0.33825 1.11173 0.158 798.795 
C5702 LC drug 0.43466 0.32952 1.08938 0.152 797.754 
C5915 LC drug 0.46359 0.37418 1.13685 0.149 786.88 
C6010 LC drug 0.42511 0.32757 1.09346 0.158 794.889 
D6105 LC drug 0.4682 0.38122 1.19795 0.17 808.887 
D6312 LC drug 0.4313 0.32456 1.03197 0.136 760.185 
D6407 LC drug 0.35202 0.26837 0.92438 0.129 754.065 
D6509 LC drug 0.45204 0.37347 1.13378 0.162 801.53 
D6603 LC drug 0.4283 0.33914 1.13407 0.161 798.34 
E4112 cKO placebo 0.48679 0.38883 1.20284 0.166 776.267 
E4209 cKO placebo 0.49835 0.37871 1.08608 0.14 762.659 
E4213 cKO placebo 0.44116 0.35947 1.05158 0.142 765.264 
E4301 cKO placebo 0.53848 0.41742 1.20528 0.159 787.01 
E4307 cKO placebo 0.43562 0.33056 1.10991 0.156 781.151 
F4409 cKO placebo 0.53759 0.42574 1.20796 0.155 772.361 
F4512 cKO placebo 0.44052 0.3536 1.07708 0.146 773.142 
F4901 cKO placebo 0.45565 0.34876 1.10683 0.154 795.084 
F4904 cKO placebo 0.49849 0.38928 1.13045 0.146 775.616 
F5008 cKO placebo 0.45796 0.37703 1.09225 0.143 768.129 
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G5013 cKO drug 0.42883 0.31373 1.11308 0.16 792.545 
G5502 cKO drug      
G5504 cKO drug 0.41868 0.32468 1.06545 0.148 779.197 
G5601 cKO drug 0.4032 0.31097 1.0042 0.14 784.146 
G5709 cKO drug 0.39956 0.31825 1.01348 0.137 764.938 
H5812 cKO drug 0.40767 0.32325 1.05129 0.141 764.092 
H6007 cKO drug 0.41864 0.30497 0.95962 0.122 748.596 
H6415 cKO drug 0.36895 0.30845 0.98244 0.139 777.635 
H6503 cKO drug 0.39292 0.30282 0.97616 0.132 769.821 
H6608 cKO drug 0.33203 0.25637 0.9282 0.134 774.249 
 
Table D.3 Indices of tibial midshaft bone from microCT of 12-week-old female pOC-
























A4204 LC placebo 0.06597 0.05287 0.5598 0.93653 
A4406 LC placebo 0.08064 0.05961 0.61561 1.01202 
A4415 LC placebo 0.06018 0.05132 0.54348 0.90561 
A4502 LC placebo 0.06332 0.05307 0.56604 0.91549 
A4508 LC placebo 0.06922 0.05061 0.56796 0.92863 
B4807 LC placebo 0.0603 0.04459 0.52375 0.87795 
B5012 LC placebo 0.0525 0.04144 0.5214 0.81663 
B5108 LC placebo 0.06959 0.05689 0.59279 0.95739 
B5110 LC placebo 0.05473 0.04536 0.5382 0.84735 
B5302 LC placebo 0.05914 0.04717 0.52403 0.88237 
C5203 LC drug 0.08171 0.05812 0.63319 0.98843 
C5605 LC drug 0.04629 0.03841 0.53012 0.76143 
C5702 LC drug 0.06323 0.05345 0.58465 0.90436 
C5915 LC drug 0.06374 0.04744 0.57164 0.87747 
C6010 LC drug 0.06824 0.05414 0.58403 0.93496 
D6105 LC drug 0.06914 0.06256 0.60533 0.97397 
D6312 LC drug 0.05471 0.04316 0.50589 0.84936 
D6407 LC drug 0.04381 0.03759 0.48748 0.76266 
D6509 LC drug 0.07052 0.05959 0.60615 0.96119 
D6603 LC drug 0.05915 0.05168 0.56714 0.88975 
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E4112 cKO placebo 0.0568 0.04933 0.54946 0.86897 
E4209 cKO placebo 0.07234 0.05136 0.57582 0.9395 
E4213 cKO placebo 0.06305 0.05 0.5362 0.90681 
E4301 cKO placebo 0.05601 0.04403 0.51335 0.85819 
E4307 cKO placebo 0.05848 0.04798 0.52835 0.88068 
F4409 cKO placebo 0.07336 0.05791 0.59666 0.97346 
F4512 cKO placebo 0.05088 0.04461 0.50159 0.84212 
F4901 cKO placebo 0.0577 0.04998 0.56586 0.87252 
F4904 cKO placebo 0.0605 0.05046 0.56255 0.88884 
F5008 cKO placebo 0.0519 0.04411 0.51642 0.83396 
G5013 cKO drug 0.0589 0.04365 0.54457 0.84549 
G5502 cKO drug 0.05275 0.04116 0.52536 0.81472 
G5504 cKO drug 0.06291 0.05176 0.56444 0.90731 
G5601 cKO drug 0.06233 0.04788 0.56717 0.88219 
G5709 cKO drug     
H5812 cKO drug 0.06023 0.04611 0.5313 0.88076 
H6007 cKO drug 0.05194 0.04257 0.50655 0.82956 
H6415 cKO drug 0.06408 0.04984 0.56378 0.90497 
H6503 cKO drug 0.06181 0.04715 0.53453 0.89764 
H6608 cKO drug     
 
























A4204 LC placebo 0.0772 0.06084 0.61844 0.98824 
A4406 LC placebo 0.08802 0.06688 0.63771 1.057 
A4415 LC placebo 0.07321 0.0571 0.60768 0.95901 
A4502 LC placebo 0.07975 0.06024 0.6091 1.00517 
A4508 LC placebo 0.07178 0.05306 0.55608 0.96684 
B4807 LC placebo 0.06587 0.04551 0.56264 0.87962 
B5012 LC placebo 0.06066 0.04704 0.56963 0.86492 
B5108 LC placebo 0.07393 0.05834 0.6168 0.96559 
B5110 LC placebo 0.06638 0.05052 0.588 0.90364 
B5302 LC placebo 0.06443 0.05443 0.57827 0.92029 
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C5203 LC drug 0.08031 0.0623 0.63888 1.00448 
C5605 LC drug 0.06629 0.04855 0.60309 0.88167 
C5702 LC drug 0.06918 0.05268 0.6179 0.91434 
C5915 LC drug 0.07482 0.05753 0.60391 0.96166 
C6010 LC drug 0.07899 0.06023 0.64066 0.98643 
D6105 LC drug     
D6312 LC drug 0.07181 0.05336 0.59156 0.9381 
D6407 LC drug 0.0519 0.04659 0.53871 0.83561 
D6509 LC drug 0.07809 0.05925 0.62574 0.97938 
D6603 LC drug 0.06952 0.05586 0.60314 0.93635 
E4112 cKO placebo 0.06532 0.05109 0.60069 0.89737 
E4209 cKO placebo 0.06974 0.05011 0.59063 0.9152 
E4213 cKO placebo 0.06787 0.05102 0.57164 0.92248 
E4301 cKO placebo 0.07402 0.06006 0.62829 0.97216 
E4307 cKO placebo 0.07912 0.0564 0.62985 0.9719 
F4409 cKO placebo 0.0784 0.06365 0.63003 1.00175 
F4512 cKO placebo 0.06729 0.05193 0.56934 0.91925 
F4901 cKO placebo 0.0621 0.05095 0.60185 0.88638 
F4904 cKO placebo 0.07149 0.05505 0.60285 0.95004 
F5008 cKO placebo 0.06544 0.04921 0.58625 0.8943 
G5013 cKO drug 0.07767 0.0589 0.65326 0.96616 
G5502 cKO drug 0.05948 0.04492 0.5486 0.86027 
G5504 cKO drug 0.07034 0.05364 0.60692 0.93335 
G5601 cKO drug 0.06721 0.05107 0.58704 0.90998 
G5709 cKO drug 0.08031 0.0623 0.63888 1.00448 
H5812 cKO drug 0.06629 0.04855 0.60309 0.88167 
H6007 cKO drug 0.06918 0.05268 0.6179 0.91434 
H6415 cKO drug 0.07482 0.05753 0.60391 0.96166 
H6503 cKO drug 0.07899 0.06023 0.64066 0.98643 




















A4204 LC placebo 0.197 949.46 0.37673 
A4406 LC placebo 0.208 962.222 0.39641 
A4415 LC placebo 0.194 948.484 0.36213 
A4502 LC placebo 0.202 958.445 0.34945 
A4508 LC placebo 0.199 959.617 0.36067 
B4807 LC placebo 0.19 951.804 0.3542 
B5012 LC placebo 0.2 957.404 0.29523 
B5108 LC placebo 0.206 962.287 0.3646 
B5110 LC placebo 0.203 964.566 0.30915 
B5302 LC placebo 0.188 937.48 0.35834 
C5203 LC drug 0.218 968.993 0.35524 
C5605 LC drug 0.218 970.686 0.23131 
C5702 LC drug 0.212 972.704 0.31971 
C5915 LC drug 0.212 960.789 0.30583 
C6010 LC drug 0.207 961.896 0.35093 
D6105 LC drug 0.21 961.571 0.36864 
D6312 LC drug 0.186 927.779 0.34347 
D6407 LC drug 0.195 940.996 0.27518 
D6509 LC drug 0.214 958.185 0.35504 
D6603 LC drug   0.32261 
E4112 cKO placebo 0.203 962.222 0.31951 
E4209 cKO placebo 0.202 958.185 0.36368 
E4213 cKO placebo 0.188 939.498 0.37061 
E4301 cKO placebo 0.189 945.489 0.34484 
E4307 cKO placebo 0.19 951.739 0.35233 
F4409 cKO placebo 0.206 955.06 0.3768 
F4512 cKO placebo 0.187 945.619 0.34053 
F4901 cKO placebo 0.212 970.165 0.30666 
F4904 cKO placebo 0.207 963.459 0.32629 
F5008 cKO placebo 0.195 948.093 0.31754 
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G5013 cKO drug 0.205 954.083 0.30092 
G5502 cKO drug 0.203 964.045 0.28936 
G5504 cKO drug 0.204 959.357 0.34287 
G5601 cKO drug 0.211 961.636 0.31502 
G5709 cKO drug    
H5812 cKO drug 0.19 941.061 0.34946 
H6007 cKO drug 0.19 938.587 0.32301 
H6415 cKO drug 0.206 951.218 0.34119 
H6503 cKO drug 0.192 931.294 0.36311 
H6608 cKO drug    
 
















A4204 LC placebo 0.212 955.906 0.3698 
A4406 LC placebo 0.209 945.163 0.41929 
A4415 LC placebo 0.213 955.581 0.35133 
A4502 LC placebo 0.207 951.023 0.39607 
A4508 LC placebo 0.19 948.874 0.41076 
B4807 LC placebo 0.208 953.367 0.31698 
B5012 LC placebo 0.214 961.115 0.29529 
B5108 LC placebo 0.219 968.147 0.34879 
B5110 LC placebo 0.215 961.636 0.31564 
B5302 LC placebo 0.207 947.832 0.34202 
C5203 LC drug 0.22 967.691 0.3656 
C5605 LC drug 0.226 970.947 0.27858 
C5702 LC drug 0.228 976.22 0.29644 
C5915 LC drug 0.21 941.386 0.35775 
C6010 LC drug 0.227 963.849 0.34577 
D6105 LC drug    
D6312 LC drug 0.208 942.038 0.34654 
D6407 LC drug 0.205 936.568 0.2969 
D6509 LC drug 0.22 956.101 0.35364 
D6603 LC drug 0.217 959.031 0.33321 
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E4112 cKO placebo 0.228 977.653 0.29668 
E4209 cKO placebo 0.216 970.1 0.32457 
E4213 cKO placebo 0.206 953.302 0.35084 
E4301 cKO placebo 0.222 949.721 0.34387 
E4307 cKO placebo 0.222 952.325 0.34205 
F4409 cKO placebo 0.218 953.627 0.37172 
F4512 cKO placebo 0.201 947.181 0.34991 
F4901 cKO placebo 0.23 975.765 0.28453 
F4904 cKO placebo 0.216 966.584 0.34719 
F5008 cKO placebo 0.218 960.789 0.30805 
G5013 cKO drug 0.236 958.836 0.3129 
G5502 cKO drug 0.209 951.153 0.31167 
G5504 cKO drug 0.22 971.532 0.32643 
G5601 cKO drug 0.213 954.799 0.32294 
G5709 cKO drug    
H5812 cKO drug 0.217 954.669 0.32747 
H6007 cKO drug 0.206 939.563 0.3939 
H6415 cKO drug 0.207 955.711 0.35564 
H6503 cKO drug    
H6608 cKO drug    
 
Table D.4 IHC and histology indices for the cancellous tibial metaphysis of 12-week-
























A4204 LC placebo 5.46579 6.50849  3.0187 
A4406 LC placebo 2.54777 2.39893 2.07743 3.76326 
A4415 LC placebo 3.58722 12.4482 5.45062 3.92354 
A4502 LC placebo  4.79951   
A4508 LC placebo     
B4807 LC placebo   4.59136 2.69503 
B5012 LC placebo 5.5711  1.93756  
B5108 LC placebo 5.83622 6.24583 2.99133 2.18484 
B5110 LC placebo 2.59642 3.88438 7.6661 2.49904 
B5302 LC placebo     
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C5203 LC drug 1.93641 2.69687 1.2377 4.05683 
C5605 LC drug 5.54803  5.52692 3.3957 
C5702 LC drug  7.41239 3.63786  
C5915 LC drug     
C6010 LC drug 1.90743 3.32022 2.73674 2.69268 
D6105 LC drug 4.68363 2.3533 5.44437 1.74729 
D6312 LC drug 5.34769 3.84114  1.13419 
D6407 LC drug     
D6509 LC drug 3.93944 4.03362 7.0032 1.51255 
D6603 LC drug     
E4112 cKO placebo     
E4209 cKO placebo 3.91936 5.49151 6.41444 2.94263 
E4213 cKO placebo 2.66057 3.44162 5.20834  
E4301 cKO placebo 2.29501 5.9205 6.3175 3.80454 
E4307 cKO placebo     
F4409 cKO placebo 4.31775  4.20317 2.54669 
F4512 cKO placebo  5.8581  2.86903 
F4901 cKO placebo 2.74065 5.90659 4.81099 4.26763 
F4904 cKO placebo     
F5008 cKO placebo 3.91564 6.77309 3.64236 4.37372 
G5013 cKO drug     
G5502 cKO drug     
G5504 cKO drug  2.84617  2.01678 
G5601 cKO drug 2.43069 2.86424 2.08325 2.85902 
G5709 cKO drug     
H5812 cKO drug 4.19626 3.78159  4.82041 
H6007 cKO drug 3.19986 2.1283 0.61042 1.86188 
H6415 cKO drug  6.90793 5.14352 2.83774 
H6503 cKO drug 3.68551 5.15355 5.13376  
H6608 cKO drug 1.9588  2.23412 2.57204 
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Table D.5 Indices of cancellous vertebra measured by microCT in 12-week-old 














A4204 LC placebo 0.1913 0.053 0.2421 630.225 
A4406 LC placebo 0.2445 0.0571 0.2451 631.722 
A4415 LC placebo 0.2279 0.0553 0.2301 622.672 
A4502 LC placebo 0.1691 0.0523 0.2721 623.779 
A4508 LC placebo 0.1784 0.051 0.2701 591.029 
B4807 LC placebo 0.1679 0.0479 0.2444 591.615 
B5012 LC placebo 0.2134 0.0505 0.2232 590.052 
B5108 LC placebo 0.234 0.0557 0.2303 618.505 
B5110 LC placebo     
B5302 LC placebo     
C5203 LC drug 0.2334 0.0627 0.2588 656.204 
C5605 LC drug 0.3261 0.069 0.1974 661.087 
C5702 LC drug 0.3013 0.0665 0.2226 648.065 
C5915 LC drug 0.2963 0.0655 0.2277 653.925 
C6010 LC drug 0.3259 0.068 0.2144 651.32 
D6105 LC drug 0.2579 0.0632 0.2472 652.102 
D6312 LC drug 0.3185 0.0672 0.1917 655.618 
D6407 LC drug 0.333 0.0714 0.1875 667.663 
D6509 LC drug     
D6603 LC drug     
E4112 cKO placebo 0.2245 0.0555 0.2209 631.722 
E4209 cKO placebo 0.1374 0.0475 0.2683 608.804 
E4213 cKO placebo 0.1917 0.0488 0.2098 602.293 
E4301 cKO placebo 0.171 0.0478 0.2285 603.53 
E4307 cKO placebo 0.1653 0.0467 0.2379 583.476 
F4409 cKO placebo 0.1931 0.0534 0.2408 618.31 
F4512 cKO placebo 0.1664 0.0466 0.2364 591.094 
F4901 cKO placebo 0.158 0.0474 0.2449 590.182 
F4904 cKO placebo     
F5008 cKO placebo 0.1913 0.053 0.2421 630.225 
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G5013 cKO drug 0.2253 0.0611 0.2417 653.99 
G5502 cKO drug 0.2844 0.0608 0.2064 631.267 
G5504 cKO drug 0.2755 0.0634 0.2095 655.943 
G5601 cKO drug 0.2256 0.0612 0.2434 657.18 
G5709 cKO drug 0.2687 0.063 0.2015 657.962 
H5812 cKO drug 0.3339 0.0648 0.1801 652.623 
H6007 cKO drug 0.3278 0.0632 0.1724 641.359 
H6415 cKO drug 0.2263 0.063 0.2651 651.776 
H6503 cKO drug     
H6608 cKO drug     
 
Table D.6 Indices of cortical shell vertebra from microCT of 12-week-old female LC 



























A4204 LC placebo 0.26117 0.05955 0.51325 0.088 713.891 
A4406 LC placebo 0.27988 0.05808 0.53126 0.087 711.482 
A4415 LC placebo 0.18706 0.06892 0.46403 0.083 707.38 
A4502 LC placebo 0.24936 0.05539 0.50241 0.086 715.063 
A4508 LC placebo 0.23612 0.05666 0.48912 0.082 703.148 
B4807 LC placebo 0.20438 0.04311 0.43944 0.08 695.921 
B5012 LC placebo 0.28375 0.05393 0.5216 0.083 704.841 
B5108 LC placebo 0.24643 0.07777 0.52445 0.087 724.7 
B5110 LC placebo      
B5302 LC placebo      
C5203 LC drug 0.38075 0.07862 0.64874 0.098 722.161 
C5605 LC drug 0.33246 0.06262 0.62473 0.107 739.089 
C5702 LC drug 0.35647 0.06153 0.65455 0.104 724.7 
C5915 LC drug 0.32748 0.06444 0.62303 0.102 737.462 
C6010 LC drug 0.30841 0.06351 0.61061 0.102 730.69 
D6105 LC drug 0.24017 0.05118 0.52246 0.099 738.243 
D6312 LC drug 0.30836 0.07103 0.59903 0.097 724.895 
D6407 LC drug 0.30386 0.06339 0.58917 0.099 724.635 
D6509 LC drug      
D6603 LC drug      
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E4112 cKO placebo 0.20164 0.04875 0.47311 0.088 720.012 
E4209 cKO placebo 0.25712 0.06135 0.48674 0.081 707.966 
E4213 cKO placebo 0.23399 0.05039 0.47062 0.082 711.547 
E4301 cKO placebo 0.22472 0.05213 0.44234 0.074 696.116 
E4307 cKO placebo 0.20257 0.04534 0.42003 0.076 696.312 
F4409 cKO placebo 0.21732 0.05101 0.47454 0.086 720.858 
F4512 cKO placebo 0.19521 0.04708 0.43703 0.079 695.66 
F4901 cKO placebo 0.20043 0.04565 0.43907 0.079 693.317 
F4904 cKO placebo      
F5008 cKO placebo      
G5013 cKO drug 0.24281 0.05684 0.49645 0.088 729.257 
G5502 cKO drug 0.19103 0.05032 0.45614 0.083 695.075 
G5504 cKO drug 0.31461 0.06387 0.56978 0.092 724.44 
G5601 cKO drug 0.27516 0.06269 0.53668 0.089 728.671 
G5709 cKO drug 0.18643 0.04843 0.47486 0.091 713.241 
H5812 cKO drug 0.18998 0.05218 0.47302 0.088 724.895 
H6007 cKO drug 0.28025 0.0675 0.53873 0.082 695.335 
H6415 cKO drug 0.22772 0.06145 0.52888 0.092 721.249 
H6503 cKO drug      
H6608 cKO drug      
 
Table D.7 Indices of femoral midshafts from microCT of 12-week-old female LC and 
























A4204 LC placebo 0.21274 0.12064 0.73939 1.73815 
A4406 LC placebo 0.25641 0.13663 0.82178 1.84992 
A4415 LC placebo 0.18893 0.10593 0.70045 1.62548 
A4502 LC placebo 0.21832 0.12233 0.77089 1.72423 
A4508 LC placebo 0.20726 0.13273 0.76646 1.7481 
B4807 LC placebo 0.15507 0.09633 0.65852 1.49796 
B5012 LC placebo 0.19518 0.09126 0.71653 1.53112 
B5108 LC placebo 0.22688 0.12569 0.80157 1.72183 
B5110 LC placebo     
B5302 LC placebo     
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C5203 LC drug 0.24289 0.12941 0.83576 1.75328 
C5605 LC drug 0.16072 0.1 0.74087 1.44707 
C5702 LC drug 0.21143 0.11259 0.80698 1.60969 
C5915 LC drug 0.20395 0.1132 0.76835 1.63017 
C6010 LC drug 0.21538 0.12308 0.81978 1.65985 
D6105 LC drug 0.22603 0.13171 0.82292 1.73625 
D6312 LC drug 0.17736 0.09837 0.73773 1.502 
D6407 LC drug 0.15608 0.09345 0.66803 1.48467 
D6509 LC drug     
D6603 LC drug     
E4112 cKO placebo 0.17332 0.11275 0.72662 1.57179 
E4209 cKO placebo 0.21681 0.11083 0.7446 1.6836 
E4213 cKO placebo 0.18933 0.10983 0.70509 1.64434 
E4301 cKO placebo 0.17901 0.10175 0.68018 1.5941 
E4307 cKO placebo 0.19262 0.12006 0.71825 1.68642 
F4409 cKO placebo 0.2387 0.12686 0.79651 1.77149 
F4512 cKO placebo 0.19998 0.1149 0.73583 1.66705 
F4901 cKO placebo 0.20637 0.11425 0.74874 1.66494 
F4904 cKO placebo     
F5008 cKO placebo     
G5013 cKO drug 0.18982 0.11763 0.76324 1.61414 
G5502 cKO drug 0.17264 0.09866 0.6988 1.52715 
G5504 cKO drug 0.21956 0.12403 0.78981 1.7124 
G5601 cKO drug 0.20752 0.11166 0.76521 1.63244 
G5709 cKO drug 0.18528 0.10374 0.67451 1.63924 
H5812 cKO drug 0.213 0.12164 0.74666 1.73399 
H6007 cKO drug 0.20185 0.10515 0.70942 1.65459 
H6415 cKO drug 0.18921 0.11027 0.74024 1.59983 
H6503 cKO drug     
H6608 cKO drug     
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A4204 LC placebo 0.176 946.4 0.99876 
A4406 LC placebo 0.188 945.684 1.02814 
A4415 LC placebo 0.172 940.801 0.92503 
A4502 LC placebo 0.184 950.437 0.95334 
A4508 LC placebo 0.184 955.515 0.98164 
B4807 LC placebo 0.17 939.498 0.83944 
B5012 LC placebo 0.182 949.656 0.81459 
B5108 LC placebo 0.193 955.776 0.92026 
B5110 LC placebo    
B5302 LC placebo    
C5203 LC drug 0.201 959.813 0.91752 
C5605 LC drug 0.201 961.766 0.7062 
C5702 LC drug 0.205 970.426 0.80271 
C5915 LC drug 0.192 951.088 0.86182 
C6010 LC drug 0.204 964.305 0.84007 
D6105 LC drug 0.199 966.714 0.91333 
D6312 LC drug 0.192 944.707 0.76427 
D6407 LC drug 0.174 924.393 0.81664 
D6509 LC drug    
D6603 LC drug    
E4112 cKO placebo 0.185 944.056 0.84517 
E4209 cKO placebo 0.179 948.679 0.939 
E4213 cKO placebo 0.173 945.163 0.93925 
E4301 cKO placebo 0.169 939.173 0.91392 
E4307 cKO placebo 0.174 936.243 0.96817 
F4409 cKO placebo 0.189 946.856 0.97498 
F4512 cKO placebo 0.179 942.624 0.93122 
F4901 cKO placebo 0.183 951.283 0.9162 
F4904 cKO placebo    
F5008 cKO placebo    
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G5013 cKO drug 0.194 951.479 0.8509 
G5502 cKO drug 0.177 939.368 0.82835 
G5504 cKO drug 0.192 945.554 0.92259 
G5601 cKO drug 0.19 959.748 0.86723 
G5709 cKO drug 0.164 912.999 0.96473 
H5812 cKO drug 0.177 921.333 0.98733 
H6007 cKO drug 0.173 912.608 0.94517 
H6415 cKO drug 0.187 944.902 0.85959 
H6503 cKO drug    
H6608 cKO drug    
 
Table D.8 Indices of femur and vertebra mechanical testing from 12-week-old female 






















A4204 LC placebo 24.0465 2647.93 18.894 114.906 
A4406 LC placebo 28.5765 2559.08 24.855 243.724 
A4415 LC placebo 24.525 3038.98 19.796 98.3205 
A4502 LC placebo 24.204 2053.74 19.781 240.338 
A4508 LC placebo 27.219 2097.68 17.157 127.68 
B4807 LC placebo 22.1685 3575.71 16.207 99.7807 
B5012 LC placebo 22.4565 2832.24 19.619 175.981 
B5108 LC placebo 28.002 2489.38 20.962 175.716 
B5110 LC placebo 22.3755  21.252 121.678 
B5302 LC placebo 20.439  22.631 160.303 
C5203 LC drug 31.2135 2900.54 25.987 270.517 
C5605 LC drug 27.111 2986.36 27.369 198.733 
C5702 LC drug 30.789 3223.51 26.244 213.037 
C5915 LC drug 24.651 2159.54 15.864 136.377 
C6010 LC drug 27.6225 3428.38 31.825 224.676 
D6105 LC drug 27.117 2491.92 25.559 309.731 
D6312 LC drug 25.3485 2606 28.7 248.193 
D6407 LC drug 20.8455 3225.46 29.452 314.864 
D6509 LC drug 27.792  35.023 362.387 
D6603 LC drug 27.741  32.78 230.372 
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E4112 cKO placebo 26.568 3948.19 23.968 229.26 
E4209 cKO placebo 26.3565 2519.5 18.447 103.077 
E4213 cKO placebo 22.935 1567.71 18.296 161.636 
E4301 cKO placebo 24.381 2880.55 12.96 74.9212 
E4307 cKO placebo 23.355 1993 15.859 145.302 
F4409 cKO placebo 28.878 2882.7 15.974 118.472 
F4512 cKO placebo   16.423 128.614 
F4901 cKO placebo 23.8365 2080.3 16.32 133.579 
F4904 cKO placebo 26.424  17.017 118.212 
F5008 cKO placebo 21.855  16.816 69.8506 
G5013 cKO drug 28.533 2471.42 26.052 183.216 
G5502 cKO drug 24.0975 2804.33 22.267 152.496 
G5504 cKO drug 24.567 2457.47 32.234 216.045 
G5601 cKO drug 25.5975 2422.18 21.608 141.178 
G5709 cKO drug 21.0345 2257.61 28.926 230.166 
H5812 cKO drug 24.306 2543.74 30.567 221.496 
H6007 cKO drug 21.1815 1567.38 24.159 288.486 
H6415 cKO drug 26.0535 2418.43 33.033 222.641 
H6503 cKO drug 22.2945  24.026 151.583 
H6608 cKO drug 23.634  25.82 201.053 
  
